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Abbreviations 
Abbreviations for amino acids and peptides follow the lUPAC-IUB 
nomenclature where applicable {Eur. J. Biochem., 1984, 9-37). 
Ac 
(Ac)20 
AcOH 
Acm 
Alloc 
BASEC 
Boc 
BOP 
BSA 
'Bu 
n-BuLi 
Bzl 
CD 
CDCI3 
CE 
2-ClZ 
DBU 
2,6-DCB 
DCC 
DCM 
DCU 
Dde 
Acetyl 
Acetic anhydride 
Acetic acid 
Acetamidomethyl 
Allyloxycarbonyl 
2-[(A^-Biotinyl)-aminoethylsulphonyl]ethyl/7-nitrophenyl 
carbonate 
rerr-Butoxycarbonyl 
Benzotriazol-1 -yloxy-tris-pyrroUdinophosphonium 
hexafluorophosphate 
Bovine semm albumin 
fe/t-Butyl 
n-Butyl Uthium 
Benzyl 
Circular dichroism 
Deuteriochloroform 
Capillary electrophoresis 
2-Chlorobenzyloxycarbonyl 
l,8-Diazabicyclo[5.4.0]undec-7-ene 
2,6-Dichlorobenzene 
A'.A '^-Dicyclohexylcarbodiimide 
Dichloromethane 
A/,A '^-Dicyclohexylurea 
(4,4-Dimethyl-2,6-dioxocyclohex-1 -ylidene)ethyl 
DIEA 
DIPCDI 
DKP 
DMAP 
Dmc 
DMMD 
DMF 
DNP 
DSC 
DSS 
DVB 
EDC 
EDT 
EI 
EMS 
Eq. 
ES-MS 
Eton 
FAB-MS 
Fmoc 
Fmoc-Cl 
For 
HATU 
HBTU 
DUsopropylamine 
A/^ ,A '^-DUsopropylcarbodiinude 
Diketopiperazine 
4-Dimethylaminopyridine 
4,4-Dimethyl-2,6-dioxocyclohexylidenemethylene 
5,5 -dime thyl-2 -(die thy la minom ethyl ene)cy clohe xane-1,3 
dione 
Dimethylformamide 
Dinitrophenyl 
A'.A '^-Disuccirumidyl carbonate 
3-(Trimethylsilyl)-l-propanesulphoruc acid sodium salt 
Divinylbenzene 
l-(3-Dunethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride 
1,2-Ethanedithiol 
Electron impact (MS) 
Ethyl methyl sulphide 
Molar equivalent 
Electrospray mass spectroscopy 
Ethanol 
Fast atomic bombardment mass spectroscopy 
9-Fluorenylmethoxycarbonyl 
9-Fluorenylmethylchloroformate 
Formyl 
0-(7-Azabenzotiiazol-1 -yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate. 
0-(Benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate. 
HF 
HMB 
HMPA 
HOAt 
HOBt 
HPLC 
KLH 
LDA 
Hydrogen fluoride 
2-Hydroxy-4-methoxybenzyl 
4-Hydroxymethylphenoxyaceticacid 
1 -Hydroxy-7-azabenzotriazole 
I -Hydroxybenzotiiazole 
High performance liquid chromatography 
Keyhole Umpet haemocyanin 
Lithium dUsopropylamide 
MALDI-TOF 
MS 
MAP 
4-MeBzl 
MeOH 
m.p. 
MS 
NCA 
Nde 
NOE 
NMR 
OcHex 
OdDHL 
ODmab 
OHHL 
PAM 
Pd/C 
PEG 
Matrix assisted laser desorption time of flight mass 
spectroscopy 
Multiple antigenic peptide 
4-Methylbenzyl 
Methanol 
Melting point 
Mass spectroscopy 
A^-Carboxyanhydride 
1 -(4-Nitro-1,3-dioxoindan-2-ylidene)ethyl 
Nuclear Overhauser enhancement 
Nuclear magnetic resonance 
Cyclohexyl ester 
A^-(3-Oxododecanoyl)-L-homoserine lactone 
4-{N-[l-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-3-meth-
ylbutyl]amino}benzyl ester 
N-(3-Oxohexanoyl)-L-homoserine lactone 
Phenylacetamidomethyl 
PaUadium on charcoal 
Polyethyleneglycol 
PGC 
PLC 
PS 
RAFT 
RPHPLC 
SPOC 
SPPS 
Tbfmoc 
TBTU 
TCA 
TEA 
TFA 
TFE 
TFFH 
TFMSA 
THF 
TIPS 
TLC 
TMS 
TNBS 
Tos 
UNCA 
UV 
Z 
Porous graphitised carbon 
Preparative thin layer chromatography 
Polystyrene 
Regioselectively addressable functionalised template 
Reverse phase high performance liquid chromatography 
Solid phase organic chemistry 
Solid phase peptide synthesis 
Tetrabenzo [a, c, g, i]fluorenyl-17-methoxycarbonyl 
0-(Benzotriazol-1 -yl)-1,1,3,3 ,-tetramethylurounium 
tetrafluoroborate 
Tricarboxylic acid 
Triethylamine 
Trifluoroacetic acid 
Trifluoroethanol 
Tettamethylfluoroforamidiiuum hexafluorophosphate 
Trifluromethylsulphonic acid 
Tetrahydrofuran 
Triisopropylsilane 
Thin layer chromatography 
TetramethylsUane 
2,4,6-Trinitrobenzenesulphonic acid 
Toluenesulphonyl 
Urethane protected A/^ -carboxyanhydrides 
Ultraviolet spectroscopy 
Benzyloxycarbonyl 
Abstract 
Solid phase peptide synthesis (SPPS) of branched/cyclic peptides, 
multiple antigenic peptides (MAPs), pseudopeptide toxins etc. requires amine 
protection orthogonal to the established FmocABoc protocols. It was envisaged 
that progression from Dde to A^-1-(4-Nitro-l,3-dioxoindan-2-ylidene)ethyl 
(Nde) amino acid protection would maintain tiie stipulated orthogonality, whUst 
improving the hydrazine mediated deprotection. A selection of A^«-Nde-amino 
acids were efficientiy synthesised and their compatibUity with SPPS conditions 
demonstrated by the synthesis of a number of peptides. The Nde group 
displayed a faster and more easily monitored deprotection profile and simUar 
orthogonality when compared with the Dde group. The selective primary amine 
protecting characteristics of the Nde group was illustrated by the synthesis of 
NfN8-bis Nde-spermidine which was subsequently utiUsed m the soUd phase 
synthesis of the natural product, dihydrotrypanothione. 
Large peptides synthesised by SPPS often demand elaborate, expensive 
and cumbersome piuification protocols. Dde based reversible amine protecting 
groups incorporating hydrophobic and affinity probes have been developed. 
Their ease of preparation and efficacy in the purification of synthetic peptides 
has been demonstrated. 
Intercellular communication in various Gram-negative microorganisms 
is often mediated by small signalling molecules, e.g. A'-(3-oxohexanoyl)-L-
homoserine lactone (OHHL). Detection of these molecules is often extremely 
difficult. To address this, SPPS procedures have been employed to couple A^ -
p-ketoacyl-L-homoserine lactone containing haptens to a dendritic lysine 
scaffolding, and the resultant macromolecule evaluated for its ability to raise 
anti-A^-p-ketoacyl-L-homoserine lactone antibodies. 
l-Carbapen-2-em-3-carboxylic acid is a broad spectmm antibiotic 
produced by the Gram-negative Erwinia and Serratia microorganisms. Some 
key intermediates for the putative synthetic precursors have been successfully 
prepared in order to study the biosynthetic pathways by feeding blocked 
mutants of the above bacteria, and also to transpose the methodologies to a solid 
phase to constmct carbapenem libraries. 
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Introduction 
Thousands of organic molecules owe their biosynthetic origins to nature; 
the foremost generator of molecular diversity. For decades, organic chenusts 
have attempted to recreate many of these molecules within their laboratories; a 
task which has provided a continually evolving and fluxing challenge. 
Peptides and proteins are two such natural product families which have 
created an enormous area of interest for the organic chemist. The initial 
attention was generated from the recognition by Hofmeisteri and Fisher2 that 
protein stracture was ideally represented by chains of amino acids, linked to 
each other via anude bonds. This observation being predated by the synthesis 
of the first simple peptides by Curtis3 and later by Fisher.4 By the middle of the 
century, realisation that other biologically important molecules had simpler 
amino acid sequences escalated the stimulus and reduced the dimension of 
peptide synthesis to attainable levels. 
A new era in both chemistry and biology was begun in the early 1950's, 
when du Vigneaud and his co-workers isolated, 5 determined the stmcture6 and 
synthesised^ the lactogenic nonapeptide amide hormone oxytocin (1). 
I 1 
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 
(1) 
This was soon foUowed by Sanger's historical stmctural elucidation of insuUn.8 
His work set new and higher aims for peptide synthesis, since it could faciUtate 
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medicine in the study of peptide hormones and other pharmacologically relevant 
peptides which exhibit a function in the regulation of life processes. 
Biologically active peptides were isolated apace, many requiring novel 
and improved methods for their solution synthesis. However, the expectations 
have taken longer than expected to come to fmition, and the synthesis of 
complex peptides is still as much of a challenge now as in the early half of the 
century. 
1.1. The biosynthetic origins of peptides and proteins 
Naturally occurring peptides and proteins are macromolecules assembled 
under nucleic acid control from the nineteen L-amino acids of general stmcture 
(2) and the imino acid L-proline (3). For a full list of the proteinogenic anuno 
acids and their coding systems (see Appendix, p.229). 
H R 3<: H2N' "CO2H ' N CO2H 
(2) (3) 
'Peptide' bonds (-CO-NH-) link the amino acids, forming macromolecules (4) 
containing 'polypeptide' backbones and diverse side chain functionalities 
depending upon the amino acid. Peptides, by definition, contain between two 
and fifty amino acid residues within their structure and, unlike proteins, 
naturally occurring peptides often include modified sequences. 
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-AA/'CONH 
These may be expressed as A^- or C- terminal modifications, or the inclusion of 
D or atypical anuno acids. The other common stmctural modification exhibited 
is the existence of the peptide in a cyclic or polycyclic form. These 
characteristics often bestow the conformational restrictions essential for 
biological activity and confer an increased resistance to enzymatic degradation. 
1.1.1 The formation of the peptide bond 
Nature synthesises peptides and proteins via stepwise assembly from the 
amino acid building blocks, and the organic chemist generally proceeds this 
way in the laboratory. However, the products formed by the uncontrolled 
solution synthesis of even a simple dipeptide (5), bearing no side chain 
functional groups, remains uncertain. 
HaNCHR^COjH H- H2NCHR^C02H — • H 2 N C H R ' C O N H C H R ^ C 0 2 H 
(5) 
The target product (5) would be accompanied by the dipeptides (6-8) and any 
polycondensation permutations from the four possible dipeptides. 
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H2NCHR^CONHCHR^C02H H2NCHR^CONHCHR^C02H 
(6) (7) 
H2NCHR^CONHCHR^C02H 
(8) 
A means of controlling the synthesis of (5) would require the blockade (or 
'protection') of the anune of one amino acid, and the carboxyl group of the 
other. Condensation of these two components followed by removal of the 
blocking groups (or 'protecting groups') from the intermediate (9) would afford 
the dipeptide (5) as one product (Scheme 1), the whole process requiring a 
minimum of four reactions. 
HjNCHR'COaH 
a 
P'-NHCHR^C02H 
V 
HoNCHR^OiH 
H2NCHR^0-0P2 
J 
~V" 
pi-NHCHR^CONHCHR^CO-OP^ 
(9) 
H 2 N C H R ' C O N H C H R 2 C 0 2 H 
(5) 
Conditions: a) protection; b) condensation; c) global deprotection 
Scheme 1. Controlled synthesis of a dipeptide 
Further elongation of the peptide can be accomplished by selective removal of 
the anune protecting group (Pi) over the carboxyl protecting group (P2) in an 
orthogonal manner (Scheme 2). 
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P'-NHCHR'CONHCHR^CO-OP^ 
(9) 
H2NCHR^C0NHCHR2C0-0P2 
P^-NHCHR^C02H 
P^-NHCHR^CONHCHR^CONHCHR^CO-OP^ 
H2NCHR^CONHCHR^CONHCHR^C02H 
(10) 
Conditions : a) Selective deprotection; b) Condensation; 
c) Global deprotection. 
Scheme 2. Controlled synthesis of a tripeptide 
An orthogonal system means one using two or more independent classes of 
protecting groups that are removable by differing chemical mechanisms.9,i0 
Stepwise selective deprotection, followed by condensation (or 
'coupling') with the next A^-protected amino acid can be repeated until the 
desired peptide is formed. The possibility of participation of side chain 
functional groups in the above reactions adds a further level of complexity to the 
procedure, which must be addressed if the synthesis is to proceed in an 
unambiguous manner. ConsequenUy there is a requirement for side chain 
protection which can be removed only at the very end of the synthesis. 
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Furthermore, all of the transformations in peptide synthesis must be performed 
without the loss of chirality at any of the a-centres, as production of often 
inseparable diastereoisomers then becomes an issue. Finally, the global 
deprotection of the finished peptide must be executed without destraction of the 
peptide backbone, or deleterious side reactions. 
The chemistry required to achieve these synthetic challenges has been 
attained and the solution phase synthesis of small peptides is now a reasonably 
efficient process. However, as the target peptide chain length increases, the 
efficiency of a solution based synthesis decreases rapidly. Solubility problems 
of the protected fragments leads to poor acylation rates resulting in low yields 
and high levels of impurities. Lengthy purification procedures are then required 
to isolate the target molecule, with the overall process becoming highly labour 
intensive and inefficient. The development of solid phase peptide synthesis 
(SPPS) attempted to address these problems. 
1.2 Solid phase peptide synthesis 
More than three decades ago the concept of solid phase peptide synthesis 
was introduced by Merrifield, 11 with the full experimental paper published in 
1963.12 The principle employed is outiined below (Scheme 3). 
The A^«-amine and side chain protected C-terminal amino acid of the 
target peptide was covalently attached to an insoluble resin support via an ester 
bond. The resin was thus acting in a dual faceted mode; as both a 
heterogeneous support and semi-permanent a-carboxy protecting group. The 
temporary a-amino protecting group was then removed allowing subsequent 
acylation of the resin bound amino acid with the second residue of the peptide. 
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PNHCH(R')C02H + Insoluble support I 
PNHCH(R')C02- Insoluble support 
11 
PNHCH(R^)C02H + NH2CH(R^)C02 Insoluble support 
111 
PNHCH(R^)CO NHCH(R^)C02 Insoluble support I 
IV 
PNHCH(R'')CO NHCH(R^)CO NHCH(R^)C02 Insoluble support 
NH2CH(R")CO NHCH(R^)CO NHCH(R1)C02H 
Scheme 3. General principle of SPPS. (i) attachment of 
protected amino acid to insoluble polymeric support; 
(ii) A^«-deprotection; (iii) coupling of second 
protected amino acid; (iv) repetition of (ii) and (iii) 
as required; (v) cleavage of peptide-polymer link and 
side chain deprotection. 
The A a^-amino protection utilised in the Merrifield approach was the acid 
labUe f-butoxycarbonyl- (Boc) group, the chemistry of which is discussed later 
(see section 1.5.1, p.l6). 
This sequential process was continued until the desired peptide sequence 
was completed. The most obvious advantage of this methodology was the 
ability to exploit large excesses of reagents in order to drive the acylation and 
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deprotection reactions to completion, after which any unused materials could be 
removed from the resin by a simple washing procedure. Secondly, since the C-
terminal amino acid was anchored to a heterogeneous solid support, the 
problems associated with purification of intermediates were effectively 
removed. 
1.3 The solid support 
The first naturally occurring peptide synthesised by Merrifield et a/i3 via 
solid phase methodology was bradykinin. In this example the solid support 
consisted of polystyrene strands cross-linked together by the inclusion of a 
small amount of divinylbenzene during the polymerisation process (Scheme 4). 
CH2CI 
Ph 
-I-
. - ^ = 
\ ^ 
+ 
Ph 
i) copolymerisation 
ii) MeOCH2Cl / SnC^ 
Ph 
ciCH2-^ y—^^ 
r ^ ^ = = ^ 
Ph Ph 
CH2CI 
(11) 
Scheme 4. Synthesis of the 'Merrifield Resin'. 
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FunctionaUsation of the inert resin via chloromethylation was essential in 
order to incorporate the first iV-protected amino acid residue. This was 
subsequently achieved via a nucleophilic displacement with the 
triethylammonium salt of the iV-protected amino acid to afford a benzyl ester 
type linkage. After completion of the required synthetic sequence, the peptide-
resin bond was cleaved via an acidolytic mechanism employing liquid HF with 
concomitant removal of the acid labile side chain protecting groups. 
This synthesis was indeed a landmark in peptide chemistry, taking just a 
few days to complete (it would probably have taken as many weeks using 
solution chemistry), and presented an ideal solution to the incredible demand for 
peptides in both pharmacological and other biological sciences. However, very 
little new chemistry appeared after the seminal 1964 Merrifield paper, and the 
technique was widely practised unchanged for a number of years. 
It was not until 1971, when Sheppard et al^'^ proposed that the growing 
peptide-polymer conjugate could be regarded as analogous to a graft co-polymer 
system consisting of various types of chains, that a major step-change in SPPS 
was realised. From this observation he argued that it would be advantageous 
for the polymer support to be chemically similar to the growing peptide chain. 
This would allow both the polymer and peptide to be well solvated by an 
appropriate polar solvent, forming an open gel system which permitted greater 
access of reagents to reactive sites. The Merrifield approach favoured the use 
of dichloromethane (DCM) as the solvent for swellmg the polystyrene resin core 
(11). Unfortunately, DCM does not adequately solvate the growing peptide 
chain and aggregation (depending upon both the sequence and choice of side-
chain protection) can often result, decreasing the availability 
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of reactive sites. From these considerations emerged the chemistry of the 
current Fmoc-polyamide system, 15,16 with the insoluble polymer matrix being 
synthesised from dimethylacrylamide (12), bisacryloylethylene diamine (13) 
and acryloylsarcosine methyl ester (14) (Scheme 5). Solid phase resins based 
on this polar polydimethylacrylamide support allowed peptide synthesis to be 
carried out using DMF as the solvent, thereby improving the overall solvation as 
originally proposed. 
C0NMe2 
C0NMe2 C0NMe2 
(13) 
CONHCH2 
COlSfHCH, 
CONHCH2 
I 
CONHCH2 
Me2NC0 
C0NMe2 CONCH2C02Me 
Me2NC0 CONCH2C02Me 
Me 
(12) Me (14) 
Scheme 5. Synthesis of polydimethylacrylamide resin. 
Conditions: Suspension co-polymerisation of 
dimethylacrylamide (12) with approx. 5% molar 
portions of the two other monomers performed in 
DCM/DMF/H2O at 50 OC, in the presence of cellulose 
acetate butyrate and ammonium persulphate. 
The polystyrene and polyamide based polymer matrices described above 
still provide the insoluble core of many modem solid phase supports. 
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1.3.1 Base resins commonly exploited in SPPS 
A selection of base resin supports commonly used in SPPS are 
illustrated below (Table I). 
Table 1. Base resins commonly exploited in SPPS. 
Solid support General comments Ref. 
Kieselguhr/polyamide Pressure stable, yet displays low 
(Pepsyn K) swelling properties due to the inorganic 17 
nature of the support. Fairly brittle so 
not very robust. 
PS/DVB copolymer Good swelling properties (up to five 18,19 
(1-5% cross-linking) times its dry volume) 
Poly[A'^ -{2-(4-hydroxy- Base resin support displaying high 
phenyl)ethyl}]acrylamide loading values. 20 
(Core Q) 
Poly(A^-acryloylpyrrol- Base resin support that swells well in 
idine)resins, PAP-and many solvents, e.g. H2O, DMF and 21,22 
SPARE-polyamide resins CH2CI2 
PolyHipe, PS/polydimet- High loading base resin support with 23 
hylacrylamide copolymer high pore volume and porosity. 
TentaGel, PEG-PS/DVB Displays excellent physical stabUity and 
co-polymer sweUs in a wide variety of solvents, e.g 24,25 
H2O, MeOH, MeCN, DMF and & 26 
CH2CI2. 
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1.4 The peptide-resin linker 
As stated earlier, the Merrifield approach to SPPS utilised both an acid 
labile A o^-amino and side chain protecting group strategy alongside an acid labile 
peptide-resin bond. Despite the latter requiring strong acid for its cleavage, 
significant acidolysis was observed during TFA mediated A^« -deprotection, 
resulting in premature loss of peptide from the insoluble support. 27 This 
deleterious side reaction prompted the development of resin modifications via 
electronically modulated linking reagents. The first example of this chemical 
tempering was demonstrated by the acylation of an aminomethylpolystyrene 
polymer matrix with the 4-hydroxymethylphenylacetic (16) acid linker to 
generate the so called PAM resin (17).28 
'•^J HOCH2—(\ /)-CH2C02H 
(16) 
HOCH2—(\ /)—CH2CONHCH2—^\ /? 
(17) 
Once formed, the acid stability of the benzyl ester linkage between an anuno 
acid and the resin support is substantially enhanced due to the electron-
withdrawing nature of the p-carboxamidomethyl substituent decreasing the 
potential to protonate the now electron denuded benzyl ester carbonyl.29 
However, the general hazards of HF use initiated the search for milder 
conditions with which to remove the completed peptide from the resin support. 
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and the development of the Sheppard's polydimethylacrylamide polymer 
matrix, coupled with the exploitation of the base labile 9-
fluorenylmethoxycarbonyl (Fmoc) (see Section 1.5.2, p. 19) amino protecting 
group allowed such an evolution to occur. 
In the Sheppard approach, the growing peptide chain is exposed to mild 
base treatment using piperidine during Fmoc group deprotection. Acid 
treatment is therefore only necessary for the final cleavage and deprotection of 
the target peptide from the resin. The orthogonal nature of this methodology 
allowed the development of a vast array of acid labile hnkers displaying a broad 
spectmm of physico-chemical properties (Table 2). 
Table 2. Commonly employed linkers in Fmoc based SPPS. 
Linker 
Wang Linker 
H0CH2—/ \ — 0 C H 2 - / \-^ 
4-Hydroxyniethylphenoxyacetic 
acid (HMPA) 
HOCH2-/ \—O-CH2-CO—5 
Rink Amide 
OCH3 NHj 
H j C C ^ S / ^ \ # ^ 0 - C H 2 - ! 
Cleavage 
Conditions 
95% TFA 
95% TFA 
95% TFA 
Cleavage 
Product 
Peptide 
Acid 
Peptide 
Acid 
Peptide 
Amide 
Ref. 
30 
31 
32 
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Table 2. Continued. 
Linker 
2-ChlorotrityIchIoride 
n 
T / -N 
°v 
I \ < 
^xJ^ 
o 
Rink Acid 
OCH3 OH 
f i T ^ 
H j C O ^ ^ / ^ ^^**^0-CH2-J 
Sieber Amide 
NH2 
^ ^ JL ^^^ 
i 1 ^ ll 1 
\ j # i « ^ 0 ^ ^ J * * ' * ^ 0 - C H 2 — ? 
Cleavage 
Conditions 
AcOH/TFE 
/DCM 
(1:1:8) 
20% AcOH 
in DCM 
1% TFA 
in DCM 
Cleavage 
Product 
Protected 
Peptide 
Acidt 
Protected 
Peptide 
Acidt 
Protected 
Peptide 
Amidet 
Ref. 
33 
32 
34 
t The extremely mild acid mediated cleavage 
conditions leave side-chain protecting groups 
intact, thereby allowing the synthesis of protected 
fragments. 
Two of the linkers illustrated in Table 2. afford a peptide amide upon 
cleavage. This requirement arose from the need to synthesise biologically 
active peptides expressing an amide function at the C-terminal, eg. vasopressin. 
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Historically, ammonolysis of a 4-hydroxymethylbenzoic acid linker was the 
common practise,35 (Scheme 6). However side reactions such as esterification 
were frequently reported, 36 and the newer acid-sensitive amide-producing 
linkers are now recommended. 
O 
Peptide —C O — C H 2 — ( \ / ) CONleNH(CH2)2NHCO— 
Ammonia 
Peptide 
t 
o 
•C—NH2 
Scheme 6. Peptide amide formation via ammonolysis of the 
4-hydroxymethylbenzoic acid linker. 
1.4.1 Continuous flow SPPS 
Larger scale production of A a^-Fmoc protected amino acids along with 
competitive pricing when compared with their N^^-Boc counterparts have 
contributed to the much wider acceptance of the Fmoc strategy towards SPPS. 
This was supported by reports of the superiority of the Fmoc strategy for the 
synthesis of difficult sequences.37 However, it was the ability to monitor the 
release of the cleaved Fmoc group at 300-320nm that tmly highlighted the 
advantage of this strategy, and allowed the development of automated 
techniques where acylation, deprotection and washes were monitored by UV 
spectroscopic analysis of the DMF solutions passing through the resin. 
Continuous-flow Fmoc SPPS, as it was termed, has since proved to be an 
15 
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efficient and reliable technique for the routine production of linear peptides and 
numerous manual and automatic synthesizers suitable for this approach are now 
available. 38 
A review and discussion of the current chemistry of amino acid 
protecting groups and protocols for peptide bond formation is essential in order 
to ascertain areas of SPPS which still require further development. 
1.5 Ar«-Amino protection 
Within the field of SPPS, A^a-amino protection must suppress the 
reactivity of the amine group by either decreasing its nucleophilicity or creating 
a steric barrier. The protecting group should be easily introduced, stable to the 
conditions of amino acid coupling and preserve the chiral integrity of any 
asymmetric centres. On completion of the aforementioned condensation, it 
should be easily removed under conditions that will not damage the rest of the 
peptide or peptide resin bond. A degree of compromise has frequently been 
necessary to meet these exacting requirements, as illustrated below. 
1.5.1 Acid-labile urethane protection 
The original use of A^«-urethane protection arose from the substantial 
racemisation observed39 upon carboxy activation of A a^-acyl protected amino 
acids such as A'^ a-formyHO and A^«-tiifluoroacetyl.4i Urethane protection can be 
regarded as both amide and ester in nature. As amides, they possess low 
nucleophilic reactivity at the nitrogen atom, and as esters, the -i-M effect of the 
ester oxygen reduces the -I effect of the amide and thereby renders the a-proton 
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less acidic, dramatically reducing the risk of racemisation during coupling. 
Urethane protection, unlike amide protection, also displays the advantage of 
mUder acidolytic cleavage conditions, thus making deprotection less deleterious 
to the growing peptide chain. The first successful urethane type protecting 
group was the benzyloxycarbonyl (or 'carbobenzyloxy', Cbz or Z) group 
(18).42 
\ ^ 
Unfortunately, the strong acid required for its removal (HBr/AcOH)43 dictated 
its unsuitability as an A^«-protecting group in SPPS. 
The Merrifield approach to SPPS utiUsed a benzyl ester Unkage between 
the C-ternrunal carboxylic acid of the peptide and the resin support, again 
necessitating the use of a strong acid for its final cleavage. The semi-permanent 
A^a-protection therefore had to be removed under nulder acidic conditions, 
mling out reagents like the Z group. Consequently the A^a-?-butoxycarbonyl, or 
Boc group (19)44 was chosen, which merely required exposure to 50% TFA in 
DCM at room temperature for 30 min. for its removal, (Scheme 7). 
The mild acid labiUty of the Boc group can be explamed mechanisticaUy 
by the ease of formation of the relatively stable ?-butyl carbocation in an Sj\fl 
type process, following protonation of the urethane carbonyl. The resulting 
unstable carbamic acid intermediate spontaneously decomposes to yield the 
amine as its corresponding TFA salt. In the Merrifield approach to SPPS, the 
trifluoroacetate salt is neutralised by exposure of the peptide-resin to 5% DIEA 
17 
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in DCM, regenerating the amine for subsequent coupling to the next amino acid 
residue . 
" " > . . , 
O 
,A, TFA 
H 
(19) 
'"'... 
'Nuc 
+ 
OH 
"'/-.. 9L. O V N-'vv' 
H 
H2N./wr 
> 
Scheme 7.TFA mediated deprotection of the N-Boc protecting group. 
A common obstacle of most acid sensitive protecting groups is the 
potential alkylation of amino acid side chains by the carbocation generated 
during the deprotection. This is marufested by electrophiUc aromatic substitution 
of the phenol in tyrosine or the indole in tryptophan. Altematively, products 
formed with the deprotection solvent, e.g. tert-butyl trifluoroacetate,45 can act 
as alkylating agents. The remedy to this problem lies in the addition of cation 
scavengers to the deprotection medium,46 and this is discussed in more detail 
later (see Section 1.11.6, p.58). 
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1.5.2 Base-labile urethane protection 
The problem of side chain alkylation and possible damage to the peptide 
by strong acids led to the exploration of alternative deprotection procedures to 
acidolysis. Carboxyl-protection using ethyl esters containing election 
withdrawing substituents at their p-carbon (20) provided the necessary template 
for adaption to an amine protecting group47, 48. in the presence of base, proton 
abstraction occurs and the resulting carbanion p-eliminates to form, in the case 
illustrated, a vinylsulfone and the carboxylic acid (Scheme 8). 
11 %^y^ Base 
' ^ „ . 
R O Y R' R-" ^O 
H 
(20) 
Scheme 8. Base catalysed deprotection of a p-sulphone ester. 
Transposition of this mecharusm to a urethane led to the development of the 9-
fluorenylmethyloxycarbonyl (Fmoc) group49,50 (21), where the p-carbon is, in 
this example, part of the fluorenyl ring system. 
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The Fmoc group is very stable to acidic reagents, yet is readUy cleaved 
at room temperature under basic conditions, e.g. 20% piperidine m DMF. The 
cleavage proceeds through an Elcb type mechanism, via the stabilised 
dibenzocyclopentadienide anion (Scheme 9). The dibenzofulvene (22) produced 
reacts with piperidine to form the adduct (23) as the co-product. 
H2N«'w« 
Scheme 9. Piperidine mediated deprotection of the A -^Fmoc group. 
20 
Introduction 
The Boc and Fmoc amino-protecting groups, both based on urethane 
chemistry, have between them dominated the field of SPPS for almost three 
decades, and will probably continue to do so. They both exhibit good stabiUty 
and mild cleavage conditions, with carboxy activation and coupUng normally 
proceeding with retention of chiral integrity. There are however, other amino 
protecting groups which meet these requirements and these are beginning to 
gain popularity in modem SPPS. 
1.5.3 The A^-l-(4,4-dimethyl-2,6-dioxocyclohex-l-ylid-
ene)ethyl (Dde) protecting group 
Vinylogous amides have found some appUcation as amine protection in 
peptide synthesis using p-dicarbonyl compounds, such as pentane-2,4-dione, as 
the protecting group5i. 52. However, their lability to aqueous and weakly acidic 
conditions limited their use. The interest in vinylogous amides was rekindled 
with the initial introduction of the A^-(4,4-dimethyl-2,6-
dioxocyclohexylidenemethylene (Dmc)53 group (24), quickly followed by its 
successor, the A^-l-(4,4-dimethyl-2,6-dioxocyclohex-l-ylidene)ethyl (Dde) 
group54 (25). 
\ / \ / 
O H Oini'H 
(24) (25) 
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The Dde group is stable to acid and many bases, including piperidine, but is 
readily removed at room temperature by dinucleophiles such as hydrazine 
(Scheme 10). The process being aromaticity driven by the formation of the 
deprotection by-product 3,6,6-trimethyl-4,5,6,7-tetrahydro-lH-indazol-4-one 
(26). 
H2N—NH2 
+ H+ 
H, 
H2N-rt/\/' 
N ' 
(26) H 
Scheme 10. Deprotection of die Dde amine protecting group 
using the dinucleophile hydrazine. 
Dde's stability to piperidine introduces a level of orthogonality to the 
Fmoc protecting group, and thus can be exploited in amino acids possessing 
two amine functions within their stmcture, e.g. lysine and omithine. Difficult 
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synthetic targets such as cyclic peptides,55 multiple antigenic peptides56 (MAPs) 
and spider toxins57 have all benefitted from this orthogonality in their solid 
phase assembly. 
1.5.4 The A^-allyloxycarbonyl (Alloc) protecting group 
The development of '71-allyl palladium complex' chemistry has led to a 
powerful and increasingly exploited means of protection strategy in orgaruc 
chemistry.58 Thus, allyl carbamates,59 or any function possessing an acidic 
leaving group, can be readily cleaved via an irreversible Pd(0)-catalysed tiansfer 
of the allyl moiety to an acceptor nucleophile, e.g. dimedone (Scheme 11). 
r^ 
\f OCONHR 
L = (Ph3P)4 Pd(0)L 
+ Nuc 
v^ 
Nuc 
R—NH2 
Scheme 11. Pd(0) catalysed Alloc cleavage. 
Kunz first introduced the Alloc protection for the a-amino group in 
solution phase peptide synthesis,60,6i and recently a few AUoc based soUd 
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phase syntheses have been reported.62-64 For the solution phase peptide 
synthesis, standard nucleophilic reagents such as dimedone or morphoUne have 
proved highly successful. Unfortunately, these did not prove as efficient in 
SPPS where side reaction free cleavage of the Alloc group was essential.62,63 
Instead use of premixed 8eq:3eq trimethylsilylazide/tetrabutylammonium 
fluoride (TMSN3/Bu4NF[3H20]) and 20mol% Pd(PPh3)4 has been 
demonstrated to quantitatively cleave resin bound A -^Alloc protected peptide 
fragments.65 
1.6 Amide bond protection in SPPS 
Over 20 years ago it was recognised that certain peptide sequences 
posed special problems associated with their solid phase synthesis.66 These 
have subsequently become termed 'difficult sequences'67 and are postulated to 
arise from the inter-chain association of resin-bound peptides into extended p-
sheet structures.68 The ensuing steric hindrance leads to a serious reduction in 
reagent penetration resulting in significant decreased reaction rates in both 
acylation and deprotection processes.69,70 
Chain association had been observed when both polystyrene7i and 
polydimethylacrylamide-amide72 resins were employed for SPPS. However, 
the observation that replacement of secondary by tertiary amide bonds prevented 
this hydrogen bonded association of resin bound peptide chains,73 led to the 
development of a reversible A/^ -amide protecting group, namely the A -^(2-
hydroxy-4-methoxybenzyl) (Hmb) (27) group.74 The 2-hydroxy substituent is 
the essential feature of the reagent. 
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o 
OH N K 
MeO' 
(27) 
During coupling to a resin bound AT-Hmb derivatised amino acid, itntial 
acylation occurs via an intemally base catalysed mechanism onto the phenolic-
OH. This is then followed by an intramolecular O -^N acyl transfer74 (Scheme 
12), to yield the fully protected dipeptide fragment (28). 
FmocHN^ R' O 
OH HN R 
FmocNHCH(R')C02H 
MeO' MeO 
FmocHN 
OMe 
(28) 
Scheme 12. Two step acylation of a resin bound Hmb-derivatised amino acid. 
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N-Substituted amino acids tend to exhibit massive steric hindrance 
towards subsequent acylation.75 Despite the intramolecular acyl transfer 
described, 0-acylation tends to be slower than normal A^-acylation. Therefore 
care must be exercised in the selection of amino acid residues within the target 
peptide that are to be protected with the Hmb group, to ensure quantitative 
incorporation of the next residue proceeds efficiently. 
The Hmb group is removed under the normal conditions required for 
cleavage and side chain deprotection of peptides synthesised via the Fmoc/tert-
butyl strategy, however acylation of the Hmb group with acetic anhydride in 
the presence of DIEA, greatly increases its acid stability, allowing backbone 
protected fragments also to be isolated.76 
Hmb protection of residues sequentially preceeding aspartic acid has 
also been demonstrated to prevent aspartimide formation,77 and coupled with its 
general applications to SPPS this group has received significant attention.78-80 
1.7 Carboxy protection 
In the context of SPPS, the C-terminal carboxylic acid is effectively 
protected during the synthetic sequence by the resin-linker support. Side chain 
carboxylic acids, present in aspartate and glutamate residues, are also blocked 
during the synthesis by protecting groups displaying a similar orthogonality 
towards the deprotection conditions of the semi-permanent A^«-protecting group 
employed as that of the Unker (see section 1.8, p.29). 
However, the abUity to protect/deprotect either the a- or side chain 
carboxyl groups of such residues in an orthogonal manner to either Boc or 
Fmoc deprotection potentially allows for the synthesis of atypical peptides. 
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1.7.1 Allyl ester protection 
Exploitation of 'n-allyl palladium complex' chenustry with respect to 
carboxyl protection has proved as effective as that of the A -^Alloc group. 
Displaying a similar orthogonal deprotection mechanism as that of the carbamate 
reagent, the allyl ester has been successfully exploited in the solid phase 
synthesis of many atypical peptides.8i.82 
1.7.2 The 4-{A^-[l-(4,4-dimethyl-2,6-dioxocyclohexyli-
dene)-3-methylbutyl]amino}benzyl ester(ODmab) 
protecting group. 
Utilising the A -^Dde amino protecting group, it was reasoned that the 
combination of its deprotection characteristics with the weU documented labiUty 
of 4-aminobenzyl esters,83 should furnish a novel carboxy-protecting group. 
From this hypothesis emerged the reagent, 4-{N-[l-(4,4-dimethyl-2,6-
dioxocyclohexylid-ene)-3-methylbutyl]anuno} benzyl alcohol (29) and hence 
the 4- {N-[ I-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino} 
benzyl ester (ODmab) protecting group (30).84 
The ODmab protecting group is stable to both TFA and 20% piperidine 
in DMF, but is quantitatively removed with 2% hydrazine monohydrate in DMF 
within minutes (Scheme 13). 
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••nil 
2% Hydrazine.H20 
in DMF 
R 
cM 
(31) 
NH2 
o + NHo 
R—CO2 
Scheme 13. Hydrazine mediated ODmab deprotection. 
The dinucleophilic reagent initially removes the vinylogous anude in a 
transamination type process, foUowed by spontaneous collapse of the resultant 
4-aminobenzyl ester (31) via a 1,6 electron pair shift to reUnquish the 
carboxylic acid. 
The ODmab group has been subsequently utilised in cyclic peptide 
synthesis by incorporation onto the a-carboxyl of aspartic acid of Fmoc 
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-Asp(0'Bu)-OH via a carbodiimide mediated condensation. Removal of the 
side chain protection and subsequent coupling of the free carboxylic acid to 2-
chlorotrityl chloride polystyreneSS then allowed Fmoc deprotection and 
construction of the linear peptide. Final deprotection of the A -^terminus with 
piperidine and the C-terminal with hydrazine, allowed the DCC-HOAt mediated 
coupling of the two unmasked groups to yield the cyclic product in good 
yield.84 
1.8 Side chain protecting groups 
More than half the amino acids commonly encountered in peptides and 
proteins contain functional side chains. These include carboxylic acids 
(aspartic and glutamic acid); basic residues (lysine, arginine, histidine); 
hydroxyl/phenolic groups (serine, threonine, tyrosine); sulphur containing 
amino acids (cysteine, methionine); and finally heterocyclic side chains 
(tryptophan and histidine). Due to the potential ability of these side chain 
functional groups to participate in side reactions during anuno acid coupUngs, 
their semi-permanent protection is required. These protecting groups must be 
stable to coupling conditions and the deprotection conditions for the semi-
permanent A a^-amino masking group. Upon completion of the peptide/protein 
synthesis, they should ideally be removed in a global manner, along with the 
carboxy terminal protecting group. A vast artay have been reported in the 
literature but we will concern ourselves with those that have become favoured 
for solid phase peptide synthesis. 
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1.8.1 Side chain protection employed in Boc SPPS 
Table 3. Commonly employed side chain protection in Boc SPPS. 
Amino 
Acid Side chain protection 
Abbrevi-
ation 
Deprotn. 
Condition Ref. 
Ser 
Thr 
Benzyl ethers 
RO \ / 
Bzl HF(,) 0 OC 
Tyr 
2,6-Dichlorobenzyl 
ether 
CI 
RO 
2,6-Dcb HF(,) 0 »C 
CI 
Cys 
S-4-Methyl-Benzyl 
RS \ / 
-Me 4-MeBzl HF(,) 0 OC 
5-Acetamidomethyl 
o 
RS' • A Acm Hg2+or I2 86 
Asnt 
Glnt 
A^-Trityl 
RHN-
Trt 
\ ^ 
TFA 87 
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Table 3. continued 
Amino 
Acid 
Lys 
Arg 
His 
Asp 
Glu 
Trp 
Side chain protection 
2-Chlorobenzyl-
oxycarbonyl 
0 ^ ^ ^ ^ 
Km^o^yj 
a 
iVff-/»-Toluenesulphonyl 
NH 
H [\Y_/ 
o ^—' 
A^im.^;.Toluenesulphonyl 
0 — 
Benzyl ester 
A-O 
Cyclohexyl ester 
T 
o 
N'-Formyl 
i^^ 
7^ 
% / ^ / 
CHO 
Abbrevi-
ation 
2-ClZ 
Tos 
Tos 
OBzl 
OcHex 
For 
Deprot". 
Condition 
HF(,) 0 OC 
HF(,) 0 OC 
HF(,) 0 OC 
HF(,) 0 OC 
HF(,) 0 OC 
HF/Me2S 
('low' HF 
cleavage) 
Ref. 
88-
91 
92 
93 , 
94 
• 
95 , 
96 
97 
31 
Introduction 
t Asn and Gin side chain protection is generally not necessary 
although its inclusion protects against dehydration during 
coupling. The A -^trityl group is removed during A a^-Boc 
deprotection. 
1.8.2 Side chain protection employed in Fmoc SPPS 
One of the foremost advantages inherent in the Sheppard approach to 
SPPS is the absolute orthogonality displayed between the A'^ -a-Fmoc protecting 
group and the side chain protecting groups; the former being removed with base 
treatment and the latter requiring exposure to mild acid. Hence, premature loss 
of the side-chain moieties during A «^-Fmoc deprotection is not problematic, 
unlike the Boc based methodology. The most commonly exploited side-chain 
protecting groups in Fmoc based SPPS are illustrated below (Table 4). 
Table 4. Commonly employed side chain protection in Fmoc SPPS. 
Amino 
Acid 
Ser 
Thr 
Tyr 
Lys 
Asp 
Glu 
Side chain protection 
/-Butyl ethers 
/-Butoxycarbonyl 
R N H ^ O - ^ " 
NButyl 
RCOj— 
esters 
Abbrevi-
ation 
'Bu 
Boc 
O-'Bu 
Deprotn 
condition 
TFA 
TFA 
TFA 
Ref. 
-
44 
-
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Table 4. Continued. 
Amino 
Acid Side chain protection 
Abbrevi-
ation 
Deprot" 
condition Ref. 
Cys 
S-Trityl 
Trt 
RS-
\ / 
S-Acetamidomethyl 
o 
RS N 
H 
A 
TFA 98 
Acm Hg2+orl2 86 
Asn 
Gin 
A^-Trityl 
RHN-
Trt 
\ / 
TFA 87 
A^^-2,2,5,7,8-Pentamethyl-
chroman-6-sulphonyl 
NH 
Arg RNH ^ - 1 - ^ Pmc TFA 99 
iV«-/-Butoxycarbonyl 
Trp Boc TFA* 100 
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Table 4. Continued. 
Ammo „ . . , . ^ .^ Abbrevi- Deprot" _ „ 
. . , Side chain protection ,. ,. . Ref. Acid ation condition 
t deprotection with TFA yields a carbamic acid intermediate 
which protects against alkylation during peptide 
cleavage/deprotection. Decarboxylation ensues during 
aqueous work up. 
1.9 Synthetic methods of peptide bond formation 
Generally, solid phase peptide bond formation involves the aminolysis 
of the reactive carboxy component (-COX) of one amino acid with the free 
amine of another resin bound amino acid (Scheme 14). 
O 
II r> 
RCO2H • R—C—X • R — C O N H — O + ^^ 
HoN- O 
Scheme 14. Simplified representation of peptide bond formation. 
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Conversion of the carboxylic acid into an acylating agent requires replacement 
of the hydroxyl group by an election withdrawing substituent (X). Polarisation 
of the carbonyl group is thus enhanced creating a more electrophiUc carbon 
centre, thereby facilitating the nucleophilic attack of the amine group of the 
amino acid to be acylated. 
The level of activation must be sufficient to promote fast, unambiguous 
coupling, yet not excessive so as to cause 'overactivation' of the carboxy 
component. If this occurs, then intramolecular attack by the weakly 
nucleophilic protected amine is a real risk. An excellent example is the 
formation of an N-carboxyanhydride (NCA) (33) when a Z-protected amino 
acid is activated to the corresponding acid chloride (32), Scheme 15.102 
Scheme 15. A'^-Carboxyanhydride formation from a Z-
protected amino acid chloride. 
The three general methods for coupling are; 
1) Formation of the reactive acylating agent from the carboxylic acid in a 
separate step or steps, followed by immediate treatment with the 
amine. 
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2) Formation of the reactive acylating agent separately, in a form which can be 
both isolated and even purified before aminolysis. 
3) Formation of the reactive acylating agent in the presence of the amine, by 
introduction of an activating (coupling) agent to a mixture of the two 
compounds. 
It is important to note that the distinctions between the above are blurred, with 
the underpinning chemistry being essentially universal. 
1.9.1 Via anhydrides 
Treatment of an amine, or any nucleophile, with an anhydride of a 
carboxylic acid is one of the most simple and efficient methods of acylation. 
Acetylation using acetic anhydride was common practise amongst synthetic 
chemists, yet the use of anhydrides for peptide synthesis played no part in the 
earliest experiments. This was presumably owing to the requirement of two 
moles of protected anuno acid to form one mole of activated species. Certainly 
a wasteful process, yet now, with protected amino acids being prepared in a 
cheap and efficient manner, the use of symmetrical anhydrides (34) is more 
frequently applied. 103 
P 
R 
1 
0 
R 
1 
-Y--
0 
P P 
R 
1 
HN'"'^ Y 
0 
. 0 . 
0 
• • I I I ! 
(34) (35) 
Formation of the peptide bond via mixed or unsymmetrical anhydrides e.g. 
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(35) gained popularity after their introduction by Chantrenne in 1947.104 These 
particular intermediates are designed such that the protected amino acid is 
practically the sole acylating species, while the second acid of the anhydride is 
eliminated. The physicochemical basis behind this mode of selective aminolysis 
requires a decrease in the reactivity of the unwanted partner within the 
anhydride. Branched alkyl chain acids, such as isovaleric acidios (36) and 
trimethylacetic (pivalic) acidi06 (37) fulfilled these requirements. 
O 
OH 
(36) (37) 
A further extension of this mode of activation was attained by the use of 
alkyl chloroformates to form the reactive intermediates, e.g. isobutylcarbonic 
acid mixed anhydrides,i07 (Scheme 16). 
O R' 
R O (>99%) 
+ ( C H 3 ) 2 C H - C H 2 0 H + CO2 
+ ^ H - C H ( R ) - C 0 2 H 
O (<1%) 
Scheme 16. Dipeptide formation via isobutylcarbonic acid mixed anhydride 
activation. 
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In this example, undesired attack of the amine at the carbonic acid carbonyl, 
route (b), is suppressed since its electrophUicity, and thus its reactivity, is 
substantially reduced by the unshared pairs of electrons on the neighbouring 
oxygen atom. 
Mixed anhydrides formed from an A^-protected amino acid and 
diphenylphosphinyl chloride 108 are extremely reactive and more regioselective 
than the mixed carboxylic and carbonic anhydrides. Aminolysis occurs 
exclusively at the amino acid carbonyl, even when steric factors might normally 
dictate otherwise. 
1.9.2 Via carbodiimide reagents 
Since its inception in 1955,109 dicyclohexylcarbodiimide, DCC, (38) has 
achieved global recognition as one of the most important agents for carboxy 
activation in peptide synthesis. The primary mode of activation involves 
addition of the carboxylate anion to the carbodiimide functionality to generate an 
(9-acylisourea (39), which is a powerful acylating species (Scheme 17). 
R 
O 
O 
O 
R A. H NH I 
O — C 
II 
N 
H 
(39) 
Scheme 17. Carbodiimide mediated activation of a carboxylic acid. 
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Peptide coupling simply requires mixing of an A -^protected amino acid, 
resin bound amino acid and DCC in an anhydrous organic solvent at or a littie 
below room temperature. 0-Acylisourea generation proceeds rapidly, with 
peptide formation occurring via direct aminolysis of the above species, or via 
the symmetrical anhydride (Scheme 18). 
P i N ^ 
H* >r 
R 
0 
X 
R' 
^N C O . — ^ 
Scheme 18. Carbodiinude mediated dipeptide formation via 
the (a) symmetrical anhydride or (b) direct 
aminolysis of the 0-acylisourea intermediate. 
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The main drawback to the use of DCC is the formation of the 
dicyclohexylurea by-product, which is orUy sparingly soluble in most common 
solvents and therefore thorough washing of the resin is essential. Alternative 
carbodiimides which form DCM soluble ureas are now more commonly 
employed, e.g. dUsopropylcarbodUmide (DIPCDI) 110,111 
A perturbing side reaction associated with carbodiimides is the 
intramolecular rearrangement of the 0-acylisourea to the AT-acylurea (40) 
(Scheme 19). 
(40) 
Scheme 19. Intramolecular A -^acylurea formation. 
This side reaction can significantiy lower the yield of the coupling unless large 
excess of the acylating species and activating reagent are employed, a distinct 
advantage of solid phase methodology. The final problem associated with 
carbodiimide couplings is substantial racemisation of the activated amino acid 
(see Section I.IO. p.5l). 
These side reactions can be greatiy reduced by the intioduction of an 
auxiliary nucleophile, such as iV-hydroxysuccinimideii2 (4 1) or 1-
hydroxybenzotriazoleii3 (42) (HOBt). These reagents wiU rapidly react with 
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the 0-acylisourea before the above side reactions occur. 
O 
HO—N 
O 
(41) 
Ideally an acylating agent, such as (43), of decreased reactivity is 
formed, which is still adequately electrophiUc in nature with respect to 
subsequent aminolysis, yet does not racemise or participate in alternative side 
reactions. 
R 
[gHN-" Nf^^ '^N^^ '^N 
O 
\ / 
(43) 
The ability of additives such as HOBt to provide alternative pathways to 
the required product, whilst continually being regenerated and providing the 
kinetic drive for completion of the coupling with minimum deleterious side 
reactions, makes this a powerful reagent for the peptide chemist (Scheme 20). 
1.9.3 Via phosphonium and uronium reagents 
The success of HOBt as an auxiUary nucleophile initiated the 
development of coupling reagents for the in situ generation of benzotriazolyl 
esters. 
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R—CO2H + DCC 
O 
N H 
H 
R—CO2H 
O O 
R ^ O - ^ R 
H2N—R' 
O 
HOBt 
H2N—R' 
O 
.A.,.^ ' 
R N 
H 
N = N 
A..^ ' R-"^  N ' 
H 
Scheme 20. The role of the auxiliary nucleophile HOBt in the 
DCC mediated formation of a peptide bond. 
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Benzotiiazol- l-yloxy-tris-dimethylaminophosphonium hexafluorophos-
phate (BOP) (44), 114 and more recently 0-(benzotriazol-l-yl-l,l,3,3-
tetramethyluronium salts, HBTU (45) and TBTU (46)ii5 displayed this 
mechanistic requirement. 
P[N(CH3)2]3 
PFfi 
(44) (45) X=PF6 
(46) X=BF4 
A typical coupling requires addition of an equivalent of the reagent to a 1:1 
nuxture of the two protected amino acids, in a suitable solvent, in the presence 
of a tertiary amine. The coupling proceeds via the intermediary benzotriazolyl 
ester (Scheme 21). This method of coupling affords excellent yields with few 
side reactions and low, but not always acceptable, levels of racenusation. 
Recentiy, the pyridyl analogue of HOBt, namely 7-azabenzotriazole (47)ii6 
(HOAt) and its uronium salt HATU (48) have revealed themselves as more 
efficient reagents; accelerating coupling processes, reducing the loss of chiral 
integrity even further and providing visual evidence (yellow to colourless) of the 
reaction end-point. 
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(45)X=PF6 
(46) X=BF4 
<r^ 
N ^%:A 
HN 
R 
H 
' ' I 
HN 
N . .COj—I 
°=< 
N(CH3)2 
N(CH3)2 
iProEtNIf" X" 
O R' 
OH 
I 
N. 
Scheme 21. HBTU/TBTU mediated mechanism of dipeptide formation. 
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Reaction rates of HOAt esters appear to be enhanced with respect to the 
HOBt esters and although precise mechanistic details have not been established, 
it has been postulated that the neighbouring group effect, as shown in (49) 
plays a prominent role. 
H O 
N " i C ^ O 
(49) 
1.9.4 Via active esters 
Unlike anhydrides, esters possess only one electrophiUc centre available for 
nucleophilic attack, thus reducing the ambiguity of aminolysis. It was realized 
in the early 1950's that the process of aminolysis of a protected amino acid ester 
would be expedited if the ester had a good leaving group; e.g if they were esters 
of phenols or similar acidic moieties. Pentafluorophenyl (50)ii7 or 
succinimidyl (51)us esters are two examples of stable crystalline compounds, 
which meet this requirement and are convenient to use and store. 
HN 
(50) 
HN 
O 
O — N 
O 
(51) 
r 
45 
Introduction 
1.9.5 Via N-carboxyanhydrides 
A -^Carboxy or Leuchs' anhydrides of a-amino acids (NCAs) (52),ii9 
are readily obtained by treatment of the amino acid in question with phosgene, 
or as mentioned in section 1.9, decomposition of alkoxycarbonyl-a-amino acid 
chlorides (Scheme 15). 
Provided conditions are carefully controlled, NCAs can be employed for peptide 
synthesis in aqueous media (Scheme 22). Nucleophiles attack predominately at 
the carbonyl of the amino acid, with acylation being rapidly followed by 
decarboxylation of the carbamic acid intermediate (53). 
H^ 
CO2 
H2N 
(53) 
Scheme 22. An example dipeptide synthesis using an NCA. 
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The ease and simplicity of this regime attracted the interest of many 
investigators at the time. 120-124 However, premature decarboxylation of the 
unstable carbamic acid intermediate (53), before aminolysis is complete, can 
lead to double incorporation of the same amino acid residue since the free amine 
generated can attack any unreacted NCA still present. 122 
A recent development has attempted to circumvent this problem by 
utilising urethane protected NCAs.125-127 Fmoc and Boc protected NCA 
derivatives are normally crystalline compounds exhibiting good stabUity even in 
DMF solution. Aminolysis and subsequent decarboxylation of the carbamic 
acid intermediate (54) results, in this case, in the formation of a urethane 
protected peptide which cannot participate in any further reactions (Scheme 23). 
Fmoc 
O^ O 
(54) 
R 
•vH H 
„+l Fmoc^ / ^ ^ N \ A O 2 -
O R' 
CO2 
Scheme 23. Peptide coupling using an Fmoc protected NCA. 
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1.9.6 Via acyl halides 
Both A^-protected amino acid chlorides and fluorides have received 
considerably attention. 
1.9.6.1 Amino acid chlorides 
The chloride ion seemed an ideal choice for the role of the electron-
withdrawing substituent. The powerful activation displayed in acid chlorides 
was well established when Fischer both prepared and utilised amino acid 
chlorides (55) in coupling reactions. 128 
R 
C\ 
HN'" 
O 
(55) 
The reagents required for acid chloride synthesis (thionyl chloride, phosphorous 
pentachloride, etc.) were however, too vigorous, and were capable of affecting 
side chain functionalities, e.g. they can convert the carboxamide group in 
asparagine to a nitrile. Coupled with the problem of NCA formation from Z-
protected acid chlorides, 102 and significant racemisation via oxazolone 
formation from simple A/-acyl amino acid chlorides (Scheme 15), it was hardly 
surprising that this method of activation lost its popularity. This position has 
been dramatically altered by the recent discovery that A^ o^ Fmoc protected amino 
acid chlorides are simple to prepare, and are stable to the acid chloride 
preparation with thionyl chloride. 129 Fmoc amino acid chlorides are 
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stable crystalline compounds offering rapid acylation rates (in the presence of 
pivalic acid/TEA or HOBt/DIEA) with low levels of racenusation reported, i so-
ns 
1.9.6.2 Amino acid fluorides 
The potential offered by amino acid chlorides unfortunately did not 
extend to any residues bearing side-chain protection containing the tert-butyl 
moiety. For example, Fmoc-Asp(0'Bu)-OH reacts with thionyl chloride to 
form the cyclic anhydride (57) presumably via the acid chloride intermediate 
(56) (Scheme 24). 
FmocHN ^C02H 
FmocHN 
(57) 
Scheme 24. Side-reaction during acid chloride generation 
from Fmoc-Asp(0'Bu)-OH. 
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However, the well documented stability of tert-butyl fluoroformate 
compared to the corresponding chloro analogue, 134,135 inspired Carpino et at to 
investigate Fmoc amino acid fluorides as an alternative. 136 Using the 
commercially available cyanuric fluoride, 137 Fmoc-Asp(OfBu)-OH gave the 
corresponding acid fluoride as a stable, crystalline solid. This was also the case 
for all Fmoc anuno acids bearing tert-butyl side-chain protection containing the 
f erf-butyl moiety. 
This means of carboxy activation has subsequently been demonstrated to 
afford efficient, fast-acting coupling reagents for both solution and solid phase 
peptide synthesis, being particularly valuable in the case of hindered amino 
acids, or those containing a, a-dialkyl substituents.i38-i4i A recent publication 
highlighted the methodology available to generate Fmoc amino acid fluorides in 
situ using tetramethylfluoroformamidinium hexafluorophosphate (TPTH) (58) 
(Scheme 25).i42 This overcame the problem that suitably side-chain protected 
His and Arg residues could not be converted to shelf-stable amino acid 
fluorides. 
Me2N 
Me2N 
A P pp^- FmocNHCH(R)C02H/B:^ FmocNHCH(R)COF 
(58) o 
A. 
Me2N NMe2 
Scheme 25. TFFH mediated in situ generation of an Fmoc 
amino acid fluoride. 
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1.10 Racemisation 
Within the field of peptide chemistry the term racemisation covers both 
the strict definition (conversion of a single enantiomer to a mixture of 
enantiomers) and epimerisation, i.e. loss of chiral integrity at one of two or 
more chiral centres within a molecule. With the exception of glycine, all the a-
anuno acids that are constituents of proteins are optically active at the a-carbon 
atom. To obtain an enantiomerically pure target peptide via synthetic 
methodology, chiral integrity must remain intact throughout the various 
operations during the synthesis. If this criterion is not fulfilled, a complex 
mixture will be produced and subsequent separation and purification of the 
target peptide from a mass of similar compounds becomes an onerous task. 
Racemisation is predominately a base-induced process and is generally 
only a concern at the activation and coupling stages of synthesis. The two chief 
mechanisms are dUect enolisation and oxazolone formation. 
1.10.1 Direct enolisation 
Carboxyl activated AT-protected a-amino acids suffer from extension of 
the electron-withdrawing effect of the activating group (X) through to the a-
carbon atom, thus facilitating a-proton abstraction in the presence of a suitable 
base (Scheme 26). This mode of racemisation is a unimolecular process and 
occurs most readily when (X) is strongly electron withdrawing, and 
activation/coupling is carried out in a polar aprotic solvent such as DMF. 
Danger of racemisation is over once coupling is complete, so apart from certain 
specific anuno acids and couplings that are renowned for their slowness, the 
degree of racemisation produced by this route is very slight. 
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tBase ( a ) ^ H ^ 
R H 
BaseH-" 
H -Iv '^^. W.o^COX R 
(b)^ H^ 
R H 
Scheme 26. Carboxy-activated amino acid racemisation via direct enolisation 
1.10.2 Oxazolone formation 
This is the most frequently invoked route of racenusation encountered in 
peptide synthesis, and is highly detrimental to the chiral integrity of AT-acyl 
protected amino acids or the C-terminal of a peptide chain upon activation 
(Scheme 27). 
R H P 
HN 
R' 
X =5S= 
R O 
^ O 
R' 
R H O 
\ ^ // 
N. ,0 
HX R' 
(59) 
Scheme 27. 5(4//)-Oxazolone formation under basic conditions. 
Proton absti:action from the chkal centre affords a resonance stabilised anion 
that was initially postulated and subsequently proven by ir spectral 
measurementsi43 (Scheme 28). 
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^ o 
N ^ . 0 = ^ 
R' 
(59) 
R O 
N ^ ,0 
R' 
R o 
H 
N . . 0 
R' 
(60) 
H2N. 
O R 
.AA/'NHo 
o 
H H 
N. 
'^ R'^ ^ N^ Y ' " ^ 
O O 
Scheme 28. Base mediated racemisation of an 5(4//)-oxazolone. 
As shown, the oxazolones formed, (59) and (60), are themselves activated 
towards aminolysis, with reaction leading to peptide bond formation. 
However, racemisation proceeds at a faster rate when compared to the latter and 
any peptide produced is substantially racemised. 
When the amino protecting group is urethane in nature, oxazolone 
formation is not such a facile process. Until recently it was assumed that these 
particular compounds did not produce oxazolones and were therefore resistant 
to racemisation during activation and coupling. Isolation of optically pure 
oxazolones from the reaction of Boc-L-valine with water soluble 
carbodUmidesi44 invalidates this hypothesis, suggesting that chiral protection is 
afforded by the electron release provided by the urethane moiety, destabilising 
the anion which could form via proton abstraction. This evidence indicates that 
oxazolone formation per se is not a sufficient explanation of racemisation, and 
the stability of the cyclic intermediate towards various bases demands further 
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appraisal. 
1.11 Common side reactions observed in SPPS 
General side reactions, such as those associated with amino acid 
chlorides, carbodiimides and base catalysed racemisation, have already been 
discussed. However, there are also several amino acid specific side reactions 
which have been reported during acylation, deprotection and peptide resin 
cleavage/deprotection in SPPS. Since the work embodied within this thesis is 
concerned with the Fmoc/?-butyl strategy we will limit the discussion to this 
particular area. 
1.11.1 Diketopiperazine formation 
Upon completion of the dipeptide stage of SPPS, deprotection of the 
Na-Fmoc group can result in nucleophiUc attack of the free amine at the peptide-
resin ester linkage. 145 The overall result is release of the dipeptide from the 
resin support as its corresponding cyclic diketopiperazine (DKP) (Scheme 29). 
Scheme 29. Intramolecular diketopiperazine (DKP) formation. 
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This intramolecular aminolysis has been demonstrated to be sequence 
dependent, with the presence of Pro, Gly, D-amino acids and ^-methyl amino 
acids accelerating the overall process. 146-149 The cyclisation is also catalysed by 
acidsiso and basesi5l.i52 commonly employed for deprotection in SPPS. 
1.11.2 Asparagine and glutamine 
The most commonly encountered side reaction when Asn and Gin 
(without side-chain protection) are coupled to a resin bound peptide is 
dehydration of the carboxamide to form the corresponding nitrilei53-i56 
(Scheme 30). 
O 
Fmoc' 
O 
O 
o 
DCC Fmoc' O 
NH, NH 
O 
-^- Fmoc' O 
'N 
Scheme 30. Intramolecular dehydration of carboxy activated Asn. 
Despite acylation with active esters demonstrating minimal 
dehydration, 10.157-159 side-chain protection is the only reUable method to 
completely eliminate nitrile formation, with trityl protection 87 now regarded as 
the methodology of choice. 
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1.11.3 Aspartic and glutamic acid 
The aspartic acid residue is the source of numerous undesired side-
reactions during both synthesis and purification. Cyclisation and ensuing p-Asp 
peptide (62) formation is by far the most troublesome in SPPS (Scheme 31). 
O 
O'Bu 
H 
N 
O 
O 
/ • 
N 
V 
R 
O R 
(61) 
• N 
R 
O 
Aspartinude 
™o 
O R 
Scheme 31. Piperidine mediated aspartimide formation. 
Aspartimide formation is dependent upon the nature of the catalyst, the 
side chain protecting group and the residue at the Asp carboxyl terminus. 160-164 
The stability of the |3-/^r/-butyl ester towards piperidine in DMF appeared to 
endow sufficient protection against cyclic imide formation. 162 However, as 
shown in Scheme 31, aspartimide and piperidide formation has been observed 
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in peptides containing the Asp(0'Bu)-Asn(Trt) sequence. 165 The base catalysed 
abstraction of the anude NH is key to the overall progress of the side-reaction 
and exploitation of the previously described Hmb amide protecting group has 
unsurprisingly been shown to completely suppress this mechanism. 166 
The base catalysed cyclisation of glutamate residues to form 7-peptides 
has not yet been reported in SPPS. However, base catalysed pyroglutamate 
formation from Fmoc-Glu(OBzl) occurs during piperidine deprotection,!68 
although this can be prevented by the use of high concentration/short 
deprotection times; e.g. 50% piperidine in DMF for 1 rmn.i67 
1.11.4 Arginine 
The most deleterious side reaction of activated Fmoc-Arg is 5-lactam 
formation (Scheme 32).i68 
[P]N NH[P] 
.NH 
DCC 
-^^ FmocHN 
FmocHN 
O 
o NH[PJ 
o 
Scheme 32. Intramolecular 8-lactam formation from carboxy activated Arg. 
Any Fmoc-Arg derivative without 6-protection can be assumed to undergo a 
degree of 6-lactam formation. 169 It should be noted that addition of HOBt to 
the coupling mixture inhibits 8-lactam formation in all mono-protected Fmoc-
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Arg derivatives, including Fmoc-Arg(Pmc)-OHi70 and Fmoc-Arg(Mtr)i7i-i73 
which tend to be the reagents of choice for Fmoc SPPS. 
1.11.5 Histidine 
Racemisation is the most serious problem during the coupling of a 
histidine residue. 10,174-176 it is believed to proceed via intramolecular a-proton 
abstraction by the inudazole n-nitrogen (Scheme 33). 177 
FmocHN 
.H 
H 
• N 
/ > / 
• N 
a FmocHN' 
H 
N 
. / > 
N H 
O 
Scheme 33. Intramolecular His racemisation. 
Racemisation can therefore be suppressed by blocking the 7i-nitrogen,i78 e.g 
Fmoc-His(Bum)-OH.i79 However in actuaUty, most His protecting groups 
block the x-nitrogen, suppressing racemisation by their electron withdrawing 
nature, thereby decreasing the overall basicity of the n-nitrogen, e.g. Fmoc-
His(Trt)-OH.ioi 
1.11.6 Side reactions during peptide-resin cleavage and 
deprotection 
During TFA mediated cleavage of the majority of peptides synthesised 
using the Fmoc/'Bu strategy, the side chain protecting groups are 
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concomitantiy removed. TFA cleavage of 'Bu and Boc groups generates the t-
butyl carbocation, 180,181 and r-butyl trifluoroacetate,45 and these reactive 
species can potentially r-butylate Tyr, Met and Trp. 182 These side reactions can 
be miiumised by the addition of cationic scavengers to the deprotection cocktail. 
1,2-Ethanedithiol (EDT) has been demonsti-ated to be the most efficient 
scavenger of r-butyl trifluoroacetate but as a stand alone scavenger is not enough 
to completely prevent Trp alkylation. 183,184 However, the introduction of 
Fmoc-Trp(Boc)-OH,ioo has dramatically altered the indole alkylation problems 
associated with this residue. 185 TFA cleavage generates the relatively stable 
N'w-carboxy intermediate, which has been demonstrated to provide adequate 
protection against both alkylation and sulfonation. Spontaneous decarboxylation 
then occurs during aqueous work up. 
Acid catalysed oxidation of the Met residue to Met sulphoxide during 
cleavage/deprotection of the peptide resin is another problematic side 
reaction. 186,187 it has been shown however, that addition of ethyl methyl 
sulphide (EMS),188 thioanisolei89 or EDT to the deprotection mixture can 
prevent such Met sulphoxide formation. 
One other important consideration arises form the TFA mediated 
deprotection of the Cys(Trt), which if not performed in the presence of a 
suitable scavenger, e.g. EDT or triisopropylsilane, 190 is a reversible process. It 
is also of worth to note that a very recent publication reports that racemisation 
free coupling of Fmoc-Cys(Trt)-OH can only be achieved in a medium devoid 
ofbase.191 
With an armoury of protecting groups, coupling reagents and automated 
continuous flow equipment, the peptide chemist has been able to exploit the 
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Merrifield and Sheppard phUosophies by synthesising a plethora of complex 
natural and atypical peptides; and in so-doing substantiating the Fmoc based 
approach as probably the most popular, and generally successful, of all 
strategies to chemical peptide synthesis. Research continues to be highly active 
within this still advancing science, and the following chapters illustrate this 
point with investigations into the; 
i) Development of new amino protecting groups. 
U) Development of reversible reagents for the chromatographic or affinity 
based purification of peptides synthesised via SPPS. 
iU) Exploitation of a poly-lysine SPPS constructed scaffold for anchoring of 
immunogenic haptens, in an attempt to raise anti-hapten antibodies, 
iv) Potential exploitation of an asymmetric solution based synthesis of 
biosynthetic precursors to the carbapenem antibiotics, in order to raise a 
library of side-chain and ring modified p-lactams. 
These and alternative improvements of new and existing methodologies will 
transport solid phase peptide synthesis (SPPS) and solid phase organic 
chemistry (SPOC) into the next millennium. 
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Development of a Primary 
Amine Protecting Group 
Orthogonal to the Fmoc/ 
^Boc Strategy for SPPS 
2.1 Introduction 
Advances over the last 50 years associated with the chemical synthesis 
of peptides and proteins, as detailed within the previous chapter, have been 
enormous. However, the necessary requirement for side-chain modifications 
of a linear peptide to synthesise for example; cycUc/branched peptides,55 
multiple antigenic peptides (MAPs),56 spider toxins57 and regioselectively 
addressable functionalised templates (RAFTs)i92 via solid phase 
methodologies, requires a side-chain protecting group that is cheap to 
synthesise, displays orthogonality towards the Fmoc group and can be easily 
removed under, ideally, continuous flow conditions. The side-chain primary 
amines contained in both lysine and ornithine residues have provided an 
excellent functional group with which to further modify a linear peptide 
sequence, and work within this Department was initiated to develop a novel 
amine protecting group displaying the stipulated orthogonality described above. 
2.1.1 Vinylogous amides as amine protection 
The concept of vinylogous amides as ATa-amino acid protection had 
already received some attention. 51,52 The inabUity of the carboxy activated 
intermediate to form an oxazolone precluded racemisation via this route (see 
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section 1.10.2, p.52), and subsequently N-(4-oxopent-2-enyl)amino acids 
(64), derived from pentane-2,4-dione (63), were successfully activated via 
mixed anhydrides and cyanomethyl esters 193 and utilised in peptide synthesis 
(Scheme 34). 
O O R 
R 
H 
+ |...NH KOHMeOH ^ ^ ^ x ^ ^ 
H2N CO2H 
H20 y^Q.-^ 
(63) (64) 
CO2H 
Scheme 34. Vinylogous amide protection of an anuno acid. 
However, the lability displayed by N-(4-oxopent-2-enyl)anuno acids towards 
aqueous and mildly acidic conditions limited their use as synthetic reagents. 
2.1.2 Development of the A^-l-(4,4-dimethyl-2,6-
dioxocyclohexylidenemethylene) (Dmc) amino 
protecting group 
Within our laboratories the cyclic 1,3-diketone, 5,5-dimethylcyclohex-
ane-l,3-dione (dimedone) (65) was employed as the template starting material. 
The reaction between (65) and dimethylformanude dimethylacetali94 afforded 
5,5-dimethyl-2-(dimethylaminomethylene)cyclohexane-1,3-dione (DMMD) 
(66), which was demonstrated further to react with amino acids at room 
temperature to yield stable, crystalline A^o^Dmc-derivatives (67)53 (Scheme 35). 
Intramolecular hydrogen bonding provides the driving force for the 
formation and chemical stability of (64) and (67). This hydrogen-bond 
formation is not possible with secondary amines and although A -^Dmc-proline 
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and other A -^methyl-A -^Dmc amino acids can be synthesised, they lack adequate 
stability for use in SPPS. 
O p 
(CH3)2NCH(OCH3)2 
(65) 
QN(CH3)2 
(66) 
R 
H2N CO2H 
NH(CH3)2 
(67) 
Scheme 35. Protection of an amino acid as its A -^(4,4-
di me thy 1-2,6-di 0x0 cy do he xyl ide ne met hyl en e) 
(Dmc) derivative (67). 
Cyclic 1,3-diketone derivatised amino acids were found to be more 
robust than their open chain counterparts and showed remarkable stability 
towards acidic conditions. However, their deprotection could be 
rapidly effected by a dilute hydrazine solution in a polar solvent at room 
temperature, with the overall process being driven by the formation of the 1,2-
diazolei95,i96 (68) (Scheme 36). 
Carbodiinude mediated coupUng of A^a-Dmc-anuno acids under SPPS 
conditions were found to be racemisation free, as demonstrated by the synthesis 
of Leu-enkephalin, where deprotection of the A «^-Dmc group was achieved, 
following each coupling, using continuous flow 2% hydrazine in DMF. 
63 
Orthogonal amine protection 
H2N 
O NH R 
„uH -H+/+H+ 
CO2H 
(68) 
Scheme 36. Hydrazine mediated deprotection of a A -^Dmc amino acid. 
However, the use of uronium salt reagents for carboxyl activation (see 
section 1.9.3, p.41), which requires the employment of strong non-nucleophilic 
bases such as DIEA, led to red coloration of the activation mixture and a 
subsequent complex mixture of products. 197 This result coupled with the 
observation that the Dmc group was removed in 20% piperidine in DMF under 
continuous flow conditions meant that the protecting group was both lacking 
orthogonality with Fmoc and a realistic application to SPPS. 
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2.1.3 Development of the A^- l - (4 ,4 -d ime thy l -2 ,6 -
dioxocyclohex-l-ylidene)ethyl (Dde) amino 
protecting group 
The instability of The Dmc group to piperidine was postulated to be a 
result of nucleophilic attack at the enamine double bond, with ensuing 
displacement of the amino acid. It was proposed that introduction of steric 
hinderance at the enamine position would discourage this attack and thereby 
render the protecting group more stable to piperidine. This reasoning led to the 
introduction of a methyl group, resulting in the A^-l-(4,4-dimethyl-2,6-
dioxocyclohex-l-ylidene)ethyl (Dde) amino protecting group.54 
The Dde group has been demonstrated as displaying a quasi-
orthogonality to Fmoc (6.5% loss after 4 h treatment with 20% piperidine in 
DMF under continuous flow conditions), allowing the synthesis of medium 
sized peptide chains without serious loss of the Dde group. Unlike A^«-Dmc-
amino acids the A «^-Dde equivalents (except glycine) 198 are compatible with 
uronium salt coupling reagents. The A a^-Dde group has received considerable 
attention and its application within SPPS has already been dealt with in more 
detail in the previous chapter (see Section 1.5.3, p.21). 
2.2 Development of the A^-l-(4-nitro-l,3-dioxoindan-
2-ylidene)ethyl (Nde) amino protecting group 
The A a^-Dde group has provided an excellent template for amine 
protection displaying quasi-orthogonality to Fmoc. However, hydrazine does 
cause significant removal of the Fmoc group, dictating that in a few-protected 
residue (e.g Fmoc-Lys(Dde)-peptide) the Fmoc group must be removed first 
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and that chain extended before the peptide is exposed to the 2% hydrazine in 
DMF for Dde deprotection. 
Another problem that has been identified with the Dde group is 
associated with its removal. It has on several occasions displayed a slow 
deprotection profUe, and also in all instances requires monitoring at 300-3 lOnm 
as the deprotection adduct, 3,6,6-trimethyl-4,5,6,7-tetrahydro-l//-indazol-4-
one (69) has a less powerful chromophore than the Fmoc deprotection adduct 
(Scheme 37). This requires re-calibration of automated equipment designed to 
monitor the Fmoc deprotection adduct at 290nm. 
N + Amino 
/ Acid 
(69) 
(a) (b) 
Scheme 37. Comparison between (a) a typical Fmoc deprotection profile 
monitored at 290nm and (b) a poor Dde deprotection profUe 
monitored at 3lOnm. 
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It was envisaged that incorporation of an extended chromophore onto 
the already well established ring encased diketone nucleus, would generate a 
structure that could be more efficientiy monitored during the deprotection cycle, 
preferably at the Fmoc wavelength of 290nm. It was anticipated that an 
extended chromophore with a fused aromatic ring would meet this requirement. 
Furthermore, if the ring had an electron withdrawing substituent, the increased 
electrophUicity of the exocycUc enol may generate a more reactive entity. Thus 
the potential for a reagent capable of coupling to amino acids quicker than 2-
acetyldimedone, and subsequently its deprotection easier than Ar«-Dde, could 
produce an ideal amine protecting group that exhibits total orthogonality to 
Fmoc; since it may potentially be removed using extremely weak nucleophiles 
such as thiourea that, unlike hydrazine, would not affect the integrity of Fmoc 
protection. 
These considerations led us to formulate 2-acetyl-5-nitroindane-l,3-
dione (70) as our target, which possessed both the extended chromophore and 
electron withdrawing substituent on the fused aromatic ring. Presence of the 
methyl substituent on the exocyclic enol, should once again deter the attack of 
piperidine. 
Oi'" H O i i i i i i K ' H 
(70) 
Fortunately, the literature search revealed that the desired compound 
(70) could be synthesised by a regioselective one-pot reaction, involving a 
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sequential cross-condensation-cycloacylation of 4-nitrobenzoyl chloride with 
acetyl chloride in the presence of aluminium chloride (Scheme 38). 199 
CI 
CH3COCI + AICI3 =^;i^ CHjCOCl-AlClj^JS^ H 2 C = C + HCl 
O—AICI2 
CH3COCI 
CI CI 
^ A l +HC1 
4-nitrobenzovl chloride o' \ 
CI 
+ HCl 
Scheme 38. Synthesis of 2-acetyl-5-nitroindane-l,3-dione (70) 
Unfortunately, even after several attempts, the originally reported poor 
35% yield could not be improved. This led us to return to the Uteratiu-e to locate 
an efficient and facUe synthesis of either (70) or (71). 
A paper published by Mosher and Meier in 1970 described the synthesis 
of both the 2-acetyl-4-nitroindane-l,3-dione (71) and 2-acetyl-5-nitroindane-
1,3-dione (70) molecules, with the former being attainable in higher yield. The 
synthesis involved the reaction between a nitrophthalic anhydride and 2,4-
pentanedione using pyridine as a solvent.200 A putative mechanistic 
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interpretation suggests an initial condensation reaction followed by two 
nucleophile (piperidine) assisted reartangements to furnish the target molecule 
as its pyridinium salt (Scheme 39). In our hands, synthesis of 2-acetyl-4-
nitroindane-1,3-dione (71) was achieved with a similar overall yield of 63%, 
affording fine yellow crystals after neutralisation of the pyridinium salt. 
O (^O 
~ :NUC 
O rO it o 
Scheme 39. Synthesis of 2-acetyl-4-nitroindane-l,3-dione.pyridinium salt. 
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It is noteworthy that the IH NMR (CDCI3) spectrum of both (70) and 
(71) show the enol proton as an exchangeable singlet at 811.5, providing 
evidence for the proposed hydrogen bonded structure. 
2.2.1 Synthesis of N«-Nde-L-amino acids 
In order to generate a cost-effective strategy, the higher yielding 2-
acetyl-4-nitroindane-l,3-dione (71) was employed as the reagent of choice for 
A «^-amino acid protection. InitiaUy, L-alanine and 2-acetyl-4-nitroindane-l,3-
dione (2:1) were refluxed together in anhydrous ethanol, with the reaction 
closely monitored by TLC, indicating a complete loss of (71) after 3 h. 
Following work-up A^-Nde-L-alanine (72) was recovered as a yellow 
amorphous powder in 65% yield (Scheme 40). 
O 
OH 
Scheme 40. Synthesis of A^-Nde-L-alanine. 
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This reaction time was significantly quicker when compared with the 
preparation of A -^Dde-anuno acids, which typically required refluxing ovemight 
to obtain acceptable yields. It is also noteworthy that the increased reactivity 
displayed by 2-acetyl-4-nitroindane-l,3-dione means only a 1.5-2.0 mole 
equivalent of the amino acid is required in order to drive the reaction to 
completion. In conti-ast, synthesis of A -^Dde-amino acids dictated the use of a 4 
molar excess of 2-acetyldimedone in order to obtain comparable yields. 
With the condensation reaction conditions optimised, a series of 
representative anuno acids were A^«-protected with 2-acetyl-4-nitroindane-l,3-
dione (71) to afford in all cases a yellow amorphous powder of good to 
excellent yield and purity (Table 5). 
Table 5. A summary of A^«-Nde-amino acids synthesised. 
Nde Amino acid 
Phe 
Lyst 
Val 
Tyrt 
Be 
Leu 
Histt 
Gly 
Ala 
Yield/% 
69 
68 
77 
78 
70 
83 
40 
81 
65 
[a]D (c=l, MeOH) 
-135.10# 
-26.20 
-1-18.50 
-136.50 
-hl0.20# 
-31.50 
- 86.90 
n/a 
-1-26.40 
t Side chain protection : B^oc 
tt Side chain protection : Trt 
# (c=l,EtOH) 
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All Nde amino acids were obtained as yellow amorphous powders via 
hexane precipitation from a concentrated ethyl acetate solution. These 
compounds were extremely difficult to recrystallise. The IH NMR displayed a 
small hexane impurity that could not be removed by vacuum desiccation over 
wax and this small degree of solvent occlusion prevented mearungful elemental 
analysis. Release of occluded solvent from the amorphous powder during 
melting point determination caused a glass formation prior to 
liquification/decomposition. Therefore, to ascertain the purity of individual N«-
Nde-amino acids, HRMS and RPHPLC analyses were undertaken for each 
compound, and found to display single peak traces of the correct mass in all 
cases. 
Interestingly, the IH NMR of all A a^-Nde amino acids displayed split 
signals (of ca ratio 2:1) for the characteristic vinylogous amide NH (5 11.0-
11.2) and vinyl methyl protons (8 2.30-2.60). This phenomenon was 
postulated to be a consequence of cis/trans isomerism around the vinyl bond, 
with sample heating resulting in collapse of the signals to the expected doublet 
and singlet for the NH and CH3 protons respectively. 
2.2.2 Compatibility of iV«-Nde-amino acids in SPPS 
Indications of improved reactivity in the condensation reaction between 
amino acids and 2-acetyl-4-nitroindane-l,3-dione (71), suggested that the 
deprotection may also proceed faster than that already established for No^Dde-
amino acids. This hypothesis was investigated by coupling A^«-Nde-L-Leu to a 
leucine derivatised resin via carbodiimide (DIPCDI)/HOBt mediated carboxy 
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activation (Scheme 41). 
Nde-Leu-OH + HjN—Leu 
No deprotection 
observed at 290 nm 
20% Piperidine 
in DMF 
DIPCDI/ 
HOBt Ih. 
Nde —Leu -Leu 
1% Hydrazine. H2O 
in DMF 
Deprotection complete 
within 6 min. monitored 
at 290 nm. 
Nde-Leu-OH 
H2N—Leu-Leu 
TBTU/HOBt 
/DIEA L5h 
No deprotection 
observed at 290 nm 
10% Thiourea 
in DMF 
Nde —Leu -Leu-Leu 
^ 
2% Hydrazine. H2O 
in DMF 
Deprotection complete 
within 4 min. monitored 
at 290 nm. 
H2N—Leu -Leu-Leu 
95% TFA, (aq) 
Leu -Leu-Leu 
Scheme 41. Compatibility of Na-Nde-amino acids in SPPS. 
Acylation was monitored by the trinitrobenzenesulphonic acid (TNBS) amine 
test20i and was complete after 1 hour. The resin was initially exposed to 20% 
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piperidine in DMF under continuous flow conditions, with the post column 
eluent monitoring at 290 nm. No deprotection peak was observed during the 10 
min cycle. After washing with DMF, the resin was subjected to a continuous 
flow of 1% hydrazine monohydrate in DMF. Post column monitoring of the 
eluent, at the Fmoc deprotection adduct wavelength of 290 nm, displayed a 
sharp deprotection peak indicating complete removal of the Nde group within 
approximately 5-6 min (Figure. 1). It is noteworthy that the deprotection is also 
visual, with the yellow resin (resulting from the Nde protected residue) 
changing to red and finally restored to the original resin colour upon complete 
removal of the Nde group. 
(a) (b) 
Fig. 1. Comparison between (a) a typical Nde deprotection 
profile monitored at 290nm and (b) a poor Dde 
deprotection profUe monitored at 3 lOnm. 
This experiment indicated that the Nde group displayed stability to piperidine, 
yet could be efficiently removed with 1% hydrazine, with post column 
monitoring possible at the same wavelength as that established for the Fmoc 
group. 
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To test the compatibility of A^a-Nde-amino acids with uronium salt 
reagents, the Leu-Leu-derivatised resin was acylated with a second A/a-Nde-L-
Leu residue via TBTU/HOBt/DIEA activation (Scheme 41). Coloration of the 
reaction mixture was no different than that observed with the carbodiimide 
reagent, and acylation was halted after 1.5 h. The TNBS test indicated a small 
but detectable amount of free amine was still present on the resin, and it was 
apparent that the Leu-Leu-Leu sequence was presenting coupling problems at 
the third residue. However, the strong yellow coloration of the resin indicated 
that the tlurd coupling had proceeded sufficientiy well to test the labUity of Nde 
towards thiourea, which if successful, would provide an additional level of 
orthogonality. Unfortunately, exposure of the resin to 10% thiourea in DMF 
under continuous flow conditions showed no detectable signs of deprotection. 
The terminal Nde group removal was therefore effected using 2% 
hydrazine in DMF under continuous flow conditions with complete deprotection 
after approximately 3-4 min. The tripeptide was cleaved from the resin, and 
shown to be two major peaks by RPHPLC, the largest of which was 
characterised as (Leu)3 by MALDI-TOF MS, with the main impurity being 
confirmed as (Leu)2. 
2.2.3 Racemisation of A^«-Nde-amino acids during 
synthesis 
With the previous experiment indicating the promising application of 
A^«-Nde-amino acids in SPPS it was important to ascertain whether chiral 
integrity of the amino acid was not jeopardised during the condensation reaction 
with 2-acetyl-4-nitroindane-l,3-dione (71). A sample of Na-Nde-L-
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phenylalanine was deprotected with 1% hydrazine monohydrate in super-dry 
ethanol. TLC monitoring indicated that deprotection was complete after 3 h, 
during which an orange/red precipitate had formed. The solid was collected and 
dried and was surprisingly elucidated as the Nde-hydrazine deprotection product 
(73), by IH NMR and mass spectrometry. 
/ v^  R = 5 or 8 NO2 
N^ 
It was anticipated that hydrazine mediated Nde deprotection would yield 
the 3-methyl-5/8-nitroindeno[l,2-c]pyrazol-4(l/f)-one (74) byproduct in a 
simUar mecharustic fashion to that previously displayed with A^ -Dmc and A -^Dde 
amino acids. However it would appear that the electron withdrawing nature of 
the fused nitro-aromatic ring sufficiently activates the reactive vinyl bond to 
allow a straightforward transamination type deprotection. 
A UV spectrum of the deprotection byproduct was obtained (Figure. 2) 
and indeed showed a A-max at 294 nm, which made this an ideal reagent for 
monitoring at the identical deprotection wavelength associated with the Fmoc 
group. 
Evaporation of the deprotection media, resulted in an oily residue which 
was partitioned between chloroform and water. Evaporation of the aqueous 
layer retumed L-phenylalanine with an optical rotation identical to that reported 
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in the literature, and an identical Rf to an authentic L-Phe sample when run 
together on a chiral TLC plate. This confirmed that no racemisation occurred 
during the synthesis of A^«-Nde-L-Phe. 
u 
u 
a 
a 
2 -
1 -
250 
• • — 1 — 
350 300 
Wavelength / nm 
• • 1 
400 
Fig.2.UV Absorption spectrum of the Nde deprotection by-
product, Nde-hydrazine in DMF 
2.2.4 Racemisation of A^a-Nde-amino acids during 
coupling 
An estimate of racemisation levels encountered when coupling N«-Nde-
amino acids was required, since despite oxazolone formation being effectively 
impossible, the enhanced electron-withdrawing nature of the Nde substituent 
may predispose the a-proton to base (e.g. DIEA) abstraction following carboxy 
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activation. L-Phenylalanine was once agam chosen as the model amino acid as it 
is one of the most easily racemised and thus ideal for this experiment.202 
Accordingly A^a-Nde-L-Phe and A'^ a-Nde-D-Phe were coupled to L-Ala-OBzl 
using both DCC/HOBt and TBTU/HOBt/TEA protocols. The two 
diastereoisomers produced, A/«-Nde-L-Phe-L-Ala-OBzl (75) and A a^-Nde-D-
Phe-L-Ala-OBzl (76) were readily separable by RPHPLC when aqueous 
methanol was used as the mobile phase for gradient elution. 
NO2 
(75) R^  = CH2-Ph, R^  = H 
(76) R^  = H, R^  = CH2-Ph 
No detectable signs of epimerisation were evident when either DCC or TBTU 
were employed as the coupling reagent. These results demonstrated that ATa-
Nde-amino acids were compatible for SPPS with theU chural integrity remaining 
unscathed during both then: synthesis and subsequent coupling. 
2.3 SPPS synthesis of Neuromendin N amide using 
iV«-Nde-amino acids 
The potential use of A^«-Nde-amino acids in SPPS was examined by the 
synthesis of three peptides. The first of which, Neuromendin N (77), was 
78 
Neuromendin N amide synthesis 
synthesised as its corresponding amide, using the A^«-Nde-amino acids, 
Lys(Boc)OH, He, Tyr(O'Bu) and Leu prepared as described earlier. 
H-Lys-Ile-Pro-Tyr-Ile-Leu-OH 
(77) 
The inability to synthesise a stable N-Nde-Pro derivative was circumvented by 
using A -^Fmoc-Pro-OH for the incorporation of the proline residue. A peptide 
amide forming resin (Novasyn® KR 100) carrying the modified Rink linker, 32 
was chosen because of the ease of initial acylation of the first residue onto an 
amine rather than an alcohol. 
Synthesis was accomplished on an LKB 4175 Biolynx manual peptide 
synthesizer, using a DIPCDI/HOBt coupling strategy under continuous flow 
conditions. Four equivalents of acylating reagents were employed for each 
residue, and every coupling was allowed to continue until the TNBS amine test 
was negative. 
Coupling of the first three residues progressed with relative ease, 
displaying excellent deprotection profiles using 2% hydrazine, both visually and 
with post colunm UV monitoring at 290 nm. As mentioned earlier, A -^Fmoc-
Pro was then incorporated into the synthetic strategy, requiring double coupling 
to obtain a negative TNBS test. Following 20% piperidine mediated Fmoc 
deprotection, the final two A^«-Nde-residues were incorporated smoothly, and 
the crude cleaved peptide was shown to be one major peak by RPHPLC, with 
the purified peptide subsequentiy characterised by +ve-ES-MS. 
79 
Angiotensin II receptor binding protein fragment synthesis 
2.4 SPPS synthesis of the angiotensin II receptor 
binding protein fragment as its corresponding amide 
using N«-Nde-amino acids 
The second model peptide, angiotensin II receptor binding protein 
fragment (78), was once again synthesised as its corresponding amide using the 
iV«-Nde-amino acids, Lys(Boc)OH, Val, Tyr(OfBu), He, His(Trt), Ala and 
Leu. The reported problems encountered with A^«-Dde-Glyi98 dictated the 
replacement of the corresponding A/«-Nde residue with A/-Fmoc-Gly-OH. 
H-Lys-Gly-Val-Tyr-Ile-His-Ala-Leu-OH 
(78) 
Under analogous conditions as those described for the synthesis of 
neuromendin N amide, the first two residues of the angiotensin II binding 
protein fragment were incorporated readily, exhibiting excellent deprotection 
profiles. However, introduction of the histidine residue, even after double 
coupling, produced a small but significant positive TNBS test. At this juncture, 
there was insufficient Ara-Nde-His(Trt) with which to perform another 
coupUng, however it was decided to proceed wUh the total synthesis to assess 
how poor the His incorporation had been, and to investigate whether any of the 
following residues posed problems in coupling. Fortunately, the remaining 
synthesis, including incorporation of the A^a-Fmoc-Gly residue, proceeded 
without further complications. 
The RPHPLC trace of the crude cleaved peptide indicated two major 
peaks as anticipated, with -hve-ES-MS of the purified peaks confirming them as 
the required peptide and the histidine deletion product, Fig. 3. 
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0 
a) 
b) 
u 
10 20 30 t/min 
F i g. 3. RPHPLC trace of the cmde cleaved angiotensin II receptor 
binding protein (as its corresponding amide) indicating (a) 
the requu-ed peptide, and (b) the histidine deletion product. 
The A^«-Nde-His(Trt) residue was re-synthesised, and a second attempt at 
the above peptide sequence was undertaken. Once again, the histidine residue 
proved difficult to couple to the Ala-Leu substituted resin, and required the 
sequential exposure to four individual acylating mixtures in order to obtain a 
negative TNBS test. As in the initial experiment, all remaining residues proved 
non-problematic in their incorporation and the crude cleaved peptide was on this 
occasion shown to be one major peak by RPHPLC, with the purified peptide 
exhibiting the correct mass by -i-ve-ES-MS. It is interesting, but not surprising, 
that the forced coupling conditions of the histidine residue led to a small but 
significant degree of epimerisation (approximately 5%), which is not 
uncommon with this particular residue.io. 174-176 
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2.5 SPPS synthesis of Leu-enkephalinamide using A -^a-
Nde-amino acids 
To further demonstrate the applicability of Nde as an N«-protecting 
group in SPPS, a final peptide, Leu-enkephalinamide (79), was chosen as a 
synthetic target via TBTU/HOBt/DIEA coupling procedures using the ATo-Nde-
amino acids Tyr(0'Bu)OH, Phe and Leu. Once again A/-Nde-Gly was replaced 
by A/-Fmoc-Gly for the introduction of these particular residues within the 
sequence. 
H-Tyr-Gly-Gly-Phe-Leu-NH2 
(79) 
The SPPS was once again performed using an LKB 4175 Biolynx manual 
peptide synthesizer and Novasyn® KR 100 resin. The total synthesis proceeded 
satisfactorily, with the crude cleaved peptide shown to be one major peak by 
RPHPLC, which on subsequent purification was characterised by -i-ve-ES-MS. 
The three peptides synthesised above demonstrate that N«-Nde-amino 
acids are suitable for use in SPPS producing peptides of good to exceUent purity 
with littie or no epimerisation. The deprotection is rapid and visual, or can be 
monitored by UV at the same wavelength required for Fmoc deprotection 
analysis. In order to establish whether Nde displayed similar or better 
Orthogonality to Fmoc than Dde, stability studies against TFA and piperidine 
were performed. 
2.6 Stability of Nde to TFA 
To confirm the stability of Nde to TFA, a sample of iVa-Nde-L-Phe was 
dissolved in freshly distilled anhydrous TFA, and monitored by RPHPLC over 
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a 24 h period. During this time no additional peak was observed, and after 24 h 
the sample was evaporated to dryness and shown to be identical to the starting 
material by IH NMR and FAB-MS. 
2.7 Stability of Nde to piperidine 
A test peptide was synthesised in order to ascertain the stability of Nde 
towards piperidine. Leu-enkephalinamide was synthesised on Novasyn® KR 
1(X) resin via standard Fmoc chemistry. At this juncture, A^a-Nde-Leu-OH was 
employed as the terminal amino acid and was coupled to the peptide using the 
DIPCDI/HOBt procedure. The Nde group was left intact and the resin bound 
protected fragment was utilised in a stability test against a continuous flow of 
20% v/v piperidine in DMF for 24 h. Periodic cleavage of a portion of the resin 
and RPHPLC analysis of the product indicated the emergence of small 
quantities of the unprotected peptide. From the visual examination of the 
relative peak heights, it could be concluded that the % loss of Nde is ca. 6% and 
13% after 3 and 6 h respectively. A contact time of 3 h with 20% piperidine 
represents 25 X 7min Fmoc deprotection cycles, thus allowing the synthesis of 
medium sized branched peptide chains, via Fmoc chemistry, without significant 
loss of the Nde group. This result is comparable to that obtained for the Dde 
group, but with improved deprotection characteristics. 
2.8 Solid phase synthesis of trypanothione disulphide 
utilising Nde as a primary amine protecting group 
The pathogenic Trypanosomidae species responsible for such diseases 
as African sleeping sickness and South American Chagas' do not use the 
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classical glutathione (GSH) based redox system present within mammalian cells 
to guard against cellular damage.203 They instead use the GSH-spermidine 
conjugate, Nf A/^-bis(glutathionyldisulphide)spermidine, commorUy referred to 
as trypanothione disulphide (80).204 This metabolite plays a pivotal role in the 
maintenance of cellular glutathione in its reduced state (Scheme 42) and is 
significantly detached from the mammalian system to make it an attiactive target 
for drug development against these parasitic diseases. 
COjH 
Disulphide reductase 
flavoprotein 
HN 
CO2H 
Scheme 42. Trypanothione disulphide mediated glutathione regulation within 
trypanosomatids. 
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UntU now only one solution phase, 205 and one solid phase206 synthesis 
of trypanothione disulphide have been reported, both with poor to moderate 
overall yields. It was envisaged that the inabUity of 2-acetyl-4-nitroindane-l,3-
dione to form stable protected secondary amine derivatives meant that this 
reagent could be utilised as a selective primary amine protecting group. 
Compounds such as spermidine, displaying both primary and secondary amines 
within its structure, provided an ideal target to investigate this hypothesis. If 
selective primary amine protection was possible, the remaining secondary amine 
functionality could be employed to attach the molecule onto a solid support, 
(Scheme 43). 
H,N 
H2N 
Selective primary 
amine protection 
HX 
Scheme 43. Atiachment of NfN8-bis protected spermidine to 
a solid support. 
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Initial attempts to synthesise A^^,N^-/?w-Nde-spermidine (81), via the 
methodology developed for Ar«-Nde amino acid synthesis, proved 
unsuccessful, with the Nde salt crashing out as a bright yellow precipitate 
almost instantaneously. However, modification of the above protocol to include 
an equivalent of base (DIEA) in the reaction mixture, afforded NfN8-bis-Nde-
spermidine (81) in almost quantitative yield (90%) (Scheme 44). The mono-
protected impurity was easUy removed by treatment of the precipitate with 1% 
AcOH in ethanol. The amorphous product, like the A a^-Nde amino acids could 
not be further recrystallised. 
NO2 
H2N 
Ethanol/DIEA 
A 
0" ' ""H 
NH 
= / (81) 
NO2 
Scheme 44. Synthesis of A^AA^S-bis-Nde-spermidine (81) 
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Solid phase peptide chain elongation is traditionally carried out from the 
C^A^ ternunals in order to reduce racemisation, hence few reports were 
available in the literature where the amine group of an amino acid was Unked to 
a resin. 
The earliest example was a carbamate Unker described by Letsinger,207,208 
in which a resin bound chloroformate was generated from hydroxymethyl 
polystyrene and phosgene. This method was exploited by Felix and Merrifield 
for the azide mediated elongation of a linear peptide in the C->N direction. 209 
This particular method suffered from three drawbacks; 
i) The use of phosgene is dangerous and should be avoided if possible. 
U) The high loading Merrifield resins are prone to a decrease in 
fiinctionalisation, possibly due to internal carbonate formation, 
iu) Phosgene in not compatible with the TFA labile p-alkoxybenzyl alcohol 
resins used for Fmoc synthesis. 
A recent publication reported the application of A',A '^-disuccinimidyl 
carbonate (DSC),2io as a means of activating an hydroxymethylphenoxyprop-
ionic acid (HMP) based Unker in order to anchor the amine side chain of a lysine 
residue for subsequent cyclic peptide synthesis (Scheme 45). More recently, a 
method for the synthesis of tripeptides has been described which exploits a 
polymer bound acylimidazole as a means of generating a carbamate linker from 
the Wang resin (Scheme 46).2ii 
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HO , / \ / 
HOSu 
O—CH2—CH2—CO 
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N - O - C - O - N 
O 
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N — o — C — 0 ^^  '^ 
0 —CH2 —CH2 —CO —I 
H2N—R 
O 
R—N—C —O 
H 
, ^ \ / 
HOSu 
O—CH2—CH2—co-
Scheme 45. DSC activation of an HMP functionalised resin, 
where H2N-R = A^«-Fmoc-Lys(NH2).OH. 
o 
/ • 
A. N^N-^N'^N 
HO 
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/ 
O 
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H 
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O 
Scheme 46. Carbonyldiimidazole mediated activation of Wang Resin. 
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However, our choice of activation was based on the seminal papers 
published by Leznoff,2i2,2i3 in which he describes the use of p-nitrophenyl 
chloroformate to prefunctionalise a polymer bound benzyl alcohol for the 
synthesis of unsymmetrical diamines. This method has also received recent 
attention for the solid phase synthesis of a hydantoin library .214 
NovaSyn® TGA resin, derivatised with the TFA labile 4-
hydroxymethylphenoxyacetic acid (HMPA) linker,31 was readily converted to 
the mixed carbonate (82) by ovemight exposure to a ten fold excess of p-
nitrophenyl chloroformate and DIEA in DCM (Scheme 47). 
A-\ / O —CH2—CO—I 
O—CH2 — co-
02N 
Nde-HN 
A^  ,A^  -few-Nde-spermidine 
O—CH, — CO—I 
NH-Nde 
Scheme 47. Attachment of A^i,N«-bis-Nde-spermidine to a p-nitrophenyl 
chloroformate pre-activated HMPA resin. 
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The extent of activation was demonstrated by ovemight exposure of (82) 
to a four fold excess of A/^ ,A^S-bis-Nde-spermidine (81) in DMF. Nde 
deprotection was subsequently executed using 2% hydrazine monohydrate in 
DMF under continuous flow conditions. After thorough washing of the resin 
and acetic anhydride capping, a four fold excess of Fmoc-Cl /DIEA was 
introduced and the resin regularly monitored until a negative TNBS test was 
obtained. The resin was sequentially washed with DMF, DCM and finally 
methanol, and dried in vacuo overnight over KOH. An Fmoc loading test on 
the dried resin indicated a nearly quantitative incorporation of spermidine 
(>95%) onto the derivatised solid support. 
With the preliminary investigation into the synthetic vaUdity proving 
successful, the fuU synthesis of trypanothione was undertaken by the sequential 
TBTU/HOBt/DIEA mediated acylation of Fmoc-Gly-OH, Cys(Trt) and 
Glu(OH)OtBu onto the hydrazine deprotected resin bound spermidine. Each 
acylation was monitored using the TNBS amine test, and A^a-deprotection was 
accomplished using 20% piperidine in DMF. 
Peptide resin cleavage with concomUant side-chain deprotection was 
effected using TFA/riPS/EDT/HiO (9.25 : 0.25 : 0.25 : 0.25), and a crude 
yield of ca 90% was obtained. RPHPLC indicated one major peak {ca. 80% 
purity) which was characterised by -Hve-ES-MS to be dihydrotiypanothione. 
This was aerially oxidised at a 0.1 mg ml-i concentration in ammonium 
acetate(aq) 0.04M (adjusted to pH 8.5 with concentrated ammonia) under 
atmospheric oxygen for 72 h. Lyophilisation and RPHPLC analysis of the 
resultant white amorphous powder displayed one major peak of reduced 
retention time when compared to the dihydrotrypanothione precursor, which 
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was confirmed by accurate FAB-MS to be trypanothione disulphide (80). 
2.9 Conclusions 
We have described the development, synthesis and exploitation of the N-
Nde group as a primary amine protecting group displaying good stability 
towards the deprotection conditions required for A «^-Fmoc removal and hence 
offering quasi-orthogonality to the well established Fmoc/'Boc combination 
commonly used in SPPS. The piperidine stability of the N-Nde protecting 
group is similar to that of N-Dde, however it displays an improved deprotection 
profile that can be monitored both visually, or by UV detection at the same 
wavelength as that required for the Fmoc group. 
We have also illustrated N-Nde as a selective primary amine protecting 
group, which can be utilised to temporarily block the primary amines present in 
polyamine structures, such as spermidine, whilst leaving the secondary amine 
free to derivatise a resin support, and thereby aUow the solid phase synthesis of 
complex structures such as trypanothione disulphide (80). 
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The Development of Reversible 
Chromatographic Probes for 
the Purification of Synthetic 
Peptides 
3.1 Introduction 
Despite enormous advances in the protecting groups, coupling reagents 
and resin supports utilised in SPPS, the process suffers intrinsically from the 
accumulation of complex mixtures of deletion peptides. The onset of either 
secondary structure,2i5 'hydrophobic collapse',216 interchain clustering or 
phase transitional change,2i7 in resin bound peptides frequently hinders 
acylation of the free amino groups, which can react with the next or ensuing 
residues.218 The individual entities of the crude product often differ by only 
gradual deletions, endowing similar chromatographic properties upon them. 
Techniques such as HPLC or CE are often insensitive to these subtle 
differences, with individual components manifesting as one peak and therefore 
making purification laborious and costiy. 
To minimize the formation of deletion sequences, acetic anhydride is 
often employed as a capping reagent at the final juncture of an acylation cycle, 
(Scheme 48)39 resulting in the formation of truncated sequences. However, 
tiiese also fi-equentiy display similar chemical and chromatographic properties as 
the desired peptide, as indicated above. Understandably, the problem of 
impurities manifests itself further when attempting the linear synthesis of 
proteins, hence very few, eg. HIV-1 protease2i9 (99 residues) and ubiquitin220 
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(76 residues), have surrendered to chemical synthesis and crystallisation. 
H2N—AAi—I 
[P]AA2 
H , N — A A i — £ j -^  [ P ] A A 2 - A A I — I 
(Ac)20 
CH3CONH—AAi- -I- [P]AA2—AAi—I 
CH3CONH—AAi—I Q 
Deprotection 
-I- H2N AA2—AAi—I 
Scheme 48. Acetic anhydride capping of unacylated residues 
during linear SPPS. 
Initially several methods were suggested for separating the target 
molecule from the truncated impurities by derivatising the A/-terminus of the 
finished peptide with a reagent capable of an affinity-type binding to a solid 
support. Examples of which included the binding of A'^ a-dinitrophenyl (DNP) 
peptides to immobilised DNP antibodies,22i A^a-biotinylated peptides to 
immobilised avidin222 and the reaction of an A a^-thiol with an iodoacetamide 
resin.223 The two former reagents had the drawback of being covalentiy linked 
to the peptide in a non-reversible manner and were therefore not suitable if the 
target peptide or protein was required in its physiological form. With respect to 
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the latter example; the chemical affinity of SH-iodoacetamide was found to be 
weaker than the biological affinity at low concentrations and therefore the 
method proved ineffectual at the purification of long peptides or proteins. 
Consequently, investigations were initiated by various groups to 
address the requirement for a reversible chromatographic probe that could be 
introduced onto the Af-terminus of the completed protected fragment, was stable 
to the cleavage/side-chain deprotection conditions, yet could be easily removed, 
following purification, to relinquish the target peptide/protein. 
3.1.1 Previously reported reversible affinity or 
hydrophobic chromatographic probes 
The first example relied once more upon the specific interaction between 
biotin and avidm as an efficient method of chromatographic purification.224,225 
The biotinylating reagent, 2-[(A^-biotinyl)-aminoethylsulphonyl]ethyl p-
nitrophenylcarbonate (BASEC) (83) was readily synthesised from 2-
(an[unoethylsulphonyl)ethanol,226 (Scheme 49) in a 48% overall yield. 
o 
II 
II 
o 
HCl. H2N OH 
^OH 
Biotinyl 1-hydroxysuccinimide ester 
' ' O O 
I 
Sv 
II 
O 
p-nitrophenyl chloroformate 
O O 
o- \ / 
NO2 
Scheme 49. 2-[(A^-biotinyl)-aminoethylsulphonyl]ethyl p-nitro-phenyl-
carbonate (BASEC) (83) synthesis. 
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N-Terminal modification of the finished peptide chain was achieved 
through the base labile sulphonylethoxycarbonyl linkage, and after cleavage of 
the biotinylated peptide from the resin, purification was effected on an avidin-
agarose column. Finally, base removal (5% ammorua solution) of the BASEC 
group afforded the pure peptide; in this instance magainin 2 (23 residues), 
hGRF (44 residues) and the transducin y-subunit 1-67 were used as examples. 
Ramage and co-workers focused their attention on the tetrabenzo 
substituted Fmoc reagent, tetrabenzo[a,c,g,/]fluorenyl-l 7-methoxycarbonyl 
chloride (Tbfmoc-Cl) (84).227 
(84) 
The aromatic polycycUc reagent, synthesised in five steps, demonstiates a high 
affinity towards porous graphUised carbon (PGC). After synthesis of Hepatitis 
B surface antigen (23 residues) via Fmoc/'Bu methodology with acetic 
anhydride capping at each residue, Tbfmoc was attached to the resin bound 
peptide via the piperidine labUe urethane Unker. TFA mediated cleavage of tiie 
peptide-resin bond and application of the crude product to a short column of 
PGC in 70% MeCN(aq) resulted in complete retention of the Tbfmoc peptide 
whilst the tiiincated impurities eluted off The pure peptide was released from 
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the Tbfmoc group by treatment of the PGC column with 10% (v/v) piperidine in 
70% MeCN(aq). Later experiments with larger peptides, e.g. bacteriophage A, 
Ral (Acm)4 (66 residues) and MeCP2 methylated DNA binding domain (78-
162) (85 residues) indicated that it was crucial to maintain deprotection 
conditions in which the peptide is soluble; the most effective being 10% (v/v) 
piperidine in 1:1 6M guanidine HCl/isopropanol. Despite this reagent 
demonstrating promising early results, the polyaromatic nature of the molecule 
raises doubts about its potential carcinogenicity and the possible solubility 
problems of the affinity probe-peptide conjugate. 
An alternative modification of the Fmoc nucleus by Mascagni et al 
generated both an affmity based reagent; {4-[(biotinylglycylglycyl)aminometiiyl] 
fluoren-9-yl}methyl succinimidyl carbonate (85) and two hydrophobic probes; 
{4-[(4.cyclohexylbutyryl)aminomethyl]fluoren-9-yl} methyl (86) and [4-
(dodecylaminocarbonyl)fluoren-9-yl} methyl (87) succinimidyl carbonates.228 
NH(COCH2NH)2CO-BIOTIN 
(85) 
CH2OCONSU 
NHCO(CH2)4 
(86) 
NH(CH2)iiCH3 
(87) 
CH2OCONSU CH2OCONSU 
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Synthesised from the 9-(hydroxymethyl)fluorene-4-carboxylic acid precursor, 
these reagents were reversibly attached to the A -^terminus of the resin-bound 
protected peptide, in a similar manner to Tbfmoc, through a base labUe urethane 
linkage. The efficiency of the probe reagents was demonstrated by the 
purification of two polypeptides of 46 and 101 residues in length. The 
biotinylated peptides were purified using an immobilised avidin column, 
whereas the hydrophobic probes allowed simple RPHPLC purification by 
imparting a significant shift in retention time for the modified peptides, thereby 
removing them from the more hydrophilUc tmncated impurities. In both cases 
probe removal was effected using 5% TEA(aq). 
The latter method of purification was also exploited recentiy; using the 
sulphonylethoxycarbonyl template described earlier, only replacing the biotin 
moiety with Cio (88) or Ci6 (89) n-alkyl chains.229 
R=n-CioH2i (88) 
R=n-Ci6H33 (89) 
Subsequent synthesis and purification of magainin 1 using a RPHPLC 
technique afforded tiie pure peptide after deprotection of the probe using a 10% 
solution of NH4OH in 2,2,2-trifluroethanol. The reaction was monitored by 
analytical RPHPLC, and mdicated that complete conversion to die free peptide 
took 18 h at room temperature. 
The most recent example of a chromatographic probe once more retmned to 
biotin-avidin affinity to effect purification. The transient biotinylating reagent 
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(90) was again based upon the Fmoc nucleus; Us synthesis involving seven 
individual steps with an overall yield not quoted. Its efficiency was 
demonstrated using 10 and 17 residue peptides, with final deprotection 
proceeding with piperidine treatment.230 
(90) 
3.2 2-Acetyl-4-nitroindane-l,3-dione (71) as a potential 
precursor for a chromatographic probe 
The above review of the literature highlights that in general, all of the 
reported chromatographic probes suffered from lengthy syntheses, on occasions 
resulting in poor overall yields, with the requirement for prior activation adding 
yet another step. However, acylation of a resin bound amine with 2-
acetyldimedone to afford the A -^Dde derivative has been demonstrated to 
proceed without prior activation, and has recentiy been exploited in the 
synthesis of polyamine spider and wasp toxins. 231 ft was therefore envisaged 
that reduction of the aromatic nitro group of 2-acetyl-4-nitroindane-l,3-dione 
(71) (see Chapter 2) and its subsequent acylation with either an affinity or 
hydrophobic probe would afford a potential reagent for peptide purification 
(Scheme 50). The absence of activation reduced the number of synthetic steps 
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to three, the first of which was already well estabUshed as high yielding (63%). 
reduction 
OH 
NH2 
R—CO2H 
j ^ _ Hydrophobic or 
affinity probe 
H2N Peptide 
0""'"H 
N Peptide 
Scheme 50. A potential chromatographic probe from 2-acetyl-
4-nitroindane-l,3-dione (71). 
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3.2.1 Acylation of a resin-bound amine using 2-acetyl-
4-nitroindane-l,3-dione 
To test the validity of our hypothesis, resin-bound Leu-enkephalinamide 
(on Novasyn® KR 100) was incubated ovemight with a four fold excess of 2-
acetyl-4-nitroindane-l,3-dione in DMF. A TNBS test performed on the resin 
was strongly positive indicating that unacylated amine was still present. A 
repeat of the experiment with larger equivalents of 2-acetyl-4-nitroindane-l,3-
dione were attempted, but all failed to quantitatively acylate the resin. A 
measurement of the pKg of 2-acetyl-4-nitroindane-l,3-dione indicated a 
surprisingly low value of 2.5,232 and it was therefore apparent that potential salt 
formation with the resin bound amine was inhibiting the acylation process. 
3.2.2 Reduction and concomitant acetylation of A^ a-
Nde-Ala via catalytic hydrogenation in the 
presence of acetic anhydride 
With the disappointing result obtained with the attempted on resin amino 
acylation with 2-acetyl-4-nitroindane-l,3-dione, it was felt that even prior 
reduction and ensuing acylation of the generated amine would not significantly 
alter the pKa of the resultant molecule, and therefore the affinity probe would 
probably need to be intioduced at the final residue stage, coupled to the relevant 
amino acid. In order to investigate whether the nitro group could be selectively 
reduced in this situation, A^«-Nde-Ala was dissolved in methanol and 
hydrogenated ovemight in the presence of a 50 fold excess of acetic anhydride 
(Scheme 51). In the original paper, 200 catalytic hydrogenation proved to be the 
most efficient means of reducing 2-acetyl-4-nitroindane-l,3-dione (71) to 2-
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acetyl-4-aminoindane-l,3-dione, yet in our hands the modified process at best 
afforded the A -^acetylated product (91)as a pale yellow amorphous powder in a 
very poor 20% overall yield. Various alternative catalytic transfer 
hydrogenation reductions were attempted; all returning the starting material. 
CH f"""\ JU»" 
[I N ' " ' ^ C O o H 
O (72) 
Scheme 51. Catalytic hydrogenation and acetylation of N"-
Nde-Ala.OH 
The unrewarding results so far obtained suggested that our initial 
ambitions to endow a multi-faceted nature to the A -^Nde protecting group were 
not going to be realised. However, the ease with which C-acylated Meldrum's 
acids could be prepared233 (see Chapter 4) led us to readdress the problem by 
exploiting the cyclic 1,3-diketone, 5,5-dimethylcyclohexane-l,3-dione 
(dimedone) (65), as our template for further modification towards a 
chromatographic probe. Generation of the C-acylated Meldmm's acid exploited 
the acidity of the carbonyl flanked methylene protons. This intrinsic 
nucleophihcity allowed the 4-dimethylaminopyridine (DMAP) catalysed 
condensation between Meldrum's acid and a carbodiimide activated carboxylic 
acid (Scheme 52). 
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Scheme 52. DCC/DMAP mediated acylation of Meldrum's acid. 
Until now, the synthesis of 2-acetyldimedone, required 5,5-
dimethylcyclohexane-1,3-dione to be refluxed in acetic anhydride in the 
presence of anhydrous sodium acetate, with the mechanism proceeding through 
initial 0-acetylation followed by an intramolecular Fries-type rearrangement to 
afford the required product as a pale yellow crystalline solid in a 64% yield. 
This particular approach required both vacuum distillation and flash column 
chromatography to purify the product, which itself was limited to the acetyl 
derivative. However the stmctural similarity displayed between Meldrum's acid 
and dimedone prompted us to readdress the synthetic sti:ategy. 
3.3 A new synthesis of 2-acetyldimedone 
In accordance with the conditions used for C-acylation of Meldrum's 
acid, dimedone, DCC and DMAP (1:1.2:1) were allowed to stir at room 
temperature in dichloromethane (DCM). A precipitate of DCU was soon 
formed, and after overnight reaction work-up afforded 2-acetyldimedone (92) 
as a pale yeUow crystalline solid in an 80% yield. During the reaction, TLC 
analysis revealed that no 0-acetyl dimedone formation occurred. This 
observation led us to postulate that mechanistically, the presence of the DMAP 
auxiliary nucleophile promoted C-acylation via attack of the soft 'Lewis base' 
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carbon centi-e of dimedone at the activated acid (Scheme 53). 
AcOH DCC/DMAP/CH?C1, 
DCU 
0'""H 
\ 
O 
CH3 
DMAP 
J O 
CH, 
b (92) 
Scheme 53. DCC/DMAP mediated acetylation of dimedone 
The significant amount of 0-acylation observed with the original 
procedure, or altematively treatment of dimedone with acetyl chloride,234 is 
presumably a result of the hard enolic oxygen anion participating as the 
predominant nucleophile towards, in these examples, the hard carbonyl centre 
of the acid anhydride or chloride. 
3.4 Development of a hydrophobic chromatographic 
probe 
Encouraged by this result, it was felt that replacement of acetic acid in 
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the above scheme by a long chain fatty acid, would generate a hydrophobic 
chromatographic probe that could be coupled to the A -^terminus of a resin bound 
peptide chain without the requUement for pre-activation (Scheme 54). 
O i i . i . H 
+ R—CO2H 
R = (CH2)nCH3 
O H 
\ 
N Peptide 
R 
Scheme 54.Synthesis of a hydrophobic chromatographic probe 
and subsequent N-acylation of a resin-bound 
peptide. 
Hexanoic acid was chosen, as it was envisaged that a five carbon chain 
would endow a substantial increase in the capped peptides hydrophobicity, 
without compromising its solubility. 
3.4.1 Synthesis of 2-hexanoyldimedone 
Using analogous conditions used to synthesise 2-acetyldimedone; 
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dimedone, hexanoic acid, DCC and DMAP were allowed to stir overnight in dry 
DCM at room temperature. Filtration of the N.A^'-dicyclohexylurea, and 
acid/base work-up afforded 2-hexanoyldimedone (93) as a yellow oil, single 
spot by TLC with an overall yield of 84%. Mass spectral and IH NMR 
analysis confumed the structure, with the latter showing an extremely low field 
singlet at 518.14 expected for the strongly hydrogen-bonded enol proton. 
3.4.2 On resin A^-acylation of the angiotensin receptor 
binding protein fragment using 2-hexanoyl-
dimedone 
The eight residue angiotensin receptor binding protein fragment was 
chosen as the test sequence to validate the ability of 2-hexanoyldimedone to 
acylate the AT-terminus of a resin-bound peptide. The peptide was synthesised 
by standard Fmoc SPPS, with RPHPLC analysis of the crude product showing 
U to be one major peak {ca. 98% purity), with the gradient conditions employed 
eluting the peptide after 7.5 min. The purified peptide was characterised by -hve 
ES-MS. 
A portion of the resin, with the peptide still attached, was incubated 
ovemight with a four fold excess of 2-hexanoyldimedone in DMF, showing a 
negative TNBS test the following moming. Consequently, a portion of the 
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resin was cleaved and side-chain deprotected to afford a white amorphous 
powder which was subsequentiy demonstrated by RPHPLC, identical to the 
gradient used for the free peptide, to be one major peak eluting at 16.8 min. 
The purified peak was characterised by -f-ve ES-MS as the A -^acylated peptide. 
It is felt that the significant (9.3 min in this example) shift in retention time is 
sufficient to separate any required peptide from the more hydrophilUc tmncated 
impurities obtained from the synthesis of a difficult sequence. 
3.4.3 Deprotection and recovery of the target peptide 
Removal of the hydrophobic probe under mild conditions was required 
to completely substantiate this reagent. Therefore, the A -^acylated peptide was 
allowed to stir in 5% hydrazine monohydrate(aq) and the deprotection monitored 
by RPHPLC (Scheme 55). 
O-i'.H 
CONH2 
5% Hydrazine monohydrate(aq) 
H2N Peptide I—CONH2 
Scheme 55. Hydrazine mediated deprotection of the hydrophobic probe. 
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After 30 min the complete removal of the hydrophobic probe was 
evident. TFA was then added dropwise to the cooled solution until pH 2 was 
attained. The solution was desalted and evaporated to dryness, with ether 
trituration affording the product as a white amorphous powder in almost 
quantitative yield. The ether soluble heterocyclic deprotection byproduct being 
removed during trituration. The RPHPLC of the cmde deprotection product 
indicated one major peak, of the original retention time 7.5 min., with the 
purified peak being characterised by +\e ES-MS as the angiotensin receptor 
binding protein fragment. The three RPHPLC traces of the original peptide, A^ -
modified and post deprotection are displayed overleaf (Fig.4). 
In summary, we have described the one-pot synthesis of a reversible 
hydrophobic chromatographic probe, which can quantitatively acylate the A^ -
terminus of a resin bound peptide without the need for any form of pre-
activation. Post-purification removal of the probe with 5% hydrazine 
monohydrate(aq) provides a mild, inexpensive and convenient procedure for 
recovery of the required peptide in almost quantitative yields. 
3.5 Development of an affinity chromatographic probe 
The facile synthesis of the hydrophobic probe from the dimedone and 
hexanoic acid precursors suggested that any reagent bearing a carboxylic acid 
could also be coupled onto the cycUc 1,3-diketone template to generate a raft of 
potential chromatographic probes. The well established non-covalent 
interactions displayed between biotin and avidin,223,224 has been previously 
exploited in affinity probes; as indicated in the inti-oduction to this chapter. 
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Figure 4. RPHPLC traces of (a) angiotensin receptor binding 
protein fragment; (b) A -^terminal modified angiotensin 
receptor binding protein fragment; (c) cmde hydrazine 
deprotection product. 
However, the synthesis of these reagents is cumbersome and often protracted, 
with only moderate overall yields. The methodology we have developed allows 
the synthesis to be complete in one step. 
We envisaged that acylation of the A -^terminus of a resin bound peptide, 
containing tmncated capped impurities, with biotinylated dimedone should be 
possible without prior activation. Application of the cmde cleavage product to 
an immobilised avidin column should result in retention of the N-modified 
peptide, whilst the tmncated impurities elute off The pure peptide could then 
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be recovered by treating the avidin column with a 5% hydrazine(aq) solution, 
thereby leaving the biotinylated heterocyclic byproduct attached to the column 
(Scheme 56). 
HoN- Peptide 
Biotinylated 
probe 
-N-
H 
Peptide |-C02H 
AcHN- Truncated Impurities |~ l 
Cleavage / 
-N-
H 
Peptide J~W 
AcHN-
deprotection 
Truncated ImpuritiesJ-COjH AcHN- Truncated Impurities I—^M 
Immobilised 
avidin column 
5% Hydrazine(aq) Deprotected biotinylated 
heterocycle retained on 
column 
AcHN- Truncated Impurities |-C02H HsN-] Peptide [-CO2H 
Scheme 56. hnmobiUsed avidin affmity column purification of 
a reversibly biotinylated peptide. 
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3.5.1 Synthesis of 2-biotinyldimedone (94) 
It was envisaged that the DCC/DMAP mediated acylation of dimedone 
with biotin should afford 2-biotinyldimedone (94) in high yield (Scheme 57). 
However, due to the poor solubility displayed by biotin in DCM, the reaction 
was extremely slow. Replacement of DCM with DMF overcame the solubility 
problem and after allowing the reaction to proceed for 48 h., work-up afforded 
2-biotinyldimedone as a white crystalline solid in 69% yield. 
O 
.A 
HN NH 
'NH 
HO2C 
DCC/DMAP 
Scheme 57. Synthesis of 2-biotinyldimedone 
The compound was fully characterised by IH NMR, 13C NMR and 
accurate FAB-MS and microanalysis. RPHPLC confirmed tiie compound to be 
>99% pure. 
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3.5.2 On resin A -^acylation of the angiotensin receptor 
binding protein fragment using 2-biotinyl-
dimedone (94) 
Once again, the eight residue angiotensin receptor binding protein 
fragment was chosen as the peptide with which to test the validity of the 
biotinylating reagent. Attached to NovaSyn®KR 125 resin, the side-chain 
protected fragment was incubated ovemight with a four-fold excess of 2-
biotinyldimedone, producing a negative TNBS test. A portion of the resin was 
cleaved and the side-chain deprotected peptide was analysed by RPHPLC. The 
trace indicated the product to be one major peak, confirming quantitative 
incorporation of the probe onto the resin bound peptide. +ve ES-MS analysis 
of the purified peak exhibited the correct mass for the AT-biotinylated peptide. 
3.5.3 Immobilisation and deprotection of the 
biotinylated angiotensin binding protein fragment 
on an immobilised avidin column 
An immobilised avidin column (Pierce) was equilibrated with phosphate 
buffered saline (pH 7.5). The cmde biotinylated peptide was dissolved in the 
same buffer solution and ran onto the column. The column was allowed to 
incubate for 1 h, and was then washed with ten column volumes of binding 
buffer. RPHPLC analysis of the washings indicated complete loss of the 
biotinylated peptide peak (Figure 5). 
The column was treated with 5% hydrazine monohydrate(aq) (5 column 
volumes, each allowed to incubate for 5 min.) and the eluent collected into a 
10% acetic acid solution. Subsequent de-sahing of the eluent and RPHPLC 
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analysis exhibited one major peak of identical retention time to the required 
peptide, Fig. 5. The purified product was characterised by -i-ve ES-MS and 
confirmed as the angiotensin receptor binding protein fragment. 
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Figure 5. RPHPLC traces of (a) angiotensin receptor binding 
protein fragment; (b) A^-biotinylated angiotensin 
receptor binding protein fragment in binding buffer; 
(c) post incubation column washings; (d) cmde 
hydrazine deprotection product. 
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In summary, we have described a facile and high yielding one-pot 
synthesis of 2-biotinyldimedone (94), a reversible biotinylating reagent which 
can be quantitatively incorporated onto the A/-terminus of a resin bound 
protected-peptide fragment without the requirement of pre-activation. FoUowing 
immobilised avidin affinity chromatography, 5% hydrazine monohydrate(aq) 
mediated deprotection provides a mild and efficient means of peptide recovery. 
3.6 Future work 
The facile nature of both the synthesis and use of these dimedone 
derived reagents offers wide exploitation. Recently, a Z^w-imidazole reagent, 
^w-(inudazo-2-yl)methylaminomethane,235 (bimam) (95) was anchored to solid 
support and subsequently demonstrated to display an excellent affinity for Cu2+ 
ions. 
It is envisaged that slight modification of the molecule, in order to incorporate a 
carboxylic acid containing linker, would furnish a molecule that once coupled to 
dimedone, could be utilised as an affinity reagent exploiting the pH reversible 
binding it would display to an immobilised Cu2+ ion column (Scheme 58). 
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Scheme 58. Potential exploitation of the bimam Cu2+ affinity 
reagent as a reversible peptide purification probe. 
Another exciting application of the reversible affinity chromatographic 
probes would be the ability to rapidly purify protected peptide fragments for 
subsequent segment condensation towards protein synthesis (Scheme 59). 
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Scheme 59. Hypothetical route for protein synthesis via rapid 
purification of protected peptide fragments using 
the reversible biotinylating reagent 2-biotinyl-
dimedone (94). 
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4 
Synthesis of a Multiple 
Antigenic Vector, Expressing 
a Non-Peptidic Hapten, via 
Solid Phase Methodology 
4.1 Introduction 
Work pioneered by Tam et al during the late eighties introduced the concept 
of multiple antigenic peptides (MAPs) as a means of eliciting the generation of 
anti-peptide antibodies.236 The ability to express multiple copies of the required 
hapten on a poly-lysine framework (96) via SPPS methodology, complemented 
the previous protocols of coupling such peptidic/non-peptidic immunogens onto 
carrier proteins such as keyhole limpet haemocyanin (KLH) or bovine semm 
albumin (BSA).237 
Peptide antigen 
Lys 
Peptide antigen 
Peptide antigen 
Lys 
Peptide antigen 
Peptide antigen 
,Lys 
Peptide antigen 
Peptide antigen 
Lys' 
/ Peptide anUgen 
Lys pAla-
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The MAP system has been demonsfrated as extremely valuable in experimental 
vaccine development,238-242 with the inherent advantage of enhanced 
reproducibility, not possible with the protein bound peptide antigens. 
These encouraging reports prompted our research group to explore this 
methodology in an attempt to raise antibodies to the A^p-ketoacyl-L-homoserine 
lactone structure of bacterial autoinducers such as Ar-(3-oxohexanoyl)-L-
homoserine lactone (OHHL) (97). 
4.2 OHHL; structure and function 
Research within this Department, focussed towards the elucidation of the 
biosynthetic pathway responsible for carbapenem antibiotic production (see 
Chapter 5) in the Gram-negative plant pathogen Erwinia carotovora , uncovered 
a small molecular weight, diffusible substance that regulated carbapenem 
synthesis in a ceU-density dependent fashion.243,244 Spectroscopic analysis of 
the molecule confirmed that it was identical to the pheromone responsible for 
bioluminescence control in the unrelated marine bacteria Vibrio fisheri; namely 
OHHL (97). 
O O 
4.2.1 Autoinduction of bioluminescence in Vibrio 
fisheri 
Before the discovery of OHHL in Erwinia carotovora, the only reports of Us 
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existence were as a pheromone controlling bioluminescence in the marine 
bacteria Vibrio fisheri.2^5,1A6 The light emission is catalysed by a collection of 
enzymes known as luciferases, whose only common feature is their requirement 
for molecular oxygen.247,248 The process involves infracellular oxidation of a 
long-chain aliphatic aldehyde (e.g. tetradecanal) and the reduced form of flavin 
mononucleotide (FMNH2) by luciferase, with the free energy Uberated as blue-
green light. 
RCHO + FMNH2 + O2 Luciferase RCO2H -I- FMN + H2O + hs! 
A 9 kilobase-pak gene was isolated from V. fisheri and demonsfrated to encode 
all the functions required for light production and regulation (Figure 6). 
lux R lux I lux C luxD lux A luxB luxE 
0 
Operons 
Genes 
Regulation , 1 Aldehyde n Luciferase 1, Aldehyde , Functions 
_, Kilobase 
9 pairs 1 8 
Figure 6. Organisation and function of lux genes cloned 
from V. fisheri (adapted from249) 
Lux A and lia B code for the luciferase enzyme, lux C, D and E code for the 
sub-units of a fatty acid reductase, whereas lux R and / are involved in 
regulation of lux expression. Bioluminescence in V. fisheri only occurs in 
dense bacterial cultures, as then, the pheromone or autoinducer can attain the 
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threshold concentration required to initiate transcription of the lux gene. The 
pheromone was established as OHHL (97) by Eberhard et a/,250 and has 
subsequentiy been shown to be generated from the lux I gene product.247,248 
OHHL then binds to and activates the LuxR protein, wUh the OHHL-Lux R 
adduct stimulating franscription of the operon indicated above (Figure 6). Since 
the first gene located within the sequence produces the Lux I protein, 
franscription results in increased levels of OHHL, ensuring a positive feedback 
circuit that generates a substantial and rapid response to a small mitial stimulus 
(Figure 7). 
Lu?(I protein 
Lw(^protein 
Primary metabolic 
precursors 
Figure 7. Regulation of the lux operon in V. fisheri by the 
OHHL autoinducer. 
4.2.2 Other bacteria possessing autoinducer molecules 
The unexpected discovery that carbapenem biosynthesis within a 
terrestiial bacterium was controlled in a similar fashion, and by exactly the same 
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autoinducer, as the bioluminescent pathway of a few marine bacteria, implied 
that other bacteria employed this mode of infracellular communication. Using 
recombinant technology, an E. coli vector was constiiicted to bioluminesce only 
in the presence of exogenous OHHL and a long chain fatty aldehyde.244,251 
Studies using this vector demonstrated that over 20 different Gram-negative 
bacterial cultures could induce bioluminescence. For Pseudomonas aeruginosa, 
Serratia marcescens, Erwinia herbicola, Erwinia carotovora, Enterobacter 
agglomerans arui Yersinia enterocolitica, the inducer molecule was characterised 
by IR, MS and IH NMR to be OHHL.251 
An indication that OHHL plays a pivotal role in the pathogenesis of 
human infection has come from studies associated with the opportunistic 
pathogen Pseudomonas aeruginosa. This bacterium can infect almost any body 
site given the correct predisposing conditions, and now displays multiple 
resistance to most commonly employed antibiotics. Secretion of exfraceUuar 
toxic factors, such as an exotoxin which inhibits protein synthesis in 
mammalian cells and various tissue damaging enzymes, e.g. an alkaline 
protease and an elastase, is key to its pathogenicity. The latter enzyme has been 
demonstrated to be the product of a gene termed lasR, and shares sigtuficant 
amino acid sequence homology with LuxR.252 The well established 
observation of the growth phase dependency of elastase production, coupled 
with the discovery in our Department that P. aeruginosa produces OHHL, 
strongly suggested the involvement of OHHL, or structurally sunilar 
compounds, in the control of this vimlence determinant. 
It has recentiy been shown that P. aeruginosa produces another A -^acyl 
homoserine lactone, A^-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) 
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(98), also involved in autoinduction pathways.253 
The similarity of the OHHL and OdDHL stmcmres, coupled with work carried 
out in our Department,254 led us to postulate that the A^-p-ketoacyl-L-
homoserine lactone was the key stmctural feature responsible for the molecules 
activity, with the alkyl chain providing the major feature of family/species 
diversity. Interference with the synthesis or transmission of these molecular 
messengers therefore presents an ideal target for the freatment or prevention of 
infection. However, a means of rapidly screening bacteria that produce such 
molecules was not yet available. 
It was envisaged that generation of a monoclonal antibody designed to 
recognise the iV-p-ketoacyl-L-homoserine lactone molecule, should therefore 
furnish a biological probe that could be used to screen any bacterial colony for 
the presence of compounds containing this particular chemical entity. The poly-
lysine stmcture described earlier in this chapter was felt to be the ideal vector 
system with which to attempt this antibody generation, with the overaU 
approach presenting two important advantages; 
i) The reproducibUity of the immunogenic reagent. 
ii) The potential to use the resin bound MAP type stmcture as an immobilised 
affinity column for both isolation and purification of the required antibody 
from a polyclonal source. 
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4.3 Synthesis of a A^-p-ketoacyl-L-homoserine lactone 
containing hapten 
Construction of the desired MAP type stmcture, incorporating the 3-
oxoalkanoyl homoserine lactone molecule, required the synthesis of the latter 
carrying a spacer and a carboxyl functionality (99) to acylate the amino residues 
of the poly-lysine MAP framework. The spacer was required to separate the 
hapten molecule from the steric buUc of the MAP macromolecule. 
O O 
HO2C-I Spacer 
The 3-oxoacylated homoserine lactone has been reported,254 and 
involves the cumbersome preparation of a 3-oxoalkanoic acid via acylating 
malonic ester, 3-oxo ketalisation, amine acylation and deprotection. Obviously, 
this method would have been even lengthier in our case, hence we sought to 
prepare (99) by a different strategy. 
The synthesis of p-ketoesters via alcoholysis and spontaneous 
decarboxylation of C-acylated Meldmm's acid is well documented.233 it was 
envisaged that replacement of the alcohol with the amine of L-homoserine 
lactone would instead afford the p-ketoamide stmctural unit characterising 
molecules such as OHHL (Scheme 60). 
The DMAP catalysed C-acylation of Meldrum's acid using a 
carbodiimide activated carboxylic acid has been reported to proceed with 
excellent yields.255 
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Acetone + CO2 
Scheme 60. p-Ketoamide synthesis. 
Acylation of Meldmm's acid with mono-protected adipic acid and 
aminolysis of the resultant molecule with L-homoserine lactone would furnish 
the required molecule with adequate spacer length. Adipic acid was therefore 
monoprotected as its benzyl ester (100),256 in a 60% yield (Scheme 61). 
HOjC" 
.CO2H 
Tosic acid / PhCHs 
] 
A /Dean-Stark 
HO2C 
'OH 
" - ^ 
Scheme 61. Mono-benzyl adipate synthesis. 
Benzyl ester protection was chosen as catalytic hydrogenolysis provided 
a convenient and mild means of deprotection, which should not effect any 
deleterious side reactions on the rest of the completed molecule. C-acylation of 
Meldmm's acid was achieved via DCC activation of the mono-benzyl adipate 
(100) with DMAP catalysis. The intermediate (101), without isolation, was 
treated with L-homoserine lactone in anhydrous acetonitrile, which after work-
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up, afforded N-(7-benzyloxycarbonyl-3-oxoheptanoyl)-L-homoserine lactone 
(102) as a white crystalline soUd with an overall yield of 42% obtained for the 
two steps (Scheme 62). 
V^ (101) Not isolated 
HO2C 
L-Homoserine lactone 
H2, Pd/C 
O O 
(103) 
Scheme 62. Synthesis of N-(7-carboxy-3-oxoheptanoyl)-L-
homoserine lactone. 
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The IH NMR of (102) displayed the characteristic singlet at 83.45, 
expected for the carbonyl flanked methylene protons, with peak integration 
indicating a predonunantly keto, rather than enol structure. FAB-MS and 
microanalysis of the product confirmed its overall purity. Catalytic 
hydrogenation removed the benzyl ester protection in almost quantitative yield, 
to afford the free acid (103) as a waxy solid. RPHPLC analysis revealed the 
product to be of single peak purity, ready for use in SPPS. 
4.4 Initial attempt at the MAP synthesis 
It was envisaged that a MAP core similar to that shown earUer (96), 
with four outermost lysine residues, should provide a vector capable of eUciting 
an immune response when injected with a suitable adjuvant. Two p-alanine 
residues, initially coupled to the resin, would also provide an adequate spacer 
between the poly-lysine core and the solid support to aUow unhindered 
synthesis of the peptide skeleton. 
A kieselguhr/polydimethylacrylanude composite support functionalised 
with tiie TFA labile HMPA linker, was used as the solid phase resin (104).3i 
/ Vo-CH,-H0-CH2-^ ^0-CH2-CO-Nle-NH(CH2)2NH-
V 
' Kieselghur/polydimethyl-
acyrlamide resin support 
4-HMPA linker 
(104) 
Esterification of an N-protected anuno acid onto a hydroxymetiiylated 
resin is readily achieved via the preformed symmetiical anhydride with DMAP 
catalysis.257,258 Hence A^-Fmoc-p-alanine was coupled to the resin with an 
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overall efficiency estimated to be 90% using the calibration plot provided,259 
(Scheme 63). 
f 
2 X FmocHN" 
FmocHN ^ = 0 
O' 
FmocHN 
V o 
'-Qr \ . ^ 
DMAP 
•HO 
(104) 
FmocHN 
\ 
O (105) 
'^ ^P 
Scheme 63. First residue (A'-Fmoc-p-alaiune) attachment to an 
HMPA modified resin. 
Using an LKB 4175 Biolynx manual peptide synthesizer, the Fmoc 
group was deprotected under continuous flow conditions using 20% piperidine 
in DMF. Acylation of the generated free amino group with a second A -^Fmoc-p-
alanine residue was effected via TBTU/DIEA/HOBt activation. A negative 
TNBS amine test indicated coupling was complete after 30 min. Piperidine 
mediated A -^Fmoc deprotection was followed by incorporation of the Fmoc-
Lys(Fmoc)-OH residue, which after Fmoc removal exposed the A/'«-and N^-
amino groups for subsequent acylation. Sequential addition and deprotection of 
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Fmoc-Lys(Fmoc)-OH residues to the growing peptide can therefore supply a 
poly-lysine core of any required dimension. As stated earlier, our synthesis 
was halted at the four lysine residue stage, allowing the incorporation of eight 
hapten molecules. Introduction of the A^-p-ketoacyl-L-homoserine lactone 
containing hapten (103) was attempted using DIPCDI/HOBt activation. The 
TNBS amine test remained strongly positive even after extended double 
coupling procedures were attempted. This disappointing result dictated the 
requfrement for fiirther solution based experiments in an attempt to ascertain the 
reason for coupUng difficulties. 
4.4.1 Attempted coupling of hapten (103) to L-valine 
methyl ester 
A solution based coupling of A^-(7-carboxy-3-oxoheptanoyl)-L-
homoserine lactone (103) to L-valine methyl ester was attempted using a 
DCC/HOBT activation procedure. After allowing the reaction to proceed 
ovemight, TLC indicated mainly the presence of starting materials. Since the 
acylating species was an alkyl carboxylic acid, there was no mechanistic reason 
why the coupling should not proceed almost quantitatively. It was therefore 
postulated tiiat the potential keto-enol tautomerism inherent withm tiie molecule 
may be generating a conformationally restricted structure that is eitiier 
deactivated or sufficiently hindered sterically to suppress activation and 
subsequent aminolysis. Temporary blockade of this enolisation via ketal 
formation, was hoped to improve the acylation efficiency. 
The benzyl ester (102) was converted to the cortesponding ethylene 
ketal (106) by the acid catalysed ketalisation with ethylene glycol in refluxing 
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benzene, with azeotropic removal of water achieved using Dean-Stark 
distillation apparatus (Scheme 64). 
^ ^ ^ , 
(102) 
HO. 
^^ "OH 
/ tosic acid 
Scheme 64. Acid catalysed ketalisation of (10 2) and 
subsequent benzyl ester deprotection. 
Work-up and purification by preparative thin layer chromatography (PLC) 
afforded the required compound as a colourless oil, with the ' H NMR 
confirming the ketal incorporation by the characteristic singlet at 8 4.0 for the 
ethylene protons and the expected upfield shift of the neighbouring methylene 
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protons. Catalytic hydrogenation of (106) afforded the ketal protected free acid 
(107). 
4.4.2 Attempted coupling of the ketal protected free 
acid (107) to L-valine methyl ester 
The ketal protected free acid (107) was coupled to L-valme methyl ester 
via DCC/HOBt carboxy activation. In this instance, a DCU precipitate was 
rapidly formed, and monitoring of the reaction by TLC indicated its completion 
within four hours. Work-up afforded the desired N-acylated valine residue 
(108) as a colourless oil in a much improved 60% yield (Scheme 65). 
HO2C' 
Me02C 
Valine methyl ester/ 
DCC/HOBt 
95% TFA(aq) 
30 min / ice bath 
Scheme 65. CoupUng of tiie ketal free acid (107) to valine methyl ester and 
subsequent ketal deprotection. 
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If coupling to the MAP core could now be achieved, it was hoped that the resm 
cleavage conditions, 95% TFA, would concomitantly remove the ketal 
protection to yield the required hapten. To test this hypothesis, (108) was 
freated with 95% TFA(aq), and was subsequently shown by TLC monitoring to 
be deprotected within 30 min. (Scheme 65). Removal of TFA in vacuo 
followed by a simple aqueous work-up afforded (109) in a quantitative yield, 
with the ^H NMR indicating complete loss of the ketal protons and a shift 
downfield of the now di-carbonyl flanked methylene protons. 
4.5 Second attempt at the MAP synthesis 
Using synthetic methodology analogous to that described in section 4.4, 
the MAP core was once again constructed on an HMPA modified 
kieselguhr/polydimethylacrylamide resin (104). Acylation proceeded more 
favourably with the ketal protection in place, yet TNBS monitoring and 
RPHPLC analysis of the poorly soluble cmde cleaved product demonstrated 
that coupling was stUl not quantitative. Double coupling of the hapten failed to 
improve the situation and it was subsequentiy felt that the 60% coupling 
efficiency displayed in solution combined with potential steric factors inherent 
with the MAP core made this particular target unattainable. 
4.5.1 Synthesis of a 4-branch MAP core 
In order to minimise the steric factors that may have been suppressing 
tiie overall coupling efficiency, it was envisaged that reduction of the MAP core 
to four available acylation sites should produce an immunogen of higher purity. 
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In this instance the synthesis of the title MAP core proceeded exfremely 
smoothly, with the RPHPLC indicating predominantly one product, which was 
characterised by MALDI-TOF MS to be of the correct mass. However, it was 
generally regarded that the decrease in both expression of the non-peptidic 
hapten on the poly-lysine framework, and the overall reduction in molecular 
weight of the immunogenic vector would seriously compromise the abUity of 
the compound to eUcit antibody production. It was therefore decided to attempt 
to couple the MAP vector onto a carrier protein. 
4.6Attempted coupling of the MAP type vector to a 
carrier protein 
Bovine semm albumin (BSA) is one of the most frequentiy used carrier 
proteins with which to elicit antibody production towards small orgaruc 
molecules. Lysine residues, located on the outer surface of the globular protein, 
provide an ideal acylation sites with which to couple a carboxy-bearing hapten 
(Scheme 66). 
NH, 
H,N 
HoN 
^ 
hapten-COHN 
carboxy-
activated , „^„^, 
NH2 ^hapten-COHN 
hapten 
NH2 hapten-COHN 
J 
y 
Bovine serum albumin protein 
NHCO-hapten 
NHCO-hapten 
NHCO-hapten 
NHCO-hapten 
NHCO-Hapten 
Scheme 66. Conjugation of a low molecular weight hapten to the lysine 
residues of BSA. 
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Various methods for hapten-protein conjugation are available,^^^ however the 
base lability of the lactone ring dictated coupling in a mildly acidic pH. Water 
soluble carbodiimide carboxy activation was therefore employed, with the 
reaction performed in phosphate buffered saline with the pH held at 6.4. 
Following ovemight reaction, lyophilisation and subsequent MALDI-
TOF MS analysis of the cmde product failed to indicate any incorporation of the 
N-P-ketoacyl-L-homoserine lactone contaiiung MAP vector. Once more, steric 
factors were potentially the greatest hinderance, with the carboxylic acid being 
almost completely obscured by the dendritic arms of the MAP framework 
(110). 
(110) 
It is likely that carboxy activation will occur, but approach of the o-
acylisourea intermediate towards the globular protein surface will be 
disfavoured because of the potential inter-chain hydrophobic interactions that 
would occur between the MAP vector and the BSA amino acid side chains 
which extend into the solvent. 
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4.7 Exploitation of a solubilisable resin suitable for 
injection into experimental animals 
With the synthesis of an 8-branch MAP system producing large 
impurities, and the inabiUty to acylate a 4-branch MAP onto a suitable carrier 
protein, another option was inspfred by a paper published by Sheppard et al}^^ 
A polymer support is described which contains cleavable cross-links, tiiereby 
making it suitable for SPPS but can subsequentiy be solubilised for 
immunisation. Novabiochem produced a similar resin, NovaSyn® KD 100, 
which consists of a polydimethylacrylamide/kieselguhr support functionalised 
with ethylene diamine (111).^ ^^ '^ ^^  
H2N (CH2)2—NH—I 
(111) 
Kieselghur/polydimethylacyrlamide 
resin support 
The peptide antigen is synthesised on the support and is permanently attached 
via an anude bond. In our case TFA mediated ketal deprotection would be 
followed by homogenisation of the resin and injection into a suitable 
experimental animal. 
4.7.1 Synthesis of the MAP vector on NovaSyn® KDIOO 
resin 
Two p-alanine spacers were initially attached to the resin support via a 
TBTU/DIEA/HOBt coupling regime. Synthesis of the 4-branch poly-lysine 
core proceeded smoothly, as did the final addition of the ketal protected A^ -p-
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ketoacyl-L-homoserine lactone hapten, with all couplings monitored until a 
negative TNBS amine test was obtained. Since the MAP vector was 
permanently attached to the resin support, it was impossible to characterise tiie 
final product. However, since our previous synthesis of this particular vector 
on the HMPA modified resin produced a relatively pure compound, it was felt 
that proper monitormg of each acylation step should furnish the expected resin 
bound immunogen. 
On completion of tiie synthesis, incubation of the resin in 95% TFA(aq) 
for 2 h was regarded to be significantiy long enough to remove the ketal 
protection. The resin was subsequentiy washed and dried ovemight in vacuo. 
4.7.2 Preparation and injection of the homogenised 
resin into experimental rabbits. 
High power sonication of 20mg of peptide resin in 1 ml of water for 
injections, resulted in the formation of an milky white paste. Introduction of 1 
ml of Freund's complete adjuvant and subsequent emulsification, provided 
enough injectable material for two experimental rabbits, both requiring six 
individual injection sites. Secondary boost injections with the same amount of 
resin were carried out week and one month after the initial injection. Bleeds 
were taken from the animals prior to the initial and subsequent booster 
injections. 
4.7.3 Analysis of plasma samples for anti-A^-p-ketoacyl-
L-homoserine lactone antibodies 
A nifrocellulose dot blot assay was performed on plasma samples from 
all three bleeds, but failed to indicate tiie presence of any anti-AT-p-ketoacyl-L-
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homoserine lactone antibodies. This result confirmed our fears that the copy 
number and hence the molecular weight of the immunogen was perhaps too low 
to Ulicit a measurable immune response. 
4.8 Conclusions and future work 
In summary we have described a facUe and efficient novel synthesis of 
the key A^-p-ketoacyl-L-homoserine lactone portion of many bacterial 
autoinducers. By including a carboxyl group at the terminus of the alkyl chain 
we successfully constructed a reagent that, once attached to the correct 
immunogenic vector, had the potential to raise antibodies to the above moiety. 
Attempts to generate an immunogenic vector via solid phase peptide synthetic 
techniques unfortunately proved unsuccessful, due probably to the overall low 
molecular weight of the completed constmct. 
To attain the requirement of antibody generation, future work should 
address glutamic acid as the reagent to initially acylate Meldrum's acid. 
Aminolysis of the resultant molecule using L-homoserine lactone and correct re-
protection of the amino acid should afford a reagent which could employed to 
generate multiple copies of the required hapten on an appropriate immunogeruc 
scaffold (Scheme 67). 
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Scheme 67. A Potential reagent for the SPPS of a MAP type 
structure incorporating multiple copies of tiie 
required A -^p-ketoacyl-L-homoserine hapten. 
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Preliminary Solution Phase 
Synthesis of Methyl (35, 
5 / f ) C a r b a p e n a m - 3 -
carboxylate for Potential 
Transposition onto Solid 
Phase. 
5.1 Introduction 
Within the last decade, the extension of SPPS techniques to solid phase 
organic synthesis (SPOS) has advanced at an unprecedented rate.264-269 The 
ability to perform a vast array of chemical transformations on a resin-bound 
synthon has allowed the generation of vast chemical libraries, for lead molecule 
identification within both the pharmaceutical and agrochemical industries. 
Within our Department, the requfrement for metabolic precursors of the 
biosynthetic pathway involved in production of the p-lactam carbapenem 
antibiotics, prompted us to address an asymmetric synthetic sfrategy that could: 
i) provide the requfred biological target molecules. 
u) generate a library of side-chain and ring modified carbapenems upon 
transposition of the solution based synthesis onto solid phase. 
5.2 The development of |3-lactam antibiotics 
Louis Pasteur's initial observation of antibiosis, i.e. the inhibition of one 
microorganism by products diffusing from another, heralded the birth of 
antimicrobial chemotherapy in 1877. The next significant advance was made m 
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1940 when Florey and Chain solved the problem of isolating the labile 
antibacterial substance from Penicillium notatum , named penicillin by 
Alexander Fleming in 1929. The efficacy of penicillin against a wide range of 
bacteria was demonstrated in vitro and was subsequently used to treat 
experimental infections in mice, with quite outstanding results. The problem of 
mass production was solved in the United States and purified penicillin was 
used to save many lives during the latter stages of the Second World War. 
During the last fifty years the antibiotic field has contmued to advance in 
a wide variety of chemotherapeutic areas, and throughout its development the B-
lactams have continued to contribute a major part. However, the battle between 
man and bacteria has never remained a one-sided battle. Many B-lactam 
containing antimicrobials can be rendered inactive by 6-lactamase enzymes 
produced by various bacteria. Now, even many semi-synthetic derivatives have 
been rendered ineffective, encouraging tiie search for new compounds, e.g. the 
cephalosporins and most recently, the carbapenems. 
5.2.1 The carbapenems 
The carbapenems form a diverse group of 6-lactam antibiotics and since 
1970 over 40 different examples have been isolated from the actinomycetes, 
with Streptomyces spp. acting as major producers.2vo,27i The carbapenems 
possess the broadest antibacterial spectra of all the p-lactam containing 
antibiotics. It is however, their high infrinsic resistance to p-lactamases tiiat 
once again makes them attractive targets to develop as clinical antimicrobial 
agents. 
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In general, the carbapenems belong to two main groups: 
i) the thienamycins, e.g. (112) 
U) the olivanic acids, e.g. (113) 
(112) (113) 
Despite their promise, the development of carbapenems as chemotherapeutic 
agents has been troublesome, with low titre concentrations and stability 
problems associated with attempts to produce them via fermentation processes. 
Consequently, the only two carbapenems licensed for use, irrupenem and 
meropenem, are produced via expensive total chemical synthetic methodologies. 
However, isolation of the stmcturally very simple parent compound, 
(5/?)-carbapen-2-em-3-carboxylic acid (114), as hs /?-nitrobenzyl ester,272 
demonsfrated it to possess the same absolute configuration at the C-5 position as 
the products isolated from Streptomyces,2^^ and was shown to display excellent 
antimicrobial activity. 
CO2H 
(114) 
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This molecule or its biosynthetic precursor, in an analogous fashion to 
6-aminopenicillanic acid, could potentially provide lead stmctures for semi-
synthetic manipulations, to generate a raft of possible antinucrobial agents. 
Attempts in this Department were therefore embarked upon to elucidate tiie 
biosynthetic pathways that produced (114) and other secondary metaboUtes 
contained within the growth medium. 274 
5.2.2 Biosynthetic studies 
An initial investigation, using labelled L-[U-14C]-glutamate as a primary 
metabolic precursor in the bacterial growth medium, confirmed that L-glutamic 
acid was involved in the synthesis of pyrroUne ring of the bicyclic p-lactam 
(114). However, during the experimental study it became increasingly evident 
that two other labelled compounds, with a similar RPHPLC retention time as 
(114), were also present within the culture medium. Exfraction and isolation of 
the unknown compounds indicated they were present in a ratio of ca. 9:1 and 
both displayed masses two units greater than the carbapenem (114). The IR 
spectta of the two molecules demonstrated strong sfretching frequencies cenfred 
at 1760 and 1745 cm-i respectively, indicative of a p-lactam carbonyl. They 
were also shown to possess a high intrinsic resistance to p-lactamases. Mass 
spectral comparisons of the two unknown compounds with (114) combined 
with thefr IH NMR identified the major isomer as the rran '^-carbapenam (115) 
and the minor compound as the ciVisomer (116).275 
In a parallel experiment, it was discovered that catalytic hydrogenation 
of (114) resulted in the production of two isomers, again in the ratio of 9:1. 
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H H 
(115) (116) (117) 
Understandably, in this instance the larger proportion was of the cw-isomer. 
The CD spectmm of the cw-isomer obtained via hydrogenation was shown to be 
identical to that of (116) from the previous labelling experiment, thereby 
estabUshing the absolute configuration around tiie two asymmetric centres. Due 
to the low yield of the trans-isomer, it was impossible to compare it to the 
natural product, so a tentative assignment of {3R, 5R) was made on the basis of 
comparative CD data. This also correlated well with the observation that the 
ring junction stereochemistiy of all naturally occurring carbapenems was also 
5/?.276 
It was not until the frans-isomer (115) was unambiguously 
synthesised,277 and its CD spectirum compared with that of the natural trans-
carbapenam, that discrepancies were apparent. The CD spectrum of the 
synthetic carbapenam exhibited a differential absorbance at 230 nm that was 
equal and opposite to that of tiie natiiral product. It followed therefore, tiiat the 
major isomer obtained from the original radioactive ttacer experiment possessed 
the enantiomeric (35,5S) configuration (117). 
This discovery suggested that L-glutamic acid was the biological 
precursor to the pyrroline moiety of the carbapenems. To confirm this, a further 
study was undertaken, which demonstrated the incorporation of [1,2-
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13C2] acetate into both the pyrroline and lactam rings. Incorporation of the 
radiolabelled acetate into glutamic acid via the TCA cycle accounts for the 
appearance of the 13C2 unit in the five membered ring (Figure 8). 
H 
H3C—CO2 
(114) CO2H 
TCA 
Cycle 
H 
SCoA N ^ 
""H 
(118) CO2H 
HO2C' 
HjN' 
, .inH 
^C02H 
O' \ " 'H 
(116) CO2H 
H 
(117) CO2H 
Figure 8. Putative biosynthetic pathway accounting for the 
incorporation of [1,2-13C2] acetate into (114), 
(116) and (117). 
The hypothetical monocyclic intermediate (118) would probably be 
generated from the condensation of acetyl-coenzyme A (acetyl-S-CoA), and y-
glutamyl pyrophosphate. 
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Conversion of the carbapenam (116) to the active carbapenem (114) 
was still unproven. It was therefore envisaged that an unambiguous synthesis of 
tiie cw-isomer would allow further investigations into this area by allowing this 
potential biosynthetic precursor to be fed to a mutant Erwinia strain, blocked in 
the early stages of the biosynthetic gene responsible for carbapenem production. 
If the carbapenem (114) was subsequentiy isolated, it could only have been 
synthesised from the fed compound. If so proven, then a potential biosyntiietic 
route, capable of exploitation for the semi-synthetic preparation of various 
modified carbapenems, would have been demonsfrated. 
5.3 Solution phase synthesis of ci.s-(35,5/{)-carbapenem-
3-carboxylic acid biosynthetic precursors with 
fur ther potential for the generation of a 
carbapenem library 
Our initial goal was the asymmetric synthesis of the cw-carbapenam 
(116), with the ambition of transposing the solution based sfrategy onto a solid 
phase support, with the ultimate target being the generation of a carbapenem 
library exhibiting subtie side-chain and ring modifications. 
To this end, L-pyroglutanuc acid was chosen from the 'chiral pool' of 
potential synthons as our starting material. The 25-stereochenustry inherent 
within the molecule, would therefore be maintained during the synthesis to 
provide the required 35-configuration of the carbapenam pyrrolidine ring. It 
was also envisaged that the L-pyroglutamic acid synthon could be chemicaUy 
manipulated to afford potential biosynthetic precursors, e.g the Co-enzyme A 
thioester analogue (136), which could then be utilised as primary metabolic 
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feeder molecules to Erwinwia and Serratia strains, to ascertain whether they can 
be converted to the carbapenem-3-carboxylate. 
5.3.1 Attempted Synthesis of methyl ( 3 5 , 5 / ? ) -
carbapenam-3-carboxylate 
The A/-Z-pyroglutamic acid methyl ester was synthesised from L-
glutamic acid (119) in four steps (Scheme 68), by the literature methods.278,279 
CO2H CO2H ^^'^ 
PhCH20C0Cl(Z-Cl)^ ^ HCHO/Tosic add. 
..,^H NaHCOa I ,H Toluene/A y\\o 
H 2 N ^ ^ 0 2 H Z H N ' ' ' ' ^ C 0 2 H ^^K f ^ 
(119) (120) ^ O 
(121) 
CO2H 
NaOMe / MeOH 
<„U2rl 
y PCI5/ether J V^^^ 
r - 7 • O ^ ^ ^ , / C02Me 
„ 0°C-r. t /36h. N 
..\»H O^C 
ZHN' ' ^C02Me Z 
(122) (123) 
Scheme 68. Synthesis of A^-Z-pyroglutamic acid methyl ester. 
The reduction of the lactam (123) to the hemi-aminal (124) and 
subsequent condensation with di-tbutylmalonate, has been reported to proceed 
smoothly to fumish (125) in good yield (Scheme 69).280 
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N 
I 
Z 
(123) 
C02Me 
i)NaBH4,-30<'C,30min 
ii) MeOH/HCl, 0°C 
H 
MeO 
(tBu02C)2CH2/TiCl4, H 
- ^ tBu02C 
-20" C, 2 h. 
tBu02C 
N 
Z 
(125) 
N 
Z 
(124) 
H 
C02Me 
H 
C02Me 
Scheme 69. Synthesis of the henu-aminal (124) from Z-L-
pyroglutarrUc acid and subsequent Lewis acid 
catalysed nucleophilic displacement of the 
methoxy group. 
Deprotection of the tert-butyl esters of (125) should result in mono-
decarboxylation. Removal of the Z-protecting group, with subsequent 
lactamisation and saponification of the methyl ester was then expected to yield 
the carbapenam as a mixture of diastereoisomers (116) and (117), which could 
be readily resolved using RPHPLC. 
H 
(116) (117) 
However, the initial reduction of (123) with sodium borohydride in 
methanol28i did not afford the hemi-anunal as hoped. Instead, alcoholysis of 
the lactam ring resulted, generating the dimethyl ester (126). 
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C02Me 
ZHN' 
,.o\H 
C02Me 
(126) 
Other reducing agents such as sodium cyanoborohydride and Uthium aluminium 
tert -butoxide were also unsuccessfully explored. 
An altemative approach was therefore undertaken, stiU using methyl Z-
L-pyroglutamate as the synthetic starting material. Ohta et a/282 had described 
an efficient addition of lithium enolates to A^-acylpyroglutamates with 
concomitant ring opening. Using tert-butyl acetate (127) as the enoUsable 
ester, we attempted the corresponding lithium enolate addition to (123) with 
outstanding success, with the product recovered as a pale yeUow oil in an 77% 
yield (Scheme 70). 
O 
A, ...v^ "^ i) LDA, -78" C H3C O 
(127) 
O ^ ^ ^ X^COzMe 
oj^o 
(128) 
HN ^C02Me 
' - X ^ 
Scheme 70. Lithium enolate mediated addition of tert-butyl acetate to (123). 
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The identity of (128) was confumed by IH NMR which displayed signals for 
the tert-butyl ester and the urethane NH. 
5.3.1.1 Synthesis of tert-buty\ (2/?,5S)-5-methoxycarb-
onyl-2-pyrrolidineacetate via chirally induced 
catalytic hydrogenation 
The precursor (128) could now be readily converted to the required 
pyrrolidine ring by catalytic hydrogenation. The reaction should theoretically 
proceed in two steps; initial hydrogenolytic deprotection of the Z group would 
release the primary amine, which spontaneously undergoes an intramolecular 
condensation to form an endocyclic imine intermediate (129). Ensuing 
reduction of this species should proceed under chiral induction from the 
asymmefric cenfre of L-glutamic acid moiety. Approach of (129) towards the 
Pd/C catalytic surface should proceed via the least hindered face, resulting in 
delivery of hydrogen to the lower face of the pyrroline ring and ultimately 
yielding a product of predominately ci '^-configuration (Scheme 71). From the 
results obtained from the catalytic hydrogenation of carbapen-2-em-3-carboxylic 
acid (113), (see 5.1.4), U was anticipated that a ratio of ca. 9:1 {cis:trans) 
would be obtained for (130) and (131) respectively. 
When hydrogenation was initially performed at 3 atm., the resultant 
yeUow oil still possessed a powerful chromophore, despite the iH NMR 
confmnation of the Z-group deprotection. EI-MS displayed a m/z =241 (mass 
required 243) suggesting that tiie Schiff s base had not been reduced. The NH 
signal in the IH NMR intimated that the endocyclic imine stmcture (129) had 
isomerised to the thermodynamically more stable exocyclic enamine (132). 
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•BUO 
'BuO 
O O .,>NH 
H2 / Pd/C, 
(128) 
HN C02Me 
'BUO2C C02Me 
Approach of the cyclic imine intermediate 
towards the Pd/C catalytic surface via the 
least hindered face. 
'BUO2C 
'BUO2C 
H 
C02Me' 
H2, Pd/C 
3 atm. 
(132) 
H2N ^COjMe 
•H2O 
H 
H 
'BUO2C 
-C02Me 
H 
(130) ^Bu02C 
^ X ^ ^ C O z M e 
(129) 
H2, Pd/C 
64 p.s.i 
H 
^ . C02Me 
H (131) 
Scheme 71. One-pot catalytic hydrogenolysis of the Z-
protecting group and subsequent hydrogenation 
of the resulting endocyclic Schiff base 
intermediate. 
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With the double bond situated in the exocyclic position, the molecule 
(132) is a vinylogous urethane, possessing extended conjugation through to the 
rerr-butyl ester, and thereby increasing Us resistant to reduction. By performing 
the hydrogenation at a very high pressure, namely 64 p.s.i., and allowing the 
reaction to proceed ovemight, the resulting product was this time obtained as a 
pale yellow oil (97% yield) with the correct FAB-MS = 244 [M -i- H+]. The IH 
NMR confumed complete loss of the Z-protection, with IH multiplets of the C-
2 and C-5 protons resonating either side of the methyl ester singlet at 53.70. 
To ascertain that the C-2 and C-5 protons were predominately held in the 
cii-configuration, a IH 400 MHz NOE difference experiment was performed. 
The results indicated that both protons appeared to be split into two discrete 
multiplets, in a ratio of 4:1 by integration, resonating either side of 
the methyl ester at 53.70. The uneven value of the integrations seemed to 
discount NH coupling. This was confirmed by re-recording the NMR after a 
D2O shake; both sets of signals remained unaltered. 
An NOE difference experiment was therefore performed upon the two 
largest representative peaks for the C-2 and C-5 protons. Irradiation at the C-2 
proton frequency produced a positive NOE difference at the C-5 position and 
also at the pyrrolidine ring proton frequencies. Irradiation of the C-5 proton 
confirmed the predominant cw-configuration by producing a positive NOE 
difference at the C-2 proton frequency and again on the ring protons. It is 
important to note that no NOE difference was observed between tiie two smaUer 
C-2 and C-5 peaks indicating a possible 20% rran^-configuration impurity. 
Since purification of the epimers at this stage was impossible, it was decided to 
lactamise the chirally impure pyrtolidine rings to their respective carbapenams 
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(116) and (117), and purify the p-lactams by RPHPLC. 
Deprotection of the tert-butyl ester in 4 M HCl in dioxane proceeded in a 
quantUative yield, and the attempted lactamisation of the resultant amino acid 
was initially tried using triphenylphosphine and pyridyl disulphide (Scheme 
72).283 
H 4MHCl/Dioxane^ ^' ' / , 
•COzMe 
»Bu02C " HO2C " HCl 
(13») H (1^3) 
Ph3P/(PyS)2/Et3N 
MeCN, A 
Scheme 72. Deprotection and lactamisation of the ci.s-pyrrolidine intermediate. 
It is noteworthy that initial attempts at tert-butyl ester deprotection using 2 M 
HCl in ether, originally exploited in the synthesis of the ?ran5-carbapenam,277 
only resulted in precipitation of the hydrochloride salt. Despite replacement of 
ether with dioxane to increase the products solubility, deprotection of the cis-
pyrrolidine tert-butyl ester took 48 h to complete, indicating a significant 
difference in the energetics of the two epimers. The anomaly of the cw-product 
was bom out further in the attempted lactamisation. 
The triphenylphosphine, pyridyl disulphide mediated lactamisation 
proceeded with reasonable yields when performed on the rran5-precursor.277 
The mechanism proceeds via a quaternary intermediate (135), with the 
generation of a stabilised hydrogen bonded six membered ring intermediate 
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dfrecting elimination of the pyridylthione and p-lactam formation (Scheme 73). 
H, 
''/, 
^ ^ ^ " 
^ 
H 
C02Me 
N 
O / - " (134) C02Me 
H 
" ° ^ 
\J ^J^ C02Me 
(135) 
Scheme 73. Mechanism of pyridyl disulphide mediated lactamisation. 
However, with the cw-epimer, work-up afforded a thin oil of 3-4% 
overall yield, with the IH NMR proving highly unsatisfactory. Various 
different coupling procedures were therefore explored, including DCC/DMAP, 
diphenylphosphinic chloride,284 and A ,^A -^Z7w[2-oxo-3-oxazolidinyl]phosphoro-
diamidic chloride,285 but none produced any tangible results. 
5.3.2 Synthesis of a Co-enzyme A analogue of the cis-
pyrrolidine intermediate 
It was felt that if the cw-carbapenam was thermodynamically unfavoured 
and Us synthesis beyond our means, then conversion of the free acid to a Co-
enzyme A thioester analogue (136), would yet furnish a potential biosynthetic 
precursor very similar to the putative cyclic imine intermediate (118), which 
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could be used as a biological feeder molecule for various mutant strains of 
Erwinia or Serratia. 
"^"J \.^ ^^  
Co-AS'^'^O 
H 
(136) 
Methodology has been described in Unking Co-enzyme A to fatty 
acids,286 and 2-arylpropionate anti-inflammatory drugs.287 However it was 
felt that the efficiency of thioester formation should be established before an 
expensive reagent such as purified Co-enzyme A was committed. The model 
thiol cysteamine protected as its AT-acetyl derivative (137) was therefore mitially 
used. 
(137) 
A DCC/DMAP coupling procedure in dry DCM was performed at room 
temperature, and following ovemight reaction, the thioester was recovered as an 
oil in a 44% overall yield. The IH NMR confirmed the presence tiie 
C//3CONH- peak, with the FAB-MS indicating the required mass for the 
compound. An improved synthesis should be obtained by protection of the 
pyrrohdine NH, thereby preventing intermolecular amide bond formation. 
It was envisaged that this model thioester could Uself be used as a 
metaboUc precursor, and is now awaiting tiie correct mutant bacterial constinict. 
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All melting points were determined on a Kofler hot-stage apparatus and 
are uncorrected. Ultraviolet spectra were recorded on a Cecil 1020S scanning 
spectrophotomter and infrared spectra were recorded using a Perkin Elmer 257 
or PhUips PU9716 spectrophotometer. Routine IH NMR spectra were recorded 
on a Varian EM390 at 90MHz. High resolution IH NMR were measured using 
either a Bmker AM 250 or a Bmker AM 400 operating at 250 and 400MHz 
respectively. The specfra were recorded in deuteriochloroform unless otherwise 
stated, and the chemical shifts stated are relative to an internal teframethylsUane 
standard. The multiplicity of a signal is designated one of the following 
abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; br, broad; m, multiplet. 
All coupling constants, / values, are reported in Hertz. 13C NMR were recorded 
in deuteriochloroform unless otherwise stated on a Bmker AM 250 at 62.9 
MHz. The chemical shifts are reported relative to an internal deuteriochloroform 
standard on a broad band decoupled mode, and the assignments were obtained 
using a DEPT pulse sequence. 
Electron impact (EI) mass spectra were recorded on a AEl MS-902. 
Fast atomic bombardment (FAB) mass spectra were obtained using a VG 
micromass 70 E. Positive ion electrospray MS (+ve ES-MS) were recorded on 
a Micromass VG platform instmment and MALDI-TOF specfra were recorded 
using a Kratos MALDI II instmment. Microanalytical data were obtained on a 
Perkin-Elmer 240B elemental analyser. Optical rotations were measured on a 
Bendix NPL automatic polarimeter type 143 C with a digital output. 
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Analytical thin layer chromatography (TLC) was performed using 
Merck silicagel 60 F254 precoated (0.2 mm) aluminium sheets. Preparative thin 
layer chromatography (PLC) was performed using Merck silicagel 60 GF254 
coated (1.0 mm) glass plates (20 cm x 20 cm). Flash chromatography was 
performed using Merck Kieselgel 60 (230-400 mesh) silica. Chiral TLC were 
performed using Chiraplate®, manufactiired by CAMLAB, Germany. 
Analytical reverse phase high performance liquid chromatography 
(RPHPLC) was performed using a Hypersil Pep Cig column (4.6 X 150mm) 
at a constant flow rate of 1.2 ml min-i, and semi-preparative RPHPLC 
performed with a HypersU Pep Cig column (8 x 150mm) at a constant flow 
rate of 2.2 ml min-i, unless otherwise stated. Mobile phases were; Eluent A -
0.06% TFA(aq), degassed with helium for 30 min, and Eluent B - 0.06% TFA 
in 90% MeCN(aq), degassed via sonication also for 30 min unless otherwise 
stated. RPHPLC was performed using either an LKB 2150 twin pump 
system, 2152 confroUer and 2151 variable wavelength monitor or a Waters 510 
twin pump system and 484 tunable absorbance detector. Post column eluent 
was monitored by UV absorbance at 220 nm, and sample lyophilisation was 
performed using an Edwards Modulyo FD freeze dryer. 
Diethyl ether, hexane and toluene were dried over sodium wfre, whereas 
all other solvents were dried by distillation from the following heterogenous 
drying reagents; THF (lithium aluminium hydride), dichloromethane 
(phosphorus pentoxide), acetonitrile (calcium hydride), pyridine (sodium 
hydroxide pellets), methanol (magnesium turnings) and ethanol (magnesium 
turnings). Dried organic solvents were stored under nUrogen. 
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Protected amino acids, coupling reagents and resins were purchased 
from Novabiochem (UK) Ltd. 
Chapter 2. 
2-Acetyl-4-nitroindan-l,3-dione (66), 
A mixture of 3-nitrophthalic anhydride (12 g, 60 mmol), anhydrous 
pyridine (25 ml), piperidine (0.2 ml) and 2,4-pentanedione (6.25 g, 60 mmol) 
were stirred together at 35-40 oC under anhydrous conditions. A dark solution 
was rapidly formed and a bright yellow precipitate soon appeared. The solution 
was allowed to stir for a further 6 h, after which the reaction mass was cooled 
and the thick crystalline mass was collected at the pump, washed with ether and 
dried to give the yeUow pyridinium salt (15.3 g, 79%). The salt was treated 
with 6 M HCl (100 ml) to fumish a yellow crystalline precipitate, which was 
coUected at the pump, washed with water and dried. 
The product was recrystallised from tert-butanol to afford 2-acetyl-4-
nitroindane-1,3-dione as fine yellow needles (8.74 g, 63%), m.p. 145-148 oc 
(lit200, 148-150 OC). 
Vn,ax(KBr) 3080, 1710, 1650, 1600, 1540, 1360, 1340, 1210 cm-i 
IH NMR 8 2.60 (3 H, d, J 3.0, CH3), 7.95 (3 H, m, ArH's) 11.3 (1 H, br, s, 
enol -OH) 
m/z (FAB) 234 (M -1- H) 
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A^a-Nde-amino acids 
N-l-(4-nitro-l,3-dioxoindan-2-ylidene)ethyl-L-alanine (Nde-L-Ala) (72). 
A suspension of finely powdered L-alanine (0.178 g, 2.0 mmol) and 2-
acetyl-4-nifroindane-l,3-dione (0.233 g, 1 mmol) were refluxed in anhydrous 
ethanol (20 ml) for 6-8 h. Ethanol was then removed in vacuo and the residue 
redissolved in ethyl acetate. The organic solution was washed with IM 
KHS04(aq) and then exfracted with sat. NaHC03(aq) (2 x 20 ml). Extracts were 
combined, carefully acidified using 6 M HCl, and the resultant yellow oil 
extracted using ethyl acetate. The orgaruc extract was washed with brine, dried 
(MgS04) and evaporated to dryness. The yellow residual oil was dissolved in a 
minimal amount of ethyl acetate, the product being precipitated by flooding 
with hexane. The mother liquor was decanted off and the product dried to 
afford a yellow amorphous powder (0.197 g, 65%) which could not be further 
recrystalUsed. m.p. 250-253 OC, Decomp. 
Vmax(KBr) 3180, 1750, 1690, 1640, 1600, 1540, 1500, 1415, 1360cm-i 
IH NMR ((CD3)2SO, 250 MHz) 5 1.53 (3 H, d, / 7.5, P-CH3), 2.60 and 2.65 
(3H, 2 x s, E/Z C=CCH3), 4.74 (1 H, m, a-CH), 7.87 (2 H, m, Ar C6 and C7 
H's), 7.99 ( 1 H, m, Ar C5-H), 11.02 and 11.10 (1 H, 2 x d, 7 8.0, £/ZNH), 
13.65 (IH, br, s, CO2H) 
m/z (FAB) 305 (M + H), 259 (M- CO2H) 
[a]D25-H26.40(c 1.0, MeOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed -1 peak at 4.0 min. 
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Nde-L arui D-phenylalanine 
The use of L-phenylalanine (0.330 g, 2 mmol) and D-phenylalanine 
(0.330 g, 2 mmol) under the conditions for the synthesis of (72) afforded Nde-
L-Phe (0.262 g, 69%) and Nde-D-Phe (0.243 g, 64%) respectively as yeUow 
amorphous powders, m.p. 166-168 oC respectively 
Nde-L-Phe. 
Vmax(KBr) 3100, 1750, 1600, 1560, 1520, 1430, 1375, 1210 cm-i 
IH N M R ((CD3)2SO, 250 MHz) 5 2.37 and 2.39 (3 H, 2 x s, E/Z C=CCY1^), 
3.15 and 3.30 (2 H, 2 x dd, J 12.5, 5.0, P-CH2), 5.00 (1 H, m, a-CH), 7.26 
(5 H, m, Ph), 7.84 ( 2 H, m, Ar C6 and C7-H's), 8.0 (1 H, m, Ar C5-H), 
10.92 and 11.0 (IH, 2 x d, 7 8.0, E/Z NH), 13.78 (IH, br, s, CO2H) 
m/z (FAB) 381 (M -I- H), 335 (M - CO2H) 
HRMS (FAB) Found: m/z 381.102180. Calcd for C20H17N2O6: (M-i-H), 
381.108662. 
[a]D25-135.10 (c 1.0, EtOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed - 1 peak at 14.0 min. 
Nde-L-Lysine(Boc)-OH 
The use of L-lysine(A^e-Boc)-OH (0.493 g, 2 mmol) under the 
conditions for the synthesis of (72) afforded Nde-L-Lys(Boc)-OH (0.313 g, 
68%) as a yellow amorphous powder. 
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Vmax (KBr) 3400, 2960, 1700, 1650, 1600, 1545, 1360 cm-i 
IH NMR (250 MHz) 6 1.41 (9 H, s, C(CH3)3), 1.46 (2 H, m, Y-CH2), 1.54 (2 
H, m, 5-CH2), 2.01 (2 H, m, P-CH2), 2.62 and 2.64 (3 H, 2 x s, E/Z 
C=CCH3), 3.14 (2 H, m, e-CH2), 4.45 (1 H, m, a-CH), 6.45 (1 H, m, e-
NH), 7.83 (3 H, m, ArH's), 8.27 (1 H, br, s, CO2H), 11.18 and 11.23 (1 H, 
2xd,y8.0,£:/ZNH) 
m/z (FAB) 462 (M -1- H), 388 (M - (CH3)3CO ) 
HRMS (FAB) Found: m/z 462.184750. Calcd for C22H28N3O8: (M-i-H), 
462.187640. 
[a]D25-26.20 (cl.O, MeOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed - 1 peak at 13.0 min. 
Nde-L-Valine 
The use of L-valine (0.234 g, 2 mmol) under the conditions for the 
synthesis of (72) afforded Nde-L-Val (0.256 g, 68%) as a yellow amorphous 
powder. 
Vmax(KBr) 3120, 2970, 1730, 1670, 1620, 1555, 1380, 1350, 1230 cm-1 
IH NMR (250 MHz) 5 1.11 (3 H, d, / 3.0, Y-CH3), 1.14 (3 H, d, / 3.0, y-
CH3), 2.44 (I H, m, p-CH), 2.63 and 2.66 (3 H, 2 x s, E/L C=CCH3), 4.32 
(IH, m, a-CH), 7.80 (3 H, m, ArH's) 7.91 (1 H, br, s, CO2H), 11.22 
and 11.28 (IH, 2 x d, 7 10.0 E/Z NH) 
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m/z (FAB) 333 (M+H), 287 (M - CO2H). 
HRMS (FAB) Found: m/z 333.104073. Calcd for C16H17N2O6: (M-HH), 
333.108662. 
[a]D25-i-18.50 (cl.O, MeOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed -1 peak at 12.0 min. 
Nde-L-Tyrosine (O'Bu)'OH 
The use of L-tyrosine(OfBu)-OH (0.475 g, 2 mmol) under the 
conditions for the synthesis of (72) afforded Nde-L-Tyr(OfBu)-OH (0.353 g, 
78%) as a yellow amorphous powder. 
Vniax(KBr) 3080, 1700, 1600, 1550, 1520, 1370 cm-1 
IH NMR (250 MHz) 6 1.32 (9 H, s, C(CH3)3), 2.20 and 2.23 (3 H, 2 x s, E/Z 
C=CCH3), 3.10 and 3.40 (2 H, 2 x dd, J 15.0, 4.0, P-CH2), 4.63 (1 H, m, a-
CH), 7.05 (4 H, ABq, / 8.0, Ph), 7.67 (IH, br, s, CO2H), 7.71 ( 2 H, m, Ar 
C6 and C7-H's), 7.87 (1 H, m, Ar C5-H), 11.19 and 11.26 (IH, 2 x d, 7 8.0, 
£XZNH) 
m/z {FAB) 453 (M + H), 351 (M - CO2H - C(CH3)3 + H) 
HRMS (FAB) Found: m/z 453.165775. Calcd for C24H25N2O7: (M-HH), 
453.166176. 
[a]D25-135.50 (cl.O, EtOH) 
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RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed - I peak at 16.5 min. 
Nde-L-Isoleucine 
The use of L-isoleucine (0.262 g, 2 mmol) under the conditions for the 
synthesis of (72) afforded Nde-L-Ile (0.242 g, 70%) as a yellow amorphous 
powder. 
Vmax (KBr) 3000, 1750, 1700, 1655, 1600, 1550, 1500, 1415, 1360 cm-i 
IH NMR (250 MHz) 6 1.01 (3 H, t, 7 5.0, 5-CH3), 1.08 (3 H, m, Y-CH3), 
1.54 (2 H, 2 X m, 7-CH2), 2.17 (1 H, m, p-CH), 2.59 and 2.65 (3 H, 2 x s, 
E/Z C=CCH3), 4.39 (IH, m, a-CH), 7.85 (3 H, m, ArH's) 8.10 (1 H, br, s, 
CO2H), 11.21 and 11.28 (IH, 2 x d, 7 10.0, £/ZNH) 
m/z (FAB) 347 (M-HH), 301 ( M - CO2H). 
HRMS (FAB) Found: m/z 347.126755. Calcd for C17H19N2O6: (M-i-H), 
347.124312. 
[a]D25-1-10.20 (cl.O, EtOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 nun. linearly. 
Observed - 1 peak at 14.0 nun. 
Nde-L-Leucine 
The use of L-leucine (0.262 g, 2 mmol) under the conditions for the 
synthesis of (72) afforded Nde-L-Leu (0.287 g, 83%) as a yellow amorphous 
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powder. 
Vmax(KBr) 3000, 1750, 1700, 1660, 1600, 1550, 1510, 1420, 1360 cm-i 
IH N M R (250 MHz) 5 1.01 (6 H, m, CH(Ci/3)2), 1.90 (3 H, m, CH-CH2), 
2.64 and 2.67 (3 H, 2 x s, E/Z C=CCH3), 4.45 (IH, m, a-CH), 7.85 (3 H, m, 
ArH's), 7.95 (1 H, br, s, CO2H), 11.02 and 11.09 (IH, 2 x d, 7 10.0, E/Z 
NH) 
m/z (FAB) 347 (M-^H), 302 (M - CO2H). 
HRMS (FAB) Found: m/z 347.124918. Calcd for C17H19N2O6: (M-hH), 
347.124312. 
[a]D25-31.50 (cl.O, MeOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed - 1 peak at 14.7 min. 
Nde-L-Histidine(NimTrt)-OH 
The use of L-histidine(A^"«-Trt)-OH (0.795 g, 2 mmol) under the 
conditions for the synthesis of (72) afforded Nde-L-His(Trt)-OH (0.244 g, 
40%) as a yellow amorphous powder. 
Vmax(KBr) 3100, 3020, 1750, 1715, 1665, 1610, 1560, 1515, 1470 cm-i 
IH NMR 5 2.45 and 2.51 (3 H, 2 x s, E/Z C=CCH3), 3.40 (2 H, m, P-CH2), 
4.85 (1 H, m, a-CH), 7.05 and 7.26 (15 H, 2 x m, CPh3), 7.65 (2 H, m, Ar 
C6 and C7-H's), 7.80 (1 H, m, Ar C5-H), 8.15 (IH, br, s, CO2H), 9.85 (2 
H, m, imidazole 2 x CH), 11.05 and 11.15 (IH, 2 x d, 7 8.0, E/Z NH) 
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m/z (FAB) 613 (M+H), 568 (M - CO2H + H). 
HRMS (FAB) Found: m/z 613.207948. Calcd for C36H29N4O6: M, 
613.208710. 
[a]D25 -86.90 (c 1.0, MeOH) 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. Unearly. 
Observed - 1 peak at 14.1 min. 
Nde-Glycine 
The use of glycine (0.150 g, 2 mmol) under the conditions for the 
synthesis of (72) afforded Nde-Gly (0.235 g, 81%) as a yellow amorphous 
powder. 
Vmax (KBr) 3100, 1730, 1650,1600, 1560, 1500 cm-i 
IH NMR ((CD3)2SO, 250 MHz) 6 2.61 and 2.64 (3 H, 2 x s, E/Z C=CCH3), 
4.23 (2H, d, 7 5.0, a-CH2), 6.85 (1 H, br, s, CO2H), 7.85 (3 H, m, ArH's), 
11.03 and 11.07 (IH, 2 x d, 7 10.0, E/ZNH) 
rn/z (FAB) 290.8 (M+H). 
HRMS (FAB) Found: m/z 291.062411. Calcd for C13H11N2O6: (M+H), 
291.061711. 
RPHPLC analysis 
Gradient - 40% to 80% Eluent B in 20 min. linearly. 
Observed -1 peak at 7.8 min. 
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L-Leucyl-L-Leucyl-L-Leucine 
UltraSyn-USA resin, functionalised with Fmoc-L-leucine at 0.1 mmol 
g-i (0.50 g) was swelled in DMF for 60 nun. Using an LKB 4175 Biolynx 
manual peptide synthesiser, the following operations were performed on the 
resin under continuous flow condUions. A constant flow rate of 3.0 ml min-i 
was maintained, with post-column morutoring performed at 290nm. 
Operation Time 
1. DMF Wash. 10 min. 
2. 20% Piperidine in DMF Wash. 7 min. 
3. DMF Wash. 5 min. 
4. Nde-Leu-OH (70 mg, 0.20 mmol) 
H0Bt.H20 (31 mg, 0.20 mmol), and 
DIPCDI (31^1, 0.20 mmol) load. 
5. Recycle. 60 min. 
6. DMF Wash. 2 min. 
7. Load Wash. 
8. DMF Wash. 10 min. 
9. Picrylsulphoiuc acid amine test. 
10. 20% Piperidine in DMF Wash. 10 min. 
{no deprotection observed at 290 nm) 
11. DMF Wash. 5 min. 
12. 1 % hydrazine monohydrate in DMF wash. 10 min. 
{deprotection complete after 6 min., monitoring at 290 nm) 
13. Nde-Leu-OH (70 mg, 0.20 mmol), H0Bt.H20 
(15 mg, 0.10 mmol), TBTU (64 mg, 0.20 mmol) 
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and DIEA (70^1,0.40 mmol) load. 
Repeat steps 5 to 9. 
14. 10% thiourea in DMF wash 10 nun. 
{no deprotection observed at 290 nm) 
15. 2% hydrazine monohydrate in DMF wash. 10 min. 
{deprotection complete after 4 min. monitoring at 290 nm) 
16. DMF wash. 10 min. 
The resin was transferred to a sintered glass funnel and sequentially 
washed with DMF (25 ml), r-amyl alcohol (10 ml), acetic acid (5 ml), r-amyl 
alcohol (5 ml) and ether (20 ml). The resin was then dried in vacuo over KOH 
ovemight. A portion of the resin (50 mg) was suspended in TFA-H2O (95:5, 
10 ml) for 2 h with occasional agitation. The mixture was then filtered through a 
glass sinter and the filtrate evaporated. The solid residue was triturated several 
times with HPLC grade ether, dissolved in distilled water and lyophilised to 
yield the product as a white amorphous powder. 
RPHPLC Analysis 
Gradient - 20% to 70% Eluent B in 20 min. linearly. 
Observed - 2 major peaks at 7.4 and 12.4 min respectively. 
m/z (MALDI-TOF) Peak I; 359.1 (M + 1 for Leu-Leu-Leu). Peak 2; 245.4 (M 
+ 1 for Leu-Leu). 
Racemisation studies with A a^-Nde amino acids. 
Racemisation during the synthesis ofN-Nde-L-Phe. 
A solution of A -^Nde-L-Phe (0.190 g, 0.5 mmol) was dissolved in 1% 
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hydrazine monohydrate in anhydrous ethanol (5 ml) and allowed to stand at 
room temperature. After 3 h a yellow/orange precipUate had formed which was 
collected at the pump, washed several times wUh ethanol and dried to yield 
Nde-hydrazine (73) as an amorphous powder (0.120 g, 97%), m.p. 194-198 
OC (dec). 
The hydrazine/ethanol solution was evaporated to dryness and the 
residue partitioned between chloroform and water. Removal and evaporation of 
the aqueous layer afforded L-phenylalanine (0.048 g, 58%), 
Nde hydrazine 
Vmax (KBr) 3330, 3260, 3100, 1650, 1570, 1490, 1350 cm-1 
IH NMR ((CD3)2SO-CDCl3) 5 2.53 (3 H, s, C=CCH3), 5.50 (2 H, br, s, 
NH2), 7.75 (3 H, m, ArH's) 11.4 (1 H, d, NH) 
m/z (+ve ES-MS) 248.2 (M + 1). 
L-phenylalanine 
m NMR (D2O, DSS external standard) 5 3.10 and 3.25 (2 H, 2 x dd, 7 8.0, 
5.5, P-CH2), 3,95 (1 H, dd, 7 8.1, 5.5, a-CH), 7.35 (5 H, m, Ph) 
[a]D28 -31.50 (c 1.0, H2O) {lit.,288 [a]D20 -33.70 to -35.20 (c 2, H2O). 
Chiral TLC analysis 
Rf = 0.625, (L-Phe; Rf = 0.625, D-Phe; Rf = 0.50). 
Racemisation during coupling of NNde-L-Phe. 
N-Nde-L-Phenylalanyl-L-alanine benzyl ester (75) and N-Nde-D-Phenylalanyl-
L-alanine benzyl ester (76) via DCC mediated coupling. 
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To stirred individual solutions of iV-Nde-L-phenylalanine and A'^ -Nde-D-
phenylalanine (0.057 g, 0.15 mmol) in dry DCM (30 ml) both containing L-
alanine benzyl ester tosylate salt (0.053 g, 0.15 mmol), HOBt (0.023 g, 0.15 
mmol) and friethylamine (0.021 ml, 0.15 mmol), was added DCC (0.034 g, 
0.165 mmol) at 0 oc. Stirring was continued at room temperature for 3 h, 
followed by evaporation of volatiles in vacuo. The individual residues were 
redissolved in cold ethyl acetate and the DCU precipUate removed via filtration. 
The organic solutions were then washed with iM KHS04(aq), sat. NaHC03(aq), 
water and brine. The organic layers were then dried (MgS04) and evaporated 
to dryness to yield AT-Nde-L-Phe-L-Ala-OBzl (75) (0.062 g, 77%) and iV-Nde-
D-Phe-L-Ala-OBzl (76) (0.057 g, 70%) as yellow oUs. 
N-Nde-L-Phenylalanyl-L-alanine benzyl ester (75) and N-Nde-D-Phenylalanyl-
L-alanyl benzyl ester (76) via TBTU mediated coupling. 
To stfrred individual solutions of A^-Nde-L-phenylalanine and A -^Nde-D-
phenylalanine (0.057 g, 0.15 mmol) in dry DCM (30 ml) both containing L-
alanine benzyl ester tosylate salt (0.053 g, 0.15 mmol), HOBt (0.023 g, 0.15 
mmol) and triethylamine (0.021 ml, 0.15 mmol), was added TBTU (0.048 g, 
0.15 mmol) at 0 oC. Stirring was continued at room temperature for 2.5 h, 
followed by evaporation of volatUes in vacuo. The individual residues were 
redissolved in cold ethyl acetate and washed with IM KHS04(aq), sat. 
NaHC03(aq), water and brine. The organic layers were then dried (MgS04) and 
evaporated to dryness to yield A^-Nde-L-Phe-L-Ala-OBzl (75) (0.060 g, 74%) 
and AT-Nde-D-Phe-L-Ala-OBzl (76) (0.065 g, 80%) as yellow oils. 
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N-Nde-L-Phe-L-Ala-OBzl (75) 
Vmax (thin film) 3300, 1750, 1650, 1580, 1535, 1495, 1350 cm-i 
IH NMR (250 MHz) 5 1.53 (3 H, d, 7 7.5, Ala P-CH3), 2.40 and 2.46 (3 H, 2 
X s, E/Z C=CCH3), 3.25 and 3.48 (2 H, 2 x dd, 7 12.5, 5.0, Phe P-CH2), 4.55 
(1 H, m, Phe a-CH), 4.76 (1 H, m, Ala a-CH), 5.26 (2 H, s, PhC//2), 6.70 
and 6.75 (I H, 2 x d, 7 7.5, E/Z CONH), 7.37 (5 H, m, Ph), 7.45 (5 H, s, 
Ph), 7.85 ( 3 H, m, ArH's), 11.20 and 11.23 (IH, 2 x d, 7 7.5, E/Z C=CNH) 
m/z (FAB) 542 (M + H), 335 (M - CO-Ala-OBzl) 
NNde-D-Phe-L-Ala-OBzl (76) 
IH NMR (250 MHz) 8 1.44 (3 H, d, 7 7.5, Ala P-CH3), 2.41 and 2.42 (3 H, 2 
x s, E/Z C=CCH3), 3.19 and 3.41 (2 H, 2 x dd, 7 8.5, 6.25, Phe P-CH2), 4.52 
(1 H, m, Phe a-CH), 4.71 (1 H, m, Ala a-CH), 5.23 (2 H, s, PhCi/j), 6.52 
and 6.75 (1 H, 2 x d, 7 7.5 E/Z CONH), 7.35 (5 H, m, Ph), 7.41 (5 H, s, Ph), 
7.85 ( 3 H, m, ArH's), 11.24 and 11.32 (IH, 2 x d, 7 7.5, E/Z C=CNH) 
m/z (FAB) 542 (M + H), 335 (M - CO-Ala-OBzl) 
RPHPLC Analysis; (Eluent A: H2O, Eluent B: 90% MeOH(aq).) 
Gradient 70% -100% Eluent B in 20 min. linearly. 
Observed - For (75) 1 peak only at 18.4 min. 
For (76) 1 peak only at 16.5 min. 
Neuromendin N amide (Lys-Ile-Pro-Tyr-Ile-Leu-NHz). 
NovaSyn® KR 100 resin functionalised at 0.12 nmiolg-i with an Fmoc 
protected modified Rink amide linker (0.10 g, 12nmol functionality) was 
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swelled in DMF for 60 min. Using an LKB 4175 Biolynx manual peptide 
synthesiser, the following operations were performed on the resin under 
continuous flow conditions. A constant flow rate of 3.0 ml min-i was 
maintained, with post-column monitoring performed at 290nm. 
Operation Time 
1. DMF Wash. 10 min. 
2. 20% Piperidine in DMF Wash. 20 min. 
3. DMF Wash. 5 min. 
4. Nde-Leu-OH (17 mg, 0.05 mmol) 
H0Bt.H20 (4 mg, 0.025 mmol), and 
DIPCDI (7.6 til, 0.05 nunol) in DMF (1 ml) load. 
5. Recycle. 60 min. 
6. DMF Wash. 2 min. 
7. Load Wash. 
8. DMF Wash. 10 min. 
9. Picrylsulphonic acid amine test. 
10. 2% Hydrazine monohydrate in DMF wash 10 min. 
11. DMF Wash. 5 min. 
4. to 11. repeated using Nde-Ile (17 mg, 0.05 mmol) 
then Nde-Tyr('Bu)-OH (22 mg, 0.05 mmol) 
then Fmoc-Pro (16 mg, 0.05 mmol)* 
then Nde-Ile (17 mg, 0.05 mmol) 
then Nde-Lys(Boc)-OH (22 mg, 0.05 mmol). 
* Substitute step 10. with 20% piperidine in DMF wash (10 min.). 
The resin was fransferred to a sintered glass funnel, and sequentially 
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washed with DMF (25 ml), r-amyl alcohol (10 ml), acetic acid (5 ml), t-amyl 
alcohol (5 ml) and ether (20 ml). The resin was then dried in vacuo over KOH 
ovemight. A portion of the resin (50 mg) was suspended in TFA-H2O-TIPS 
(95:2.5:2.5, 10 ml) for 2 h with occasional agitation. The mixture was then 
filtered through a glass sinter and the filtrate evaporated. The solid residue was 
triturated several times with HPLC grade ether, dissolved in distilled water and 
lyophiUsed to yield the product as a white amorphous powder. 
RPHPLC analysis 
Gradient - 20% to 50% Eluent B in 20 min. linearly. 
Observed - 1 peak at 11.2 min. 
m/z (+ve ES-MS) 746.2 (M + H), 617.1 ( M - Leu-NH2). 
Angiotensin II receptor binding protein fragment synthesised as its 
corresponding amide (Lys-Gly-Tyr-Ile-His-Ala-Leu-NH2) • 
NovaSyn® KR 100 resin functionalised at 0.12 mmolg-i with an Fmoc 
protected modified Rink amide linker (0.20 g, 24nmol functionality) was 
swelled in DMF for 60 min. Using an LKB 4175 Biolynx manual peptide 
synthesiser, the following operations were performed on the resin under 
continuous flow condUions. A constant flow rate of 3.0 ml min-i was 
maintained, with post-column monitoring performed at 290mn. 
Operation Time 
1. DMF Wash. 10 min. 
2. 20% Piperidine in DMF Wash. 20 min. 
3. DMF Wash. 5 min. 
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4. Nde-Leu-OH (35 mg, 0.10 mmol) 
HOBt.H20 (7 mg, 0.05 mmol), and 
DIPCDI (15.0 til, 0.10 mmol) in DMF (1 ml) load. 
5. Recycle. 60 min. 
6. DMF Wash. 2 min. 
7. Load Wash. 
8. DMF Wash. 10 min. 
9. Picrylsulphonic acid amine test. 
10.2% Hydrazine monohydrate in DMF wash 10 nun. 
11. DMF Wash. 5 min. 
4. to 11, repeated using Nde-Ala (30 mg, 0.10 mmol) 
then Nde-His(Trt)-OH (61 mg, 0.10 mmol)* 
then Nde-Ile (35 mg, 0.10 mmol) 
then Nde-Tyr(fBu)-OH (45 mg, 0.10 mmol) 
then Nde-Val (33 mg, 0.10 mmol) 
then Fmoc-Gly (30 mg, 0.10 mmol)* 
then Nde-Lys(Boc)-OH (46 mg, 0.10 nunol). 
* Required resin incubation with four individual coupling solutions to obtain a 
negative TNBS test 
t Substitute step 10. with 20% piperidine in DMF wash (10 min.). 
the resin was fransferred to a sintered glass funnel, and sequentially washed 
with DMF (25 ml), f-amyl alcohol (10 ml), acetic acid (5 ml), f-amyl alcohol (5 
ml) and ether (20 ml). The resin was then dried in vacuo over KOH ovemight. 
A portion of the resin (50 mg) was suspended in TFA-H2O-TIPS (95:2.5:2.5, 
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10 ml) for 2 h with occasional agitation. The mixtiire was then filtered through a 
glass sinter and the filtrate evaporated. The solid residue was triturated several 
times with HPLC grade ether, dissolved in distilled water and lyophilised to 
yield the product as a white amorphous powder. 
RPHPLC analysis 
Gradient - 20% to 50% Eluent B in 20 min. linearly. 
Observed - 1 major peak at 7.0 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 900.2 (M + H), 769.5 (M - Leu-NH2), 561.8 (M - His-Ala-
Leu-NH2), 450.1 (M - Ile-His-Ala-Leu-NH2 + H). 
Leucine enkephalinamide (Tyr-Gly-Gly-Phe-LeuNH2) (79). 
NovaSyn® KR 100 resin functionalised at 0.12 mmolg-i with an Fmoc 
protected modified Rink amide linker (0.20 g, 24p,mol functionality) was 
swelled in DMF for 60 min. Using an LKB 4175 Biolynx manual peptide 
synthesiser, the following operations were performed on the resin under 
continuous flow conditions. A constant flow rate of 3.0 ml min-i was 
maintained, with post-column monitoring performed at 290nm. 
Operation Time 
1. DMF Wash. 10 min. 
2. 20% Piperidine in DMF Wash. 20 min. 
3. DMF Wash. 5 min. 
4. Nde-Leu-OH (35 mg, 0.10 mmol) 
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H0Bt.H20 (7 mg, 0.05 mmol), TBTU 
(32 mg, 0.10 nunol) and DIEA (34 ^1, 0.20 mmol) 
in DMF (1ml) load. 
5. Recycle. 60 min. 
6. DMF Wash. 2 min. 
7. Load Wash. 
8. DMF Wash. 10 min. 
9. Picrylsulphonic acid amine test. 
10.2% Hydrazine monohydrate in DMF wash 10 min. 
11. DMF Wash. 5 min. 
4. to 11. repeated using Nde-Phe (38 mg, 0.10 mmol) 
then Fmoc-Gly (30 mg, 0.10 mmol)* 
then Fmoc-Gly (30 mg, 0.10 mmol)* 
then Nde-Tyr('Bu)-OH (45 mg, 0.10 mmol) 
* Substitute step 10. with 20% piperidine in DMF wash (10 min.). 
The resin was transferred to a sintered glass funnel, and sequentially 
washed with DMF (25 ml), f-amyl alcohol (10 ml), acetic acid (5 ml), r-amyl 
alcohol (5 nU) and ether (20 ml). The resin was then dried in vacuo over KOH 
ovemight. A portion of the resin (50 mg) was suspended in TFA-H2O-TIPS 
(95:2.5:2.5, 10 ml) for 2 h with occasional agitation. The nuxture was then 
filtered through a glass sinter and the filfrate evaporated. The solid residue was 
triturated several times with HPLC grade ether, dissolved in distilled water and 
lyophilised to yield the product as a white amorphous powder. 
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RPHPLC analysis 
Gradient - 20% to 60% Eluent B in 20 min. linearly. 
Observed -1 major peak at 11.5 min and 1 impurity peak at 13.0 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 555.1 (M + H), 538.8 (M - NH2 + H), 510.1 (M -
CONH2), 425.0 (M - Leu-NH2), 397.7 (M - C0-Leu-NH2). 
Assessment of Nde stability towards TFA. 
A -^Nde-L-Phe (0.190 g, 0.5 mmol) was dissolved in neat TFA (50 ml) 
and allowed to stand at room temperature for 24 hours. At 2, 4, 6 and 24 h 
intervals a 2 ml sample was removed and evaporated to dryness, with 2 nU 
fresh TFA added to the flask to maintain the original volume. The residue was 
redissolved in 0.06% TFA in 90% MeCN(aq) (mobile phase B) and a 50^1 
sample was analysed by analytical RPHPLC. After 24 h, the solution was 
evaporated to dryness and the residue analysed by IH NMR and FAB-MS. 
RPHPLC analysis 
Gradient - 20% to 80% Eluent B in 25 min. linearly. 
Observed at: t = 0 h, 1 peak at 14.0 nun. 
t = 2 h, 1 peak at 14.0 min. 
t = 4 h, 1 peak at 14.0 min. 
t = 6 h, 1 peak at 14.0 nun. 
t = 24h, 1 peak at 14.0 nun. 
An authentic sample of L-Phe displays a retention time of 3.5 min. under 
analogous conditions. 
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IH NMR ((CD3)2SO, 250 MHz) 5 2.37 and 2.39 (3 H, 2 x s, E/Z C=CCH3), 
3.15 and 3.30 (2 H, 2 x dd, 7 12.5, 5.0, P-CH2), 5.00 (1 H, m, a-CH), 7.26 
(5 H, m, Ph), 7.84 ( 2 H, m, Ar C6 and C7-H's), 8.0 (1 H, m, Ar C5-H), 
10.92 and 11.0 (IH, 2 x d, 7 8.0, E/ZNH), 13.78 (IH, br, s, CO2H) 
m/z (FAB) 381.1 (M + H), 335.1 (M - CO2H). 
Assessment of Nde stability towards 20% piperidine under 
continuous flow conditions. 
Nde-Leu-Tyr-Gly-Gly-Phe-Leu-NovaSyn® KR 100 resin. 
NovaSyn® KR 100 resin functionalised at 0.12 mmolg-i with an Fmoc 
protected modified Rink amide linker (0.20 g, 24|xmol functionaUty) was 
swelled in DMF for 60 min. The title peptide was synthesised using Fmoc-Leu-
OH (35 mg, 0.10 nunol), Fmoc-Phe (39 mg, 0.10 mmol), 2 x Fmoc-Gly (30 
mg, 0.10 mmol), Fmoc-Tyr(fBu)-OH (46 mg, 0.10 mmol) and Nde-Leu-OH 
(35 mg, 0.10 mmol) via TBTU (32 mg, 0.10 mmol)/HOBt.H20 (7 mg, 0.05 
mmol)/DIEA (35 yd, 0.20 mmol) mediated coupUng. The synthesis was 
accomplished using an LKB 4175 Biolynx manual peptide synthesiser, 
following the synthetic strategy outiined for (79), with Fmoc deprotection 
achieved with 20% piperidine in DMF. 
The resin was then washed and dried as for (79). A portion of the resin 
(10 mg) was suspended in TFA-H2O-TIPS (95:2.5:2.5, 5 ml) for 2 h with 
occasional agitation. The A -^protected peptide product was isolated as a yellow 
amorphous powder as for (79). 
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RPHPLC analysis 
Gradient - 25% to 55% Eluent B in 20 min. linearly. 
Observed - 1 major peak at 19.2 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 883.2 (M + H), 866.1 (M - NH2), 754.7 (M - Leu-NH2), 
606.0 (M - Phe-Leu-NH2), 549.1 (M - Gly-Phe-Leu-NH2), 492.2 (M - Gly-
Gly-Phe-Leu-NH2). 
Leu-Tyr-Gly-Gly-Phe-Leu-NovaSyn® KR 100 resin. 
A sample of the Nde-Leu-Tyr-Gly-Gly-Phe-Leu-NovaSyn® KR 100 
resin (20 mg) was Nde deprotected using 2% hydrazine monohydrate in DMF 
under continuous flow conditions. The resin was then washed and dried as for 
(79). A portion of the resin (10 mg) was suspended in TFA-H2O-TIPS 
(95:2.5:2.5, 5 ml) for 2 h with occasional agitation. The A -^protected peptide 
product was isolated as a yellow amorphous powder as for (79). 
RPHPLC analysis 
Gradient - 25% to 55% Eluent B in 20 min. linearly. 
Observed - 1 peak at 8.0 min. 
m/z (+ve ES-MS) 668.2 (M + H), 651.6 (M - NH2), 538.1 (M - Leu-NH2), 
390.2 (M - Phe-Leu-NH2), 277.5 (M - Gly-Gly-Phe-Leu-NH2). 
Exposure of Nde-Leu-Tyr-Gly-Gly-Phe-Leu-NovaSyn® KR 100 resin to 
piperidine under continuous flow conditions. 
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The resin-bound peptide (0.10 g) was swelled in DMF for 1 h, and 
using an LKB 4175 Biolynx manual peptide synthesiser, was exposed to a 
continuous flow of 20% piperidine in DMF at a constant flow rate of 0.5 ml 
min-i for 24 h. Samples of resin (20 mg) were removed at 3, 6 and 24 h 
intervals and washed and dried as described for (79). The resin samples were 
each 'Bu deprotected and cleaved using TFA-H2O-TIPS (95:2.5:2.5, 2 ml) at 
room temperature for 2 h. The individual peptide products were then recovered 
as described for (79) as yellow amorphous powders. 
RPHPLC analysis 
Gradient - 25% to 55% Eluent B in 20 min. linearly. 
att = Oh. 
Observed -1 peak at 19.2 min 
att = 3h. 
Observed - 1 major peak at 19.2 min. and a second peak at 8.0 min. 
Relative peak heights (94:6) 
att = 6h. 
Observed -1 major peak at 19.2 min. and a second peak at 8.0 min. 
Relative peak heights (87:13) 
att = 24 h. 
Observed - 1 peak at 19.2 min. and a second peak at 8.0 min. 
Relative peak heights (54:46) 
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Solid phase synthesis of dihydrotrypanothione 
Nf m-bis-Nde-Spermidine (81). 
To a solution of spermidine (79 ^1, 0.50 mmol) in anhydrous ethanol 
was added 2-acetyl-4-nitroindane-l,3-dione (0.350 g, 1.50 mmol) and DIEA 
(261 (xl, 1.50 mmol) and the resultant solution was refluxed for 6-8 h. A 
bright yellow precipitate had formed which was collected at the pump and 
washed with ethanol and dried. TLC indicated a ninhydrin positive base-line 
spot which was subsequently removed by digestion of the yellow powder with 
1% AcOH in ethanol. The solid was once again collected at the pump, washed 
several times with ethanol, and dried to afford Nf A '^S-bis-Nde-Spermidine 
(81), as a yellow amorphous powder (0.253 g, 88%), m.p. 165-169 oc. 
Vmax (KBr) 3440, 3100, 2940, 1688, 1645, 1600, 1535, 1495, 1350 cm-i 
IH NMR (CF3CO2H) 5 2.10 (4 H, m, NH-CH2-C//2-C//2-CH2), 2.49 (2 H, 
m, NH-CH2-C/f2-CH2-NH2), 2.83 (6 H, s, 2 x =CCH3), 3.54 (4 H, m, CH2-
NH-C/f2), 3.85 (4 H, m, 2 X =CNH-C//2), 7.39 (2 H, br, s, CH2-N+//2-
CH2), 8.00 (6 H, m, ArH's), 11.54 (2 H, d, br, 2 x =CNH) 
m/z (+ve ES-MS) 576.1 (M + H), 344.4 (M - Nde-NH), 114.3 (M - {2 x Nde-
NH}). 
Activation of NovaSyn® TGA resin with para-nitrophenylchloroformate. 
NovaSyn® TGA resin functionalised at 0.28 mmol g-i with an HMPA 
linker (0.20 g, 0.056 mmol of free alcohol), was swelled in dry DCM for 30 
mins. To this solution was added 4-nitrophenylchloroformate (O.l 13 g, 0.56 
nunol) and DIEA (98.0 ^1, 0.56 mmol) and the suspension was allowed to stir 
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at room temperature ovemight. 
The resin was then washed 5 times with dry DCM and then washed 5 
times with, and finally suspended in, peptide synthesis grade DMF. To this was 
added fiw-Nde-spermidine (0.161 g, 0.28 mmol) and DIEA (49 ^l, 0.28 mmol) 
and the suspension was again allowed to stir ovemight. 
The resin was then washed with DMF and subsequently treated with 
acetic anhydride/DIEA to cap any uru-eacted resin bound alcohol. Deprotection 
of the Nde protecting group was then achieved using 2% hydrazine v/v in DMF 
under continuous flow conditions for 7 min., at a flow rate of 3.0 ml min-i. A 
portion of the resin (20 mg) was then removed and freated with Fmoc-Cl (0.012 
g, 0.045 mmol) and DIEA (8.0 ^l, 0.045 mmol) until a negative TNBS test was 
obtained, the resin was then washed and dried as for (79). 
The remainder of the Nde deprotected resin was used for the synthesis 
of dihydrotrypanothione (see p. 179). 
Determination of Fmoc loading 
The Fmoc-protected spermidine-resin (1 mg) was placed in a 1 cm path 
length quartz cuvette and treated with 3 ml 20% piperidine in DMF. After 
allowing the resin to stand, with occasional agUation, for 4 minutes the UV 
absorbtion at 290 nm was recorded against a blank of 20% piperidine in DMF. 
UV290 absorbance = 0.792 
Now A = e.c.l where A = 0.792, £ = 5253 and 1 = 1 
therefore c = 0.792 
5253 
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= 1.51 X 10-4 niol L-i of piperidine adduct 
Therefore in 3 ml of deprotection media there is 4.52 x 10-7 mol of piperidine 
adduct. Taking into account the mass difference associated with incorporation 
of few-Fmoc-spermidine onto the resin this value is equivalent to a molar amine 
functionality found on 0.849 mg of resin. Therefore, the loading on 1 g would 
be 0.53 mmol. If 100% incorporation had occurred, then the theoretical value 
would be 0.56 mmol g-i. 
Hence, % incorporation of Nf A'^ S-bis-Nde-Spermidine (81) onto the urethane 
modified linker = 95%. 
Dihydrotrypanothione. 
Following Nde deprotection with 2% hydrazine in DMF, peptide 
synthesis was then carried out on the spermidine-NovaSyn® TGA resin using 
Fmoc-Gly-OH (133 mg, 0.448 mmol), Fmoc-Cys(Trt)-OH (262 mg, 0.448 
mmol) and Fmoc-Glu-OtBu (191 mg, 0.448 mmol) via TBTU (143 mg, 0.448 
mmol)/HOBt.H20 (34 mg, 0.224 mmol)/DIEA(87 |xl, 0.896 mmol) mediated 
coupling. The synthesis was accomplished using an LKB 4175 Biolynx 
manual peptide synthesiser, following the synthetic strategy outlined for (79), 
with Fmoc deprotection achieved with 20% piperidine in DMF. 
The resin was then washed and dried as for (79). A portion of the resin 
(10 mg) was suspended in TFA-EDT-H2O-TIPS (92.5 : 2.5 : 2.5 : 2.5, 10 ml) 
for 2 h with occasional agitation. The peptide product was isolated as a white 
amorphous powder (7 mg) as for (79). 
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RPHPLC Analysis 
Gradient - 5% Eluent B for 5 min. then 
5% to 50% Eluent B in 20 nun. linearly. 
Observed - 1 major peak at 3.0 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 724.1 (M + 1) 
Trypanothione disulphide (80). 
Dihydrotrypanothione (7 mg) was dissolved in ammonium acetate 0.04 M (70 
ml, adjusted to pH 8.5 with cone, ammonia) under atmospheric oxygen at 
room temperature and allowed to stir for 72 h. The solution was then carefully 
concentrated in vacuo and finally lyophilised to afford a white amorphous solid. 
RPHPLC Analysis 
Gradient - 5% Eluent B for 5 min. then 
5% to 50% Eluent B in 20 min. linearly. 
Observed - 1 major peak at 2.2 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 722.2 (M + 1) 
HRMS (FAB) Found: m/z 722.293257 Calcd for C27H48N9O10S2: (M+H), 
722.296558. 
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Chapter 3. 
N- l-(4-acetamido-l, 3-dioxoindan-2-ylidene)ethyl-L-alanine. 
In a high pressure hydrogenation vessel, Nde-L-alanine (0.20 g, 0.66 
mmol) was dissolved in methanol (50 ml). The solution was purged with N2 
and 10% Pd/C catalyst (40 mg) and acetic anhydride (5 nU) were introduced. 
The vessel was evacuated and filled with hydrogen to obtain a pressure of 50 
psi. The suspension was shaken at room temperature for 18 h, after which, the 
vessel was evacuated and purged with N2. The suspension was filtered 
through a damp kieselguhr pad and evaporated to dryness to yield a yellow 
amorphous powder (42 mg, 20%) 
Vmax (KBr) 3660, 1745, 1680, 1635, 1590, 1530, 1300 cm-i 
iH NMR ((CD3)2SO, 250 MHz) 5 1.50 and 1.51 (3 H, 2 x d, 7 7.5, E/Z p-
CH3),2.18 and 2.19 (3 H, 2 x s, E/Z COCH3), 2.59 and 2.60 (3H, 2 x s, E/Z 
C=CCH3), 4.72 and 4.83 (I H, 2 x m, £>Z a-CH), 7.27 (1 H, m, Ar C5-H), 
7.58 (1 H, m, Ar C6-H), 8.47 (1 H, m, Ar C7-H) 10.12 and 10.42 (I H, 2 x 
br, s, E/Z CONH), 10.68 and 13.89 (IH, 2 x d, 7 7.5, E/Z =CNH) 
m/z (FAB) 317.5 (M + H) 
2-Acetyldimedone (23). 
To a stirred solution of acetic acid (0.096 g, 3.0 mmol) in dry 
dichloromethane (10 ml) was added dimedone (0.280 g, 2.0 mmol), DCC 
(0.412 g, 2.0 mmol) and DMAP (0.244 g, 2.0 mmol). The resulting solution 
was allowed to stfr at room temperature for 18 h. 
The solution was cooled and filtered to remove the precipitated DCU. 
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The dichloromethane was removed in vacuo and the residue redissolved in ethyl 
acetate (20 ml) and washed with IM KHS04(aq). The organic extract was 
washed with brine (2 x 10 ml), dried (MgS04) and rotary evaporated to yield 2-
acetyldimedone (23) as a pale yellow crystalline solid (0.211 g, 80%), m.p. 34 
OC (IU.,234 34-36 OC). 
Vmax (Thin film) 2960, 1667, 1560, 1445 cm-i 
IH NMR 6 1.10 (6 H, s, C(CH3)2), 2.33 (2 H, s, CH2), 2.51 (2 H, s, CH2), 
2.20 (3 H, s, =CCH3), 17.92 (1 H, s, OH) ppm. 
m/z (+ve ES-MS) 183.2 (M+H). 
2-Hexanoyldimedone (92). 
To a stirred solution of hexanoic acid (0.116 g, 1.0 mmol) in dry 
dichloromethane (5 ml) was added dimedone (0.140 g, 1.0 nunol), DCC 
(0.226 g, 1.1 mmol) and DMAP (0.183 g, 1.5 mmol). The resulting solution 
was allowed to stfr at room temperature for 18 h. 
The solution was cooled and filtered to remove the precipitated A^ .A'^ '-
dicyclohexylurea. The dichloromethane was removed in vacuo and the residue 
redissolved in ethyl acetate and washed with IM KHS04(aq). The organic 
exfract was washed with brine, dried (MgS04) and rotary evaporated to yield 2-
hexanoyldimedone (92) as a yellow oU (0.20 g, 84%). 
Vmax (Thin film) 2995, 2900, 1680, 1560, 1450 cm-i 
IH NMR 6 0.85 (3 H, t, 6 Hz CH2C/73), 105 (6 H, s, C(CH3)2), 1.40 (6 H, 
m, ((C/f2)3CH3), 2.30 (2 H, s, (COCH2)), 2.47 (2 H, s, (COCH2)), 2.93 (2 
H, t, 7 Hz, (=C(0H)C/f2)), 18.14 (1 H, s, enol -OH) 
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m/z (+ve ES-MS) 239.1 (M+H) 
Angiotensin II receptor binding protein fragment synthesised as its 
corresponding amide (Lys-Gly-Tyr-Ile-His-Ala-Leu-NHz) using Fmoc amino 
acids. 
NovaSyn®KR 125 resin functionaUsed at 0.12 mmol g-i with an Fmoc 
protected modified Rink amide linker (0.2 g, 24 |a,mol functionality) was 
swelled in DMF for 60 min. The title peptide was then synthesised using 
Fmoc-Leu-OH (34 mg, 0.096 mmol), Fmoc-Ala-OH (30 mg, 0.096 mmol), 
Fmoc-His(Trt)-OH (60 mg, 0.096 mmol), Fmoc-Ile-OH (34 mg, 0.096 mmol), 
Fmoc-Tyr(tBu)-OH (44 mg, 0.096 mmol), Fmoc-Val-OH (33 mg, 0.096 
nunol), Fmoc-Gly-OH (29 mg, 0.096 mmol) and Fmoc-Lys(Boc)-OH (45 
mg, 0.096 nunol) via TBTU (31 mg, 0.096 nunol)/HOBt.H20 (7 mg, 0.048 
mmol)/DIEA (33 |il, 0.192 mmol) mediated coupling. The synthesis was 
accomplished using an LKB 4175 Biolynx manual peptide synthesiser, 
following the synthetic strategy outlined for (79), with Fmoc deprotection 
achieved with 20% piperidine in DMF. 
The resin was then washed and dried as for (79). A portion of the resin 
(10 mg) was suspended in TFA-H2O-TIPS (95:2.5:2.5, 10 ml) for 2 h with 
occasional agitation. The peptide product was isolated as a white amorphous 
powder as for (79). 
RPHPLC Analysis 
Gradient -10% to 50% Eluent B in 20 min. Unearly. 
Observed - I peak at 7.5 nun. 
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m/z (+ve ES-MS) 900.2 (M + H), 769.5 (M - Leu-NH2), 561.8 (M - His-Ala-
Leu-NH2), 450.1 (M - Ile-His-Ala-Leu-NH2 + H). 
On resin acylation of the angiotensin receptor binding protein fragment using 2-
hexanoyldimedone (92). 
Angiotensin receptor binding protein fragment attached to 
NovaSyn®KR 125 resin (50 mg, 0.12 mmol g-i), with a theoretical total amine 
functionality of 6 jxmol, was swelled in DMF for 60 min. 2-Hexanoyldimedone 
(92) (6 mg, 0.025 mmol) was dissolved in DMF (1 ml) and subsequently 
added to the resin bound peptide and was allowed to stand at room temperature 
ovemight. The picrylsulphonic acid amine test was negative, so the resin was 
transferred to a sintered glass funnel and sequentially washed and dried as for 
(79). A portion of the resin (10 mg) was suspended in TFA-H2O-TIPS 
(95:2.5:2.5, 10 red) for 2 h with occasional agitation. The peptide product was 
isolated as a white amorphous powder as for (79). 
RPHPLC Analysis 
Gradient -10% to 50% Eluent B in 20 nun. Unearly. 
Observed - I peak at 16.8 min. (a 9.3 min. shift in retention time) 
m/z (+ve ES-MS) 1120.2 (M + 1), 669.3 (M - ne-His-Ala-Leu-NH2). 
Deprotection and recovery of the angiotensin receptor biruling protein fragment. 
The hexanoylated peptide amide fragment (3 mg) was dissolved in 5% 
hydrazine(aq) (3 ml) and aUowed to stir at room temperature for 30 min. 
Trifluoroacetic acid was added dropwise to the cooled solution until pH 2 was 
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attained. The solution was then de-salted using a Millipore Cig Sep-Pak 
cartridge. The de-salted solution was evaporated to dryness using a high 
vacuum rotary evaporator, and the residue triturated with HPLC grade ether. 
The white amorphous powder was dissolved in distilled water and lyophilised 
to yield the angiotensin receptor binding protein fragment as a white amorphous 
powder (2 mg). 
RPHPLC Analysis 
Gradient - 10% to 50% Eluent B in 20 min. linearly. 
Observed - I major peak at 7.5 min. 
m/z (+ve ES-MS) 900.2 (M + H), 561.8 (M - His-Ala-Leu-NH2), 450.1 (M -
De-His-Ala-Leu-NH2 + H). 
2-Biotinyldimedone (93). 
To a stirred solution of biotin (0.244 g, 1.0 mmol) in peptide synthesis 
grade DMF, (10 ml) was added dimedone (0.154 g, 1.1 mmol), DCC (0.206 g, 
1.0 mmol) and DMAP (0.122 g, 1.0 mmol). The resulting solution was 
allowed to stfr at room temperature for 48 h. 
The solution was cooled and filtered to remove the precipitated N,N'-
dicyclohexylurea. The DMF was removed in vacuo using a high vacuum rotary 
evaporator and the residue redissolved in ethyl acetate and washed with IM 
KHS04(aq). The organic layer was then extracted with saturated NaHC03(aq), 
the extracts combined, cooled and acidified to pH 2 using 6M HCl and the oily 
product extracted with dichloromethane. The organic exfract was washed with 
brine (2 x 10 ml), dried (MgS04) and evaporated to dryness to yield a 
white/yellow amorphous powder. Recrystallisation from methanol-water (1:1) 
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afforded 2-biotinyldimedone (93) as a white crystalline soUd (252 mg, 69%), 
m.p. 142-144 OC 
Vmax (KBr) 3300, 2595, 1750, 1700, 1575, 1475 cm-i 
iH NMR (250 MHz) 8 1.07 (6 H, s, C(CH3)2), 1.54 (6 H, m, (CH2)3), 2.35 
(2 H, s, COCH2), 2.54 (2 H, s, COCH2), 2.73 (1 H, d, 7 13 Hz, CHSCHQ), 
2.91 (1 H, dd, 7 13, 5 Hz, CHSCH„), 3.04 (2 H, t, 7 7 Hz, =C(0H)CH2), 
3.16 (1 H, m, C/fSCH2), 4.31 (IH, m, ring junction H), 4.56 (IH, m, ring 
junction H), 5.87 (IH, s, NH), 6.15 (IH, s, NH), 14.85 (IH, s, OH) 
13C NMR 6 24.26 (C(OH)CH2CH2), 28.02 (C(CH3)2), 28.19 (C(OH)CH2-
CH2CH2CH2), 28.45 (C(OH)CH2CH2CH2), 30.50 (C(CH3)2), 39.87 
(C(OH)CH2), 40.44 (SCH2), 46.60 (CH2CO), 52.44 (CH2CO), 55.47 
(SCHCH2), 60.00 (SCH2CH), 61.86 (SCHCH), 111.80 (C=C(OH)CH2), 
164.01 (NHCONH), 195.01 (CH2CO), 197.55 (CH2CO), 205.191 
(=C(0H)CH2) 
Found: C, 59.15; H, 7.07; N, 7.39. C18H27N2O4S requires C, 59.00; H, 
7.15; N, 7.65%. 
m/z (FAB) 367.2 (M+H). 
HRMS (FAB) Found: m/z 367.162687. Calcd for C18H27N2O4S: (M+H), 
367.169154. 
RPHPLC Analysis 
Gradient - 20% to 80% Eluent B in 20 min. linearly. 
Observed - 1 peak at 10.5 min. 
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On resin acylation of the angiotensin receptor binding protein fragment using 2-
biotinyldimedone (93). 
Angiotensin receptor binding protein fragment attached to 
NovaSyn®KR 125 resin (50 mg, 0.12 mmol g-i) with a total functionality of 6 
|imol was swelled in DMF for 60 min. 2-Biotinyl dimedone (9 mg, 0.025 
mmol) was dissolved in DMF (1 ml) and subsequently added to the resin bound 
peptide and allowed to stand at room temperature overnight. The 
picrylsulphonic acid amine test was negative, so the resin was transferred to a 
sintered glass funnel and sequentially washed and dried as for (79). A portion 
of the resin (10 mg) was suspended in TFA-H2O-TIPS (95:2.5:2.5, 10 ml) for 
2 h with occasional agitation. The peptide product was isolated as a white 
amorphous powder as for (79). 
RPHPLC Analysis 
Gradient -10% to 50% Eluent B in 20 min. linearly. 
Observed - 1 peak at 14.0 min. 
m/z (+ve ES-MS) 1248.0 (M + 1), 1047.0 (M - Ala-Leu-NH2), 911.1 (M -
His-Ala-Leu-NH2), 796.5 (M - Ile-His-Ala-Leu-NH2). 
Immobilisation of the biotinylated angiotensin receptor binding protein fragment 
on an immobilised avidin column. 
A pre-packed immobilised avidin column (Pierce) was equilibrated 
using five colunm volumes of 20 mM phosphate buffered saline (pH 7.5, 500 
mM NaCl). Biotinylated angiotensin receptor binding protein (1 mg) was 
dissolved in the buffer solution (1 ml) and was mn into the column. The flow 
was halted, and the column allowed to stand at room temperature for 1 h. The 
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column was washed with binding buffer and the eluent monitored by RPHPLC. 
No biotinylated peptide was detected in the washings. 
The column was then treated with 5% hydrazine(aq) (5 x I ml), allowing 
each deprotection volume to incubate for 5 min. The deprotection medium was 
eluted into 10% acetic acid(aq) and the resulting solution was de-salted using a 
millipore Cig Sep-Pac Cartridge. The de-salted solution was lyophilised to yield 
a white amorphous solid. 
RPHPLC Analysis 
Gradient -10% to 50% Eluent B in 20 min. linearly. 
Observed - 1 major peak at 7.5 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (+ve ES-MS) 900.0 (M + 1), 561.7 (M - His-Ala-Leu-NH2), 450.7 (M -
Ile-His-Ala-Leu-NH2). 
Chapter 4. 
Mono-benzyl adipate (100). 
Adipic acid (11.0 g, 0.075 mol), benzyl alcohol (12.0 g, 0.111 mol) 
and tosic acid (0.190 g, 1.0 nunol) were mixed together in anhydrous toluene 
and heated under reflux for 2 h, using Dean-Stark apparatus for the azeotropic 
removal of water. The reaction mixture was cooled, water (100 ml) added and 
the solution carefully adjusted to pH 8 using 6 M NaOH. The aqueous layer 
was separated and washed with ether ( 2 x 25 ml). Fresh ether (50 ml) was 
added and the solution adjusted to pH 2 using 6 M HCl. The ether layer was 
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separated, dried (MgS04), and evaporated to dryness to yield mono-benzyl 
adipate (91) as a colourless oil (10.97 g, 62%). 
IH NMR 6 1.55 (4 H, m, CH2C//2C//2CH2), 2.26 (4 H, m, 2 x COCH2), 
5.02 (2 H, m, OCH2), 7.29 (5 H, s, Ph), 11.31 (1 H, s, CO2H). 
5-(5-benzyloxycarbonylpentanoyl)Meldrum's acid (101). 
To a stirred solution of mono-benzyl adipate (100) (2.36 g, 0.01 mol), 
Meldmm's acid (1.50 g, 0.0105 mol) in dry DCM (40 ml) was added DCC 
(2.36 g, 0.115 mol), and DMAP (1.83 g, 0.015 mol) and the mixture was 
allowed to stfr for 18 h. The solvent was removed and the residue taken-up into 
cold ethyl acetate and filtered. The organic filtrate was then washed with 2M 
HCl (2 X 20 ml), brine (2 x 20 ml) and dried (MgS04). VolatUes were removed 
in vacuo to afford a yeUow solid, (1.74 g, 48% cmde yield) which was used in 
the following reaction, without purification. 
IH NMR 5 1.70 (6 H, s, C(CH3)2), 1-75 (4 H, m, CH2C//2C//2CH2), 2.38 
(2 H, m, BZIOCOCH2), 3.10 (2 H, m, CH2C0-Meldrum's acid), 5.12 (2 H, 
m, 0CH2Ph), 7.34 (5 H, s, Ph) 
N-(7-Benzyloxycarbonyl-3-oxoheptanoyl)-L-homoserine lactone (102). 
To a stirred solution of 5-(5-benzyloxycarbonylpentanoyl)Meldmm's 
acid (101) (1.74 g, 4.8 mmol) in anhydrous MeCN (90 ml) was added L-
homoserine lactone hydrochloride (0.66 g, 5.3 mmol) and TEA (0.74 ml, 5.0 
mmol) and the resulting mixtiire was allowed to stir at room temperattire for 18 
h and then heated under reflux for 3 h. The volatiles were removed in vacuo 
and the residue partitioned between ethyl acetate and water. The organic layer 
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was separated, washed with IM KHS04(aq) and brine, dried (MgS04) and 
evaporated to dryness to yield a colourless oil. Trituration of the oil with 
diethyl ether afforded N-(7-Benzyloxycarbonyl-3-oxoheptanoyl)-L-homoserine 
lactone (102) as a white solid (1.52 g, 89%), m.p. 77-78 oc, after 
recrystallisation from ethyl acetate. 
Vmax (KBr) 3400, 2950, 1780, 1730, 1660, 1530 cm-i 
IH NMR (250 MHz) 6 1.62 (4 H, m, CH2C/72CH2CH2), 2.24 (1 H, m, 
N H C H C / / ) , 2.37 (2 H, t, 7 7.5 OCOCH2), 2.55 (2H, t, 7 7.5, 
CH2C/72COCH2), 2.73 (1 H, m, NHCHCH), 3.45 (2 H, s, COCH2CO), 
4.25 (IH, m, a-CH), 4.53 (2 H, m, C02Ci/2CH2) 5.10 (2 H, s, OC/72Ph), 
7.35 (5 H, s, Ph), 7.64 (1 H, d, 7 7.5, NH) 
Found: C, 63.42; H, 6.52; N, 3.89. C21H27NO7 requires C, 63.14; H, 6.42; 
N, 3.88%. 
m/z (FAB) 362 (M+H), 154 (M - PhCH20 - homoserine lactone). 
N-(7-Carboxy-3-oxoheptanoyl)-L-homoserine lactone (103). 
In a high pressure hydrogenation vessel, A^-(7-Benzyloxycarbonyl-3-
oxoheptanoyl)-L-homoserine lactone (102) (1.387 g, 3.8 mmol) was dissolved 
in methanol (50 nU). The solution was purged with N2 and 10% Pd/C catalyst 
(140 mg) was added. The vessel was evacuated and flUed with hydrogen to 
obtain a pressure of 3 psig. The suspension was shaken at room temperature 
for 2 h, after which, the vessel was evacuated and purged with N2. The 
suspension was filtered through a damp kieselguhr pad and evaporated to 
dryness to yield N-(7-Carboxy-3-oxoheptanoyl)-L-homoserine lactone (103) as 
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a waxy soUd (944 mg, 92%). 
Vmax (thin film) 3350, 2950, 1775, 1720, 1660, 1540 cm-i 
IH NMR ((CD3)2SO-CDCl3) 6 1.60 (4 H, m, CH2C/72C//2CH2), 2,25 (3 H, 
m, C//2CO2H and NHCHC//), 2.59 (3 H, m, CH2C//2COCH2 and 
NHCHC//), 3.41 (2 H, s, COCH2CO), 4.40 (3H, m, CO2C//2CH2 and a-
CH), 7.40 (1 H, s, br, CO2H), 8.34 (1 H, d, 7 7.5, NH) 
m/z (FAB) 272 (M+H), 254 (M - OH), 226 (M - CO2H), 171 (M - homoserine 
lactone). 
RPHPLC Analysis 
Gradient - 5% to 30% Eluent B in 25 min. linearly. 
Observed - 1 peak at 8.5 min. 
Attempted coupling ofN-(7-Carboxy-3-oxoheptanoyl)-L-homoserine lactone 
(103) to L-valine methyl ester. 
To a stirred solution of N-(7-carboxy-3-oxoheptanoyl)-L-homoserine 
lactone (103) (0.03 g, 0.11 mmol), L-valine methyl ester tosylate (0.03 g, 0.1 
mmol) and TEA (14 ^ l, 0.1 mmol) in dry DCM (5 ml) was added DCC (0.023 
g, 0.11 mmol) and HOBt (0.017 g, 0.11 nunol) and the solution was allowed 
to stir for 18 h. TLC indicated mainly the presence of starting materials, 
however the presence of a small DCU precipitate warranted overall work-up. 
Volatiles were removed in vacuo, and the residue dissolved in cold ethyl acetate 
and filtered. The organic solution was washed with IM KHS04(aq), sat. 
NaHC03(aq) and brine. The solution was then dried (MgS04) and evaporated to 
dryness to yield a colouriess oil (8mg, 21% crude yield). The IH NMR 
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indicated mainly the presence of DCU. 
N-(7-Benzyloxycarbonyl-3,3-ethylenedioxyheptanoyl)-L-homoserine lactone 
(106). 
A'^ -(7-Benzyloxycarbonyl-3-oxoheptanoyl)-L-homoserine lactone (102) 
(O.IO g, 0.28 mmol), ethanediol (16 i^l, 0.3 mmol) and tosic acid (1 mg) in dry 
benzene (50 ml) were heated together under reflux for 18 h. A dean-Stark 
apparatus was attached for azeofropic removal of water. 
The reaction mixture was cooled and evaporated to dryness. The 
residue was redissolved in ethyl acetate, washed with water and brine, dried 
(MgS04) and rotary evaporated to yield an oil which was subsequently purified 
by PLC (EtOAc-Hexane-MeOH, 4.5:4.5:1) to afford A^-(7-Benzyloxycarbonyl-
3,3-ethylenedioxyheptanoyl)-L-homoserine lactone (106) as a pale yellow oil 
(96 mg, 86%). 
Vmax (thin film) 3460, 2950, 1780, 1730, 1660, 1530 cm-i 
IH NMR 5 1.60 (6 H, m, HO2CCH2C//2C//2C//2), 2.15 (1 H, m, 
NHCHC//), 2.35 (2 H, t, 7 7.5, C//2CO2H), 2.59 (2 H, s, C(02(CH2)2)C//2 
CO), 2.72 (1 H, m, NHCHC//), 3.96 (4 H, m, OC//2C//2O), 4.45 (3H, m, 
CO2C//2CH2 and a-CH), 5.12 (2 H, s, OC//2Ph), 6.98 (1 H, d, 7 7.5, NH), 
7.38 (5 H, s, Ph) 
m/z (FAB) 406.1 (M+H), 154 (M - PhCH20 - homoserine lactone). 
N-(7-Carboxy-3,3-ethylenedioxyheptanoyl)-L-homoserine lactone (107) 
In a high pressure hydrogenation vessel, (106) (0.203 g, 0.50 
192 
Experimental 
mmol) was dissolved in methanol (20 ml). The vessel was purged with N2 and 
10% Pd/C catalyst (21 mg) was added. The vessel was evacuated and filled 
with hydrogen to obtain a pressure of 3 psig. The suspension was shaken at 
room temperature for 2 h, after which, the vessel was evacuated and purged 
with N2. The suspension was filtered through a damp kieselguhr pad and 
evaporated to dryness to yield N-(7-Carboxy-3,3-ethylenedioxyheptanoyl)-L-
homoserine lactone (107) a colourless oil (150 mg, 95%). 
Vmax (thin film) 3330, 2950, 1780, 1730, 1660, 1545 cm-i 
IH NMR 5 1.42 (6 H, m, HO2C.CH2C//2C//2C//2), 2.18 (3 H, m, 
C//2CO2H and NHCHC/f), 2.48 (2 H, s, C(02(CH2)2)C//2 CO) 2.62 (1 H, 
m, NHCHC/f), 3.83 (4 H, m, OC//2C//2O), 4.30 (3 H, m, CO2C//2CH2 and 
a-CH), 7.12 (1 H, d, 7 7.5, NH), 9.60 (1 H, s, br, CO2H) 
m/z (FAB) 316.2 (M+H), 297.2 (M - OH), 255.9 (M - OCH2CH2O + H) 
Coupling of N-(7-Carboxy-3,3-ethylenedioxyheptanoyl)-L-homoserine lactone 
(107) to valine methyl ester. 
To a stirred solution of A^-(7-Carboxy-3,3-ethylenedioxyheptanoyl)-L-
homoserine lactone (107) (0.10 g, 0.32 mmol), L-valine methyl ester 
hydrochloride (0.06 g, 0.36 mmol) and TEA (50 i^l, 0.36 mmol) in dry DCM 
(20 ml) at 0 oc was added DCC (0.074 g, 0.36 mmol) and HOBt (0.055 g, 
0.36 mmol) and the resulting solution allowed to stir for 18 h. DCM was 
removed in vacuo and the residue was redissolved in cold ethyl acetate and 
filtered. The filtrate was then successively washed with IM KHS04(aq), sat. 
NaHC03(aq), water and brine. The organic layer was dried (MgS04) and 
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volatiles evaporated to yield an oil which was subsequently purified by PLC 
(EtOAc-Hexane, 1:1) to afford the expected A -^acylated valine methyl ester 
(108) as a colourless oil (82 mg, 60%). 
Vmax (thin film) 3350, 2940, 2860, 1780, 1740, 1670, 1540 cm-i 
IH NMR 5 1.11 (6 H, d, 7 8.0, 2 x Val-y-CHs), 1.55 (6 H, m, NHCOCH2-
CH2CH2CH2), 2.20 (3 H, m, C//2CO2H and NHCHC/f), 2.35 (1 H, m, Val-
p-CH), 2.60 (2 H, s, C(02(CH2)2)C//2 CO) 2.72 (1 H, m, NHCHC//), 3.68 
(3 H, s, OCH3), 3.92 (4 H, m, OC//2C//2O), 4.30 (4 H, m, CO2C//2CH2 , 
Val-a-CH and homoserine lactone-a-CH), 6.58 (1 H, d, 7 7.5, Val-NH), 7.18 
(1 H, d, 7 7.5, homoserine lactone-NH) 
m/z (FAB) 429.6 (M+H), 397.7 (M - OMe), 328.6 (M - homoserine lactone). 
Deketalisation of (108). 
The compound (107) (0.050g, 0.12 mmol) was dissolved in 95% 
TFA(aq) and allowed to stand for 2 h. The aqueous TFA was removed on a high 
vacuum rotary evaporator and the residue partitioned between ethyl acetate and 
water. The organic layer was washed with water (3 x 20 ml), brine and dried 
(MgS04). Removal of ethyl acetate in vacuo afforded the desfred deketalised 
product as a colourless oU (46 mg, 99%). 
Vmax (thin film) 3300, 2930, 1770, 1730, 1660, 1565, 1200 cm-i 
IH NMR 6 1.12 (6 H, d, 7 7.0, 2 x Val-Y-CH3), 1.65 (4 H, m, CH2C//2-
C//2CH2), 2.35 (4 H, m, C//2CO2H, NHCHC// and Val-p-CH), 2.60 (3 H, 
m, CH2C//2 COCH2 and NHCHC//), 3.60 (2 H, s, COCH2CO), 3.74 (3 H, 
s, OCH3), 3.95 (1 H, m, Val-a-CH), 4.55 (3 H, m, CO2C//2CH2 and 
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homoserine lactone-a-CH), 7.00 (1 H, d, 7 7.5, Val-NH), 
8.08 (1 H, d, 7 7.5, homoserine lactone-NH) 
m/z (FAB) 385.2 (M+H) 
Acylation of H-Lys2P-Ala2-OUSA with N-(7-Carboxy-3,3-ethylenedioxy-
heptanoyl)-L-homoserine lactone (107) 
Ultrasyn A resin, functionalised with the HMPA linker at 0.09 nunol g-i 
was employed. To a stfrred solution of Fmoc-p-alanine (0.062 g, 0.2 mmol) in 
dry DCM (5 ml) was added DCC (0.022 g, 0.1 mmol) at 0 oc. Stirring was 
continued for 10 min at 0 oc and then 15 min at room temperature. The 
mixture as then filtered to remove DCU and evaporated to dryness at ambient 
temperature to afford Fmoc-p-alaiune anhydride as oUy residue. 
The residue was dissolved in DMF (0.5 ml) and added to the pre-
swollen resin (0.2 g, 18 ^mol -OH functionaUty), followed by a solution of 
DMAP (0.0024g, 0.02 mmol) in DMF (0.5 ml). The mixture was allowed to 
stand for 2 h at room temperature with occasional agitation. The resin was then 
washed and dried as for (79). 
Estimation of the amount of Fmoc-p-alanine attached to the resin. 
A portion of resin (10 mg) was suspended in 20% piperidine in DMF (3 
ml) for 5 min with occasional agitation. The UV absorbance of the supernatant 
was measured at 290 nm against a blank solution of 20% piperidine in DMF. 
The observed absorbance of 1.501 corresponded to a resin substitution level of 
90% (0.081 mmol g-i) using the calibration plot,259 
Using the remainder of the resin, Fmoc-p-Ala-OH (20 mg, 0.064 
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mmol), Fmoc-Lys(Fmoc)-OH (38 mg, 0.064 nrniol) and Fmoc-Lys(Fmoc)-OH 
(77 mg, 0.13 mmol), the title peptide was synthesised using HBTU/HOBt/ 
DIEA in situ activation. The synthesis was accompUshed using an LKB 4175 
Biolynx manual peptide synthesiser following the synthetic strategy outiined for 
(79), with Fmoc deprotection achieved with 20% piperidine in DMF. 
After the final Fmoc deprotection cycle, A^-(7-Carboxy-3,3-
ethylenedioxyheptanoyl)-L-homoserine lactone (107) (80 mg, 0.26 mmol), 
H0Bt.H20 (40 mg, 0.26 mmol) and DIPCDI (40 ^1, 0.26 mmol) were 
employed to acylate the resin-bound MAP core. The resin was transferred to a 
sintered glass funnel and sequentially washed and dried as for (79). A portion 
of the resin (10 mg) was suspended in TFA-H2O (95:5, 10 ml) for 2 h with 
occasional agitation. The peptide product was isolated as a white amorphous 
powder as for (79). 
RPHPLC analysis 
Gradient - 10% to 50% Eluent B in 20 min. linearly. 
Observed - 1 major peak at 10.5 min and 1 impurity peak at 6.5 min. 
The major peak was purified by semi-preparative RPHPLC under analogous 
conditions. 
m/z (MALDI-TOF) 1557.6 (M + H). 
Attempted coupling of N", N", N^, Ne-tetra[7-fN-((S)-2-oxotetrahydro-3-
furyl)carbamoyl-6,6-ethylenedioxyheptanoyl-Lys2-P-Ala2-OH to bovine serum 
albumin 
Na, Na, Ne, Ne-/efra[7-{N-((5)-2-oxotefrahydro-3-furyl)carbamoyl-6,6 
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-ethylenedioxyheptanoyl-Lys2-P-Ala2-OH (10 mg, 6.43 nmol) was dissolved 
in PBS buffer 12.5 mM at pH 5.0-5.5 (1 ml). To this was added EDC (1.0 
mg) and the Ph of the solution maintained by the careful addition of 0.01 M HCl 
for 1-2 min before the addition of BSA (5 mg ml-i, 34 ^l) with rapid 
adjustment to pH 6.4. The pH was maintained at 6.4 for 90 min and then the 
solution was left to stfr in the dark for 18 h. The solution was the lyophiUsed to 
afforded a white amorphous powder. 
MALDI-TOF MS displayed no signs of incorporation of the MAP vector. 
Na, A/«, Ne, Ne-tetra[7-{N-((S)-2-oxotetrahydro-3-furyl)carbamoyl-6,6-oxo-
heptanoyl-Lys2-P-Ala2-0-NovaSyn® KD. 
NovaSyn® KD resin, functionalised ethylene diamine at 0.07 
nrniol g-i (0.50 g) was swelled in DMF for 60 min. Using 2 x Fmoc-p-Ala-OH 
(44 mg, 0.14 mmol), Fmoc-Lys(Fmoc)-OH (83 mg, 0.14 mmol) and Fmoc-
Lys(Fmoc)-OH (166 mg, 0.28 mmol) and TBTU/HOBt/DIEA in situ 
activation, the MAP core synthesis was accomplished using an LKB 4175 
Biolynx manual peptide synthesiser following the synthetic sfrategy outiined for 
(79), with Fmoc deprotection achieved with 20% piperidine in DMF. 
After the final Fmoc deprotection cycle, A^-(7-Carboxy-3,3-
ethylenedioxyheptanoyl)-L-homoserine lactone (107) (166 mg, 0.28 mmol), 
H0Bt.H20 (97 mg, 0.64 mmol) and DIPCDI (99 ^1, 0.64 mmol) were 
employed to acylate the resin-bound MAP core. The resin was fransferred to a 
sintered glass funnel and sequentially washed and dried as for (79). 
The resin was then suspended in TFA-H2O (95:5, 10 ml) for 2 h with 
occasional agitation, transferred to a sintered glass funnel and once more 
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sequentially washed and dried as for (79). 
Preparation ofNa, A/a, Ne, Ne-tetra[7-{N-((S)-2-oxotetrahydro-3-furyl)carb-
amoyl-6,6-oxoheptanoyl-Lys2-P-Ala2-0-NovaSyn® KD for injection into 
experimental rabbits. 
Na, Na, Ne, Are-fe?ra[7-{N-((5)-2-oxotetrahydro-3-furyl)carbamoyl-
6,6-oxoheptanoyl-Lys2-p-Ala2-0-NovaSyn® KD (20 mg) was sonicated in 
water for injections (1 ml) until a miUcy white paste was obtained. Introduction 
of Freund's Complete Adjuvant and subsequent emulsification provided enough 
injectable material for two experimental rabbits (6 injection sites per aiumal). A 
bleed was taken prior to the fnst injection. Two secondary boosters were given 
at one week and one month intervals after the irutial injection, with bleeds being 
taken on each occasion. 
Analysis of plasma samples for the presence of anti-N-(7-carboxy-3-
oxoheptanoyl)-L-homoserine lactone (103) antibodies. 
N«, N«, Ne, iVe-fefra[7-{A/-((5)-2-oxotefrahydro-3-furyl)carbamoyl-
6,6-oxoheptanoyl-LyS2P-Ala2-OH (5 mg) was dissolved in tris buffered saline 
and blotted onto nitrocellulose paper and allowed to dry. The strip was washed 
in Tween for 1 h to block all unbound sites, washed twice in tris buffered saUne 
and cut into six squares, (Figure 9). 
Each square was placed into individual sample tubes and covered with tris 
buffered saline (15 ml) and the relevant plasma sample (20 nl), see overleaf; 
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Nitrocellulose blotting paper 
1 SB 
Figure 9. Preparation of nitrocellulose dot blot strips. 
1. Rabbit No 40. Pre-immunisation bleed 
2. Rabbit No 40. Post immunisation bleed (1 week) 
3. Rabbit No 40. Post immunisation bleed (1 month) 
4. Rabbit No 69. Pre-immunisation bleed 
5. Rabbit No 69. Post immunisation bleed (1 week) 
6. Rabbit No 69. Post immunisation bleed (1 month) 
After 1.5 h incubation the strips were all washed twice with tris 
buffered saline. A solution of Protein A Peroxidase (PAP) (15 ml) was added 
to each sample tube and were left to incubate for 1 h. Meanwhile a visualisation 
solution was then made-up, consisting of chloronapthol (60 mg in MeOH, 3 
ml) and 30% H2O2(50 1^) in 100 mM tris buffered saline (pH 8). After 
washing each strip twice wUh tris buffered saline, 2-3 drops of the visualising 
solution were applied to each strip, and allowed to develop at ambient 
temperature. 
None of the blot sites darkened , indicating the absence of anti-(A/-(3-
oxoheptanoyl)-L-homoserine lactone)4Lys2p-Ala2-OH antibodies. 
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Chapter 5. 
N-Benzyloxycarbonyl-L-glutamic acid (120); 
The compound was prepared using the method described in Greenstein278. 
To a suspension of NaHC03 (31.5 g, 0.375 mol) in water (200 ml) was 
added L-glutamic acid (14.7 g, 0.1 mol) and the mixture stirred vigorously. To 
the mixture was added benzyl chloroformate (15.7 ml, 0.11 mol) dropwise over 
30 min. The stirring was continued for 1 h longer. The reaction nuxture was 
then washed with ether (50 ml) and the aqueous layer was removed and 
acidified using cone. HCl with cooling and stirring. The oily product was 
extracted with ethyl acetate (2 x 100 ml), dried (MgS04) and evaporated in 
vacuo to obtain a symp/soUd mixture. Addition of a small amount of ether and 
subsequent trituration resulted in the production of white crystals, which were 
collected at the pump and afr dried (16.9 g, 60%), mp. 118-1190 (Ut.,278 mp. 
120-1210) 
Vmax (KBr) 1712, 1553, 1420, 1044 cm-i. 
IH NMR 5 2.00 (4 H, m, CH2CH2), 4.11 (1 H, m, a-CH), 4.85 (2 H, s, 
PhC//2), 5.68 (1 H, d, br, 7 7.5Hz, NH), 7.24 (5 H, s, Ph), 8.98 (2 H, s, br, 
2 X CO2H) 
(S)-3-Benzyloxycarbonyl-5-oxo-4-oxazolidine propionic acid (121); 
The compound was prepared by the method described by Itoh et a/279 
AT-Benzyloxycarbonyl-L-glutamic acid (7.0 g, 25 mmol), 
paraformaldehyde (1.25 g, 14 mmol) and toluene-p-sulphonic acid (0.25 g) 
were nuxed together in dry toluene (175 nU) and refluxed for 1 h. The water 
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liberated during the reaction was removed azeotropically by means of a Dean-
Stark distilling apparatus. The toluene solution was decanted from the brown 
residue and washed with water and then extracted with 5% NaHC03 (aq) 
solution (100 ml). The aqueous layer was removed and carefully acidified using 
6N HCl, with ice cooling. The oily product was extracted with ethyl acetate (2 x 
50 ml) and dried (MgS04). The solvent was evaporated to afford a colourless 
symp(6.l3g, 84%). 
Vmax (thin film) 3020, 1810, 1720, 1425 cm-i. 
IH NMR 6 2.38 (4 H, m, CH2CH2), 4.38 (1 H, m, a-CH), 5.19 (2 H, s, 
PhC//2), 5.22 (IH, d, br, 7 4.5Hz, 1 x NHC//-0), 5.52 (1 H, d, br, 7 4.5Hz, 
1 X NHC//-0), 7.39 (5 H, s, Ph), 10.41 (1 H, br, s, CO2H) 
m/z (FAB) 294 (M + H). 
m/z (EI) 275 (M - H2O), 158 (M - PhCH20C0), 91 (Ph-CH2). 
N-Benzyloxycarbonyl-L-glutamic acid a-methyl ester (122); 
(5)-3-Benzyloxycarbonyl-5-oxo-4-oxazoIidine propioiuc acid (4.3 g, 15 
mmol) was mixed with O.IM sodium methoxide (Na, 0.68 g) in methanol (300 
ml) at 00. The solution was stirred for 2 h and then neutralised by the careful 
addition of 2 M HCl. Methanol was removed in vacuo and the residue dissolved 
in ethyl acetate (50 ml). The organic solvent was washed with water (2 x 20 ml) 
and finally with brine (20 ml). Drying (MgS04) and evaporation of solvent 
gave a colourless symp (3.6 g, 85%). 
Vmax (thin film) 3338, 2960, 1740, 1720, 1530, 1470 cm-i. 
iH NMR 6 2.28 (4 H, m, CH2CH2), 3.67 (3 H, s, OCH3), 4.37 (1 H, m, a-
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CH), 5.10 (2 H, s, PhC//2), 5.86 (I H, d, 7 4.5, NH), 7.32 (5 H, s, Ph), 
10.23 (1 H,br, s, CO2H) 
m/z (FAB) 296 (M + H) 
m/z (EI) 250 (M - CO2H), 91 (PhCH2). 
N-Benzyloxycarbonyl-L-pyroglutamic acid methyl ester (123) 
Phosphoms pentachloride (3.0 g, 14 mmol) was added in one portion to 
a stirred solution of AZ-benzyloxycarbonyl-L-glutamic acid methyl ester (3.5 g, 
10 mmol) in dry ether (150 ml) at OO. The solution was allowed to warm to 
room temperature and stirred for a further 36 h. Ether was removed in vacuo, 
followed by the complete removal of POCI3 using a high vacuum pump for 1.5 
h. The residue was dissolved in ethyl acetate, washed with NaHC03(aq) and 
dried (Na2S04). Evaporation gave the titie product as an orange oil (2.68 g, 
97%) which was sufficiently pure for the following step. 
IH NMR 5 2.30 (4 H, m, CH2CH2), 3.63 (3 H, s, OCH3), 4.62 (1 H, m, a-
CH), 5.23 (2 H, d, 7 3Hz, VhCHi), 7.35 (5 H, s, Ph) 
m/z (FAB) 278 (M + H). 
Attempted synthesis of hemi-aminal (124). 
To a solution of A/-benzyloxycarbonyl-L-pyroglutamic acid metiiyl ester 
(0.277 g, 1.0 mmol) in dry methanol (10 nU) at -30 oc, was added NaCNBH4 
(0.250 g, 4 mmol) over a period of 4 h, and allowed to stir for 2 h. 2 M 
Methanolic HCl was then added (10 ml) and the reaction mixture left to stfr at 
ambient temperature for a further 18 h. 
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Volatiles were removed in vacuo and the residue partitioned between 
ethyl acetate and sat. NaHC03(aq). The organic layer was washed with brine, 
dried (MgS04) and evaporated to dryness to yield a colourless oil which was 
identified as being the A^-benzyloxycarbonyl-L-pyroglutamic acid dimethyl ester 
(126). 
IH NMR 6 2.28 (4 H, m, CH2CH2), 3.52 (3 H, s, Y-OCH3), 3.67 (3 H, s, a-
OCH3), 4.37 (1 H, m, a-CH), 5.10 (2 H, s, PhC//2), 5.86 (1 H, d, br, 7 
4.5Hz, NH), 7.32 (5 H, s, Ph) 
m/z (EI) 250 (M - CO2CH3), 91 (Ph-CH2). 
I-Methyl 7-tert-butyl (S) 2-benzyloxycarbonylamino-5-oxoheptanedioate(128), 
The procedure by Ohta et al^^^ was followed. 
To a 2-neck flask, equipped with a suba-seal and a magnetic stirrer bar, 
was added dry THF (40 ml) and dry dUsopropylamine (1.6 ml, 11.0 mmol). An 
atmosphere of nitrogen was maintained and the flask cooled to -25 oc followed 
by the careful addition of n-butyllithium (1.6 M in hexanes, 6.7 ml, 11.0 mmol) 
over a period of five minutes. The temperature was allowed to rise to -5 oc and 
maintained at that temperature for 40 min. This was then lowered to -78 oc and 
r-butyl acetate (1.25 ml, 9.0 mmol) was added and the mixture stirred at that 
temperature for 30 min. A solution of A^-Benzyloxycarbonyl-L-pyroglutamic 
acid methyl ester (2.5 g, 9.0 mmol) in dry THF (20 nU) was added to the 
reaction mixture and stfrred for 30 min. at -78 oc and then quenched with acetic 
acid:methanol (1:1,4 ml). The solvent was removed in vacuo and the residue 
partitioned between ethyl acetate and water. The organic 
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layer was dried (MgS04) and evaporated to a pale yellow oil which was 
purified by flash silica chromatography in ethyl acetate-hexane, 1:3 to fumish 
the title product as an pale yellow oil (2.7 g, 77%). 
Vmax (thin film) 3200-3500, 2990, 1700-1750, 1530, 1460 cm-i. 
IH NMR 6 1.47 (9 H, s, C(CH3)3), 2.10 ( 2 H, m COCH2C//2), 2.60 (2 H, t, 
7 6Hz, COC//2CH2), 3.30 (2 H, s, COCH2CO), 3.69 (3 H, s, OCH3), 4.30 
(1 H, m, a-CH), 5.12 (2 H, s, PhC/f2), 5.78 (1 H, d, br, 7 7.5Hz, NH), 
7.33 (5 H, s, Ph) 
m/z (FAB) 376 (M + H - H2O) 
m/z (EI) 319 (M - «u-OH), 185 (M - PhCH20C0 -?BuO). 
tert-Butyl (2R,5S) 5-methoxycarbonyl-2-pyrrolidineacetate (130). 
In a high pressure hydrogenation vessel 1-methyl 7-f-butyl 2-
benzyloxycarbonylamino-5-oxoheptanedioate (128) (2.0 g, 5 mmol) was 
dissolved in methanol (200 nU) and glacial acetic acid (1 ml). The solution was 
purged with N2 and 10% Pd/C catalyst (0.4 g) was added. The vessel was 
evacuated and filled with hydrogen to obtain a pressure of 64 p.s.i. The 
suspension was shaken at room temperature for 18 h, after which, the vessel 
was evacuated and purged with N2. The suspension was filtered through a 
damp kieselguhr pad and evaporated to dryness to yield the acetate salt. This 
was dissolved in 5% NaHC03(aq) and extracted into ethyl acetate. The orgaiuc 
exfract was dried (MgS04) and evaporated to afford f-butyl 5-methoxycarbonyl-
2-pyrrolidine acetate (130) as a pale yeUow oU (1.20 g, 97%). The product was 
pure by TLC (CHCl3:MeOH, 9:1), Rf = 0.40. 
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Vmax 3360, 2910, 1730, 1440, 1370 cm-i. 
iH NMR 6 1.50 (9 H, s, C(CH3)3), 2.05 (4 H, m, CH2CH2), 2.45 (2 H, dd, 7 
7.0, COCH2), 2.58 (I H, s, br, NH), 3.45 (1 H, m, C2-H), 3.73 (3 H, s, 
OCH3), 3.90 (1 H, m, C5-H) 
m/z (FAB) 244 (M + H) 
m/z (EI) 186 (M - C(CH3)3). 
(2R,5S) 5-Methoxycarbonyl-2-pyrrolidineacetic acid hydrochloride (133). 
r-Butyl {2R,5S) 5-methoxycarbonyl-2-pyrrolidineacetate (130) 
{1.211 g, 5 mmol) was added to 4 M dioxane/HCl and left to stir for 48 h. The 
solution was evaporated to dryness , redissolved in dioxane and evaporated to 
dryness again. This process was repeated two to three times to remove all 
traces of HCl, finaUy affording the title compound as a brown glass (1.17 g, 
100%). 
IH NMR (D2O, DSS external standard) 6 2.10 (4 H, m, CH2CH2), 2.88 (2 H, 
t, 7 7Hz, HO2CCH2), 3.65 (1 H, m, C2-H), 3.76 (3 H, s, OCH3), 3.99 (1 H, 
m, C5-H) 
m/z (FAB) 188 (M + H (-HC1)) 
Attempted synthesis of methyl (3S,5R)-carbapenam-3-carboxylate (134). 
To a solution of {2R,5S) 5-methoxycarbonyl-2-pyrrolidineacetic acid 
hydrochloride (133) (0.073 g, 0.33 mmol) in dry acetonitrile (80 ml) was 
added TEA (75 \il, 0.54 mmol) with stirring. After 10 min. friphenylphosphine 
(0.120 mg, 0.46 mmol) and 2,2'-dipyridyl disulphide (0.102 g, 0.46 mmol) 
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and the resulting solution heated under reflux for 7 h. Mainly starting materials 
were retumed. 
S-(2-Acetamidoethyl)(2R,5S)-5-methoxycarbonyl-2-pyrrolidinethioacetate 
(136). 
{2R,5S) 5-Methoxycarbonyl-2-pyrrolidineacetic acid hydrochloride 
(133) (0.025 g, 0.11 mmol) was dissolved in dry DCM (5 ml) with TEA (16 
i^l, 0.11 mmol). To this was added DCC (0.024 g, 0.121 mmol) and A^ -
acetylcysteamine(0.026 g, 0.22 mmol) at 0 oc and the mixture allowed to warm 
to room temperature and stirred for 18 h. The solution was evaporated to 
dryness, redissolved in cold ethyl acetate and filtered. The organic solution was 
evaporated to dryness and the cmde residue purified by PLC (CHCl3:MeOH, 
9:1) and the title compound recovered as an oil (14 mg, 44%). 
Vmax 3460, 2910, 1740, 1680, 1510, 1365 cm-i. 
IH NMR 5 1.95 (3 H, s, COCH3), 2.10 (4 H, m, CH2CH2), 2.29 (1 H, br, s 
NH), 2.62 (2 H, d, 7 7.0, SCOCH2), 3.05 (2 H, t, 7 6.0, SCH2), 3.43 (2 H, 
dt, 7 6.0 and 6.0, SCH2C//2), 3.65 (1 H, m, C2-H), 3.74 (3 H, s, OCH3), 
3.85 (1 H, m, C5-H), 6.10 (1 H, s, br, NHCO) 
m/z (FAB) 289 (M + H) 
m/z (EI) 229 (M - CO2CH3) 
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Appendix. The genetically coded anuno acids 
(a) Non-polar 
X. 
., Abbreviation Abbreviation Name Name 3 Letter 1 Letter .. 3 Letter 1 Letter 
S 
Alanine Ala A | Methionine Met M 
X HjN ^COiH Valine Val V 
Phenylalanine Phe P 
Leucine Leu L ^^ COjA 
I . . „ ^ T, W 
Isoleucine lie I 
cx. Proline Pro P 
*N COjH 
H 
(h) Polar uncharged 
Abbreviation ., Abbreviation Name , . , . Name 3 Letter 1 Letter 3 Letter 1 Letter 
HjN CO2H Glycine Gly G 
HO,,^ 
Serine Ser S 
H2N' "CO2H 
- U 2 " 
HjN^ "^^ Asparagine Asn N 
HO ^ ^ 
Threonine Thr T H2N' ^C02H 
H2N -CO2H H^^ O 
I Glutanune Gin Q 
Cysteine Cys C 
H2N CO2H H2N CO2H 
229 
(c) Basic amino acids 
Name 
H2N CO2H 
Abbreviation 
3 Letter 1 Letter 
Lys K 
H 2 N ^ . N H 
HN 
\ 
H2N 
Name 
Arginine 
^C02H 
Abbreviation 
3 Letter 1 Letter 
Arg R 
Histidine His H 
H2N "CO2H 
(d) Acidic amino acids 
Name Abbreviation 
3 Letter 1 Letter 
Name Abbreviation 
3 Letter 1 Letter 
HO2C 
1 Aspartic acid Asp D 
H2N CO2H 
CO2H 
Glutamic acid Glu E 
H2N CO2H 
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